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Common causes for heart failure (HF) include hypertension and myocardial 
infarction (MI). Although inflammation is associated with HF, the processes that 
initiate myocardial inflammation remain unknown. The immune sensor, toll-like 
receptor (TLR)-9 is involved in pressure overload-induced myocardial 
inflammation and cardiac remodelling. Various cellular pathways are activated 
after pressure overload, including the β-adrenergic receptor (β-AR) signalling 
cascade. Furthermore, the role of TLR9-mediated inflammation after MI is yet to 
be determined. Therefore, this thesis aimed to elucidate the pathophysiological 
relevance of TLR9-mediated inflammation in HF induced by chronic β-AR 
activation and MI.  
WT and TLR9KO mice were implanted with minipumps infusing 50 mg/kg/day 
isoprenaline (Iso) over 4 weeks. Cardiac dysfunction, chamber dilatation, 
hypertension, heart weight gain and tachycardia were observed in Iso-infused 
WT and TLR9KO mice. The extent of fibrosis, inflammation and apoptosis were 
similar between WT and TLR9KO mice after Iso infusion. Interestingly, Iso-
infused TLR9KO mice exhibited improved cardiac function and reduced heart 
weight gain compared to Iso-infused WT mice, suggesting that TLR9 influences 
β-AR-induced cardiac remodelling. Further investigation of the Iso infusion 
model found that Iso-induced cardiac dysfunction and tachycardia were 
recoverable 1 day after removal of Iso. Whilst metabolism, oxidative stress, 
calcium signalling and mitochondrial structure were maintained after Iso 
infusion, increased degradation of IκB was observed.  
To evaluate the role of TLR9-mediated inflammation after MI, WT and TLR9KO 
mice were subjected to coronary artery ligation. Interestingly, the mortality of 
TLR9KO mice 4 days after MI was significantly higher than WT mice due to 
cardiac rupture. There were no differences in inflammation between MI-
operated WT and TLR9KO mice. However, decreased mRNA of Timp1 and 
fewer fibroblasts and myofibroblasts were observed in MI-operated TLR9KO 
mice compared to WT mice, suggesting a life-preserving role of TLR9 in tissue 
repair.  
These findings indicate novel roles of TLR9, independent of its inflammatory 
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1.1 The heart 
The heart is a simple, yet extraordinary organ, which operates as a mechanical 
pump propelling oxygen- and nutrient- rich blood around the body to supply 
metabolising tissues with the necessary nutrients. The muscular component of 
the heart is architecturally diverse and is composed of a myriad of different cell 
types with 30% being cardiomyocytes 1, 2. Other cells that reside in myocardial 
tissue include fibroblasts, endothelial cells, pericytes, vascular smooth muscle 
cells and tissue-residing macrophages 1, 3. Collectively, these cells maintain the 
electrical, chemical and biomechanical functions of the heart. Furthermore, a 
number of extracellular matrix (ECM) components provide structural integrity 
and scaffolding 4, 5 while gap junctions between cardiomyocytes 
electrochemically integrate the contraction of neighbouring cells. 
Cardiomyocytes are terminally differentiated, contractile cells that possess 
repeating units of sarcomeres, consisting of actin and myosin among other 
contractile proteins 2. The movement of actin and myosin filaments, mediated 
by adenosine triphosphate (ATP) and calcium, provide the molecular basis for 
cardiomyocyte contraction 6, 7, 8. With ATP and calcium fundamental for 
cardiomyocyte contractile function, the cardiomyocyte possesses many ATP-
generating mitochondria whilst the sarcoplasmic reticulum (SR) is a major 
calcium store. Therefore, both ATP production and calcium handling are tightly 







1.2 Heart failure (HF) 
Within the UK, HF is a leading cause of morbidity and mortality with 900,000 
people currently diagnosed with this complex clinical syndrome 9. HF occurs 
when the heart fails to pump blood adequately to meet the demands of 
metabolising tissues 10. This condition may originate from structural cardiac 
abnormalities or it may arise as an indirect consequence of other conditions 
including chronic hypertension, myocardial infarction (MI) and cardiomyopathies 
11, 12, 13. As these conditions increase cardiac workload, the heart induces 
compensatory mechanisms, to increase cardiac function and decrease wall 
tension 14. Unfortunately, over time, these adaptations decrease myocardial 
contractility and are detrimental to the heart 15. Structural and/or functional 
cardiac abnormalities lead to myocyte dysfunction, death and/or ventricular 
remodelling which may contribute to HF 16. Among the many biochemical 
abnormalities associated with the progression of HF, are the elevated levels of 
circulating catecholamines 17, 18 and proinflammatory cytokines such as tumour 
necrosis factor (TNFα) 19, interleukin 6 (IL6) and IL1β 20, 21 as well as impaired 
β-adrenergic receptor (β-AR) signalling 18, 22.   
HF can be classified according to the length of its progression (acute versus 
chronic), the location of the dysfunction (left-sided versus right-sided) and the 
phase within the cardiac cycle that is disrupted (systolic versus diastolic) 23. 
Chronic HF cases are more common than acute incidents 23 and right-sided HF, 
observed by systemic congestion, commonly transpires following left-sided HF, 
indicated by pulmonary oedema 23. Systolic HF can be diagnosed when 
ventricles contract abnormally, such that blood is pumped into the circulation 
with insufficient force, leading to symptoms such as pulmonary congestion 24. 
Further, if the myocardium is too stiff and incapable of relaxing fully, then 
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insufficient blood enters the ventricles, referred to as diastolic dysfunction 24. 
Clinically, these conditions may manifest with reduced ejection fraction (HFrEF) 
or with preserved ejection fraction (HFpEF), which have distinct 
pathophysiologies 25, 26.  
Current medications for HF patients help to attenuate the symptoms, impede 
the progression of the condition and improve the quality and length of life. 
Common treatments include β-AR blockers (β-blockers) 27, angiotensin-
converting-enzyme (ACE)-inhibitors 28, angiotensin II (Ang II) type 1 receptor 
blockers and lifestyle changes 16. Even with current therapeutics, prognosis is 
still poor. With the number of cases of HF anticipated to increase, it becomes 
increasingly important to comprehend the molecular mechanisms of this 




As mentioned earlier, the susceptibility to develop HF increases after MI. The 
most common cause of MI is atherosclerotic narrowing of coronary arteries 
associated with plaque rupture, completely blocking the blood flow through the 
coronary artery 29. This denies the provision of oxygen and nutrients to actively 
contracting cardiomyocytes, ceasing ATP generation by oxidative 
phosphorylation. As the contractile function of cardiomyocytes corresponds to 
the rate of ATP formation, the inability to generate ATP equates to depressed 
contractile function, which reduces blood pressure (BP), cardiac output (CO) 
and stroke volume (SV). 
An estimated 1 billion cardiac cells can be lost in a typical MI 30. Cells begin to 
die within the first few hours, by necrosis and apoptosis, leading to an infarct. 
22 
 
Dying cells alter the electrical conductivity of the heart and release creatinine 
kinase, lactate dehydrogenase (LDH), troponin T (TpnT) or TpnI. Clinically, 
these electrophysiological and biochemical abnormalities can be detected and 
are routinely used to diagnose MI 31.  
In response to these dying cells, a wound healing response is initiated to 
remove debris and dead cells, promote tissue repair and stimulate scar 
formation. This can be separated into 3 distinct, yet overlapping phases 32. The 
initial inflammatory response is associated with cytokine and chemokine 
expression along with infiltration of leukocytes to mediate clearance of dead 
cells and tissue debris 33. This is followed by the proliferative phase in which 
inflammation is supressed and fibroblasts and myofibroblasts secrete matrix 
proteins to mediate remodelling of the ECM and scar formation. Lastly, the 
maturation phase is characterised by apoptosis of the participating cells, leaving 
a cross-linked collagen scar. Furthermore, myocyte and ECM remodelling of the 
infarct regions leads to infarct expansion, thinning of the myocardium and 
chamber dilatation 34, 35.   
This permanent damage to the myocardium increases the susceptibility of 
developing life-threatening arrhythmias and/or inducing rupture of the cardiac 
wall after acute MI, which accounts for 5 - 20% of hospital deaths after MI 36.  
Reperfusion is the only option to salvage an ischemic tissue and is achieved by 
thrombolytic treatment or by percutaneous coronary intervention through 
surgical insertion of a coronary balloon or stent.  However, in the early moments 
of reperfusion, significant reversible and irreversible damage is also initiated, 





BP, the force at which blood is propelled out of the heart and into the major 
arteries, is regulated by several factors including humoral mediators, blood 
vessel elasticity and neural stimulation, such as the renin-angiotensin-
aldosterone system (RAAS) 37. In developed countries, hypertension affects 20 
– 50% of adults and contributes to 49% of all heart diseases, including HF 38. 
Under hypertensive conditions, pressure on the left ventricle (LV) escalates 
leading to myocardial stiffness and cardiac hypertrophy. Renal sodium 
retention, stress associated with central and sympathetic nervous system 
activity along with the loss of elasticity and contractile nature of the vasculature 
are proposed causes of hypertension 37. Fortunately, hypertension can be 
managed with the use of ACE inhibitors and Ang II type 1 receptor blockers, 
which inhibit RAAS-induced vasoconstriction 39, 40. However, if left untreated, 
hypertension can have serious consequences since it is an adverse risk factor 
for MI, HF, stroke and vascular diseases 37, 39.  
 
1.2.3 Cardiomyopathies 
Cardiomyopathies are diseases of the myocardium that have not arisen from 
pericardial, hypertensive or valvular disorders. Although cardiomyopathies may 
transpire from a multitude of factors, such as alcohol, toxins or viral infection 41, 
42, 43, the best-described cases are congenital with more than 900 
acknowledged genetic mutations 44, of which 400 have been identified in 13 
sarcomeric proteins 43. 
The most prevalent type of cardiomyopathy is dilated cardiomyopathy (DCM) 45, 
in which one or both ventricular chambers are dilated, with thinner walls and 
larger, more spherical chambers. Whilst the volume of the chamber increases, 
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the systolic function declines. Molecular features of DCM include apoptosis, 
fibrosis, wall stiffness and inflammatory cell infiltration 45. In the case of 
hypertrophic cardiomyopathy (HCM), patients exhibit asymmetrical thickening of 
the septum, increasing myocardial muscle mass, but reduced chamber size 46, 
47. Enlarged and misaligned (myocardial disarray) cardiomyocytes in 
conjunction with interstitial fibrosis and inflammation has been described in 
HCM patients 43, 48. Alas, both DCM and HCM can progress to HF. 
 
1.2.3.1 Reversible cardiomyopathies 
Cardiomyopathies with transient LV dysfunction possess several phenotypic 
characteristics that are associated with HF and MI. However, the remodelling 
associated with HF and MI is irreversible, whilst features of the 
cardiomyopathies discussed below are recoverable.  
Tachycardia-induced cardiomyopathy (TIC) is associated with prolonged 
elevated heart rate (HR) or irregular heart rhythm. Haemodynamic features of 
TIC include fleeting systolic dysfunction, LV chamber dilatation, neurohormonal 
activation, reduced CO, increased ventricular filling pressures and increased 
vascular resistance 49, 50, 51. At the molecular level, TIC is associated with 
cellular elongation, myofibril misalignment, disorganisation of the ECM, loss of 
sarcomeric structure and mitochondrial morphological and functional defects 51, 
52, 53. Abnormal calcium handling, myocardial energy depletion, myocardial 
ischemia and ECM remodelling are proposed to induce TIC 50, 54, 55, 56, 57. Taking 
HR cadence and duration of tachycardia into consideration, TIC increases the 
risk of HF, although tachycardia can be controlled with medication.  
Another cardiomyopathy associated with transient LV function is stress-induced 
or takotsubo cardiomyopathy (SIC). In this condition, LV dysfunction is 
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associated with regional wall abnormalities, such as akinesia or hyperkinesia in 
apical, midventricular and/or basal regions 58, 59. This condition is precipitated by 
intense emotional or physical stress and is usually accompanied by a surge in 
catecholamine levels 60, 61. Lethal complications can include arrhythmias, 
cardiogenic shock and ventricular rupture. Ventricular ballooning, 
electrocardiography (ECG) abnormalities and a slight elevation of cardiac 
enzymes are prominent features of this condition together with leukocyte 
infiltration, contraction band necrosis, clustering of mitochondria of variable 
shapes and sizes and enlargement of ECM 61, 62, 63, 64. Several pathological 
mechanisms have been proposed including multivessel vasospasm, 
catecholamine-induced cardiomyocyte stunning and increased ventricular 
afterload 58, 59. The favoured hypothesis proposes that catecholamine-induced 
cardiomyocyte stunning induces the switching of β2-AR signalling from Gas to 
Gi (section 1.6.1), which mediates anti-apoptotic and negative inotropic effects 
65.  
Most surprisingly, after functional recovery the changes in myocardial 
composition and appearance can be restored to normal. Further study is 
required to understand the molecular processes involved in the recovery of the 
cardiac function in these reversible cardiomyopathies, these potential, which 







1.3 Myocardial injury and cardiac remodelling 
Cardiac remodelling may be defined as the molecular, cellular and interstitial 
modifications that manifest after myocardial stress or injury, leading to 
morphological and functional modulations to the heart 66. Cardiac remodelling 
involves amendments to the ECM and to cardiomyocytes, such as shape and 
size, in addition to changes in wall thickness, scar formation, chamber 
dilatation, cell death and fibrosis, which modify the overall structure and function 
of the myocardium (figure 1.1) 66, 67. Cardiac remodelling is a dynamic and 
time-dependent process and is influenced by haemodynamic load, 








Figure 1.1 Cardiac remodelling response. 
Injury to the myocardium activates mechanical and neurohormonal signalling 
pathways to aid and enhance the cardiac workload. Stimulation of these 
signalling pathways leads to pathological hypertrophy. Initially this response is 
beneficial to the heart but over a prolonged period, it leads to myocyte 
dysfunction, fibrosis, inflammation and myocyte cell death, all of which 
contribute to heart failure. Adapted from 68.  
 
1.3.1 Hypertrophic responses 
Under conditions such as hypertension or during exercise, the heart must adapt 
to conduct the extra work, normalise the load and reduce wall stress. The 
hypertrophic response is initiated, enlarging the size of cardiomyocytes leading 
to increased wall thickness 2. The initial decline in cardiac function is remedied 
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with an improvement in contractile function of the cardiac muscle, decreasing 
ventricular wall tension 69. Depending on the type of stress, the heart may 
undergo 2 types of hypertrophic responses: physiological cardiac hypertrophy 
and pathological cardiac hypertrophy 2, 14, 70 (figure 1.2). 
 
Figure 1.2 Cardiac hypertrophic responses. 
The adaptive and reversible physiological hypertrophic response to exercise 
and pregnancy leads to eccentric cell growth and maintained cardiac function. 
Pathological hypertrophy induces concentric hypertrophy which initially 
improves cardiac function. Over time, cardiac remodeling is detrimental as 
fibrosis and cell death impair cardiac function. Cardiac dilation may occur from 
normal hearts under conditions such as dilated cardiomyopathy (DCM) or from 
severe pathological hypertrophy. Adapted from 14.  
	  	  
	  
During exercise or pregnancy, the heart undergoes a physiological hypertrophic 
response, which is mediated through insulin-like growth factor 1 and transduced 
downstream by phosphoinositide 3-kinase-Akt signalling 9, 71, 72. A uniform 
cardiac growth response is observed, with sarcomeres added in series 
elongating the cardiomyocytes which is known as eccentric hypertrophy (figure 
1.2). There is a matched increase in ventricular wall thickness and chamber 
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dimensions. This adaptive response is accompanied with normal or enhanced 
cardiac function 69.  
Pathological cardiac hypertrophy may evolve from sustained hypertension or 
cardiomyopathies (figure 1.2). Stimulation of biomechanical and stretch 
sensitive mechanisms in addition to neurohormonal signalling (such as 
proinflammatory cytokines, hormones and growth factors) activate pathways 
that mediate pathological cardiac growth. This includes induction of mitogen-
activated protein kinases (MAPK) signalling through ERK1/2 73, 74 in addition to 
stimulation of protein phosphatase, calcineurin 75, 76 and calcium/calmodulin-
dependent protein kinase II (CaMKII) 77, 78 to evoke the changes associated with 
pathological cardiac hypertrophy. These modifications include increased size of 
the cardiomyocytes, increased protein synthesis and reactivation of the foetal 
gene program, including atrial natriuretic factor (ANF), brain natriuretic peptide 
(BNP) and β myosin heavy chain (βMHC) 70, 79. Cardiomyocytes undergo 
concentric hypertrophy, with sarcomeres added in parallel, widening the 
cardiomyocyte, which physiologically corresponds to thicker ventricular and 
septal walls and a decrease in chamber dimensions. These changes are initially 
compensatory which improve the pumping function of the heart 80. Over time, 
the compensatory state becomes maladaptive with impaired cardiac function, 
increasing the risk of adverse cardiac events 9, 80, 81. The reasons for the change 
from compensated to decompensated state remain unclear. However it maybe 
associated with the remodelling of the myocardium such as ECM adaptations, 
fibrosis and cell death, along with alterations in the expression of proteins 
involved in electrochemical (EC) coupling and changes to the energetic and 
metabolic state of the cardiomyocyte 66, 70, 82.  
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Cardiac dilation has a similar, yet more severe phenotype compared with 
pathological hypertrophy and this has been noted to be a feature of the 
transition from the compensatory state to the decompensated phase (figure 
1.2). Signalling is mediated through the MEK5-ERK5 proteins of the MAPK 
family as well as calcineurin and CaMKII 70, 83, 84 and is associated with 
eccentric hypertrophy inducing dilatory growth of the cardiac muscle 14. Cardiac 
dysfunction, fibrosis and cell death along with ECM remodelling are apparent in 
this phenotype. 
 
1.3.2 Fibroblasts, myofibroblasts, ECM remodelling and fibrosis 
Within the heart, the ECM is a network that encompasses and interconnects 
myocytes and non-myocytes, providing structural support and a means to 
distribute force through the myocardium. The ECM is comprised of a fibrillar 
collagen network with elastin, fibrillin, fibronectin, laminin, proteoglycans and 
glycosaminoglycans components 5, 85. The arrangement of the collagen fibres 
provides scaffolding for adjoining myocytes and connections to sarcomeric 
proteins through the integrin family 4, 86.  
Interruptions within the ECM network disrupt myocardial structure and support, 
subjecting cardiomyocytes to abnormal stresses and strains that perturb 
myocardial geometry and function. The ECM is maintained by cardiac 
fibroblasts (CFs), through their ability to synthesise and deposit ECM proteins 
and create and secrete matrix-degrading enzymes, a process known as ECM 
remodelling 4, 5, 85.   
Fibroblasts are highly heterogeneous cells, with distinctive phenotypic 
properties and functions in different organs or under various physiological 
conditions. These flat and spindle-shaped cells with multiple protrusions, usually 
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of mesenchymal origin 87, are derived from mesangioblasts, monocytes, 
fibrocytes and pericytes 88 (figure 1.3). Additional sources of fibroblasts include 
epicardial and endocardial cells, which undergo epithelial-mesenchymal 89 and 










Figure 1.3 The sources and functions of cardiac fibroblasts (CFs). 
CFs are sourced from a variety of cells, such as epithelial cells and endothelial 
cells, and possess the ability to perform multiple functions in physiological and 
pathological settings. CFs are capable of producing and secreting many 
mediators which facilitate processes such as ECM remodelling, angiogenesis 
and angiogenesis. Adapted from 5. 
 
CFs are described as ‘sentinels’, sensing changes in the environment and 
reacting to preserve organ function 5. In the myocardium, CFs reside in the 
cardiac interstitium and are organised in sheets and strands that run parallel 
with myofibres to maintain continuity between cells and the overall structural 
integrity of the heart 91, 92. These cells contribute to structural, mechanical, 
biochemical and electrical properties of heart, with a particular role in 
maintaining and remodelling the ECM 85.  
Another subset of cells observed during cardiac remodelling are myofibroblasts. 
In comparison to fibroblasts, these cells possess enhanced migratory, 
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proliferative, contractile and secretory properties 85, 93. The main distinction from 
fibroblasts is the expression of contractile proteins such as alpha smooth 
muscle actin (α-SMA) within myofibroblasts 32, 93, 94. Myofibroblasts are 
necessary for tissue repair and scarring and are therefore not expressed within 
the healthy myocardium, but appear after injury 95. Their contractile nature is 
proposed to aid wound closure and provide structural integrity to cardiac scar 
tissue 96, 97.  
Myofibroblasts can differentiate from fibroblasts, progenitor stem cells and 
endothelial cells 88 and are induced by transforming growth factor beta (TGFβ), 
cytokines, ECM and growth factors. While several studies have suggested that 
CFs differentiate into myofibroblasts, other studies have opposed this view 93, 98, 
99, therefore further study is required to clarify the sources of CFs.  
CFs and myofibroblasts play a key role during the pathological remodelling of 
the heart. CFs are activated by a variety of pathological stimuli including 
myocardial injury, oxidative stress, mechanical stress and autocrine and 
paracrine mediators including cytokines 85. After injury, the number of fibroblasts 
and myofibroblasts increase and migrate to the site of injury guided by a 
chemokine gradient to promote wound healing and scar formation 32. Together 
fibroblasts and myofibroblasts facilitate remodelling of the ECM by synthesising 
and secreting ECM proteins, cytokines, growth factors and matrix 
metalloproteinases (MMPs). Initial fibroblast activation and proliferation are 
essential for reparative wound healing and maintaining cardiac function, 
however the persistence of fibroblasts after injury leads to fibrotic scaring and 




1.3.2.1 ECM remodelling 
The ECM is a dynamic network that is altered in response to pathological 
stress, which can impact the morphology and function of the heart. MMPs are 
predominantly responsible for the degradation of the ECM. Whilst, these zinc-
dependent proteases degrade a wide spectrum of ECM proteins, each MMP 
has its own specificity and the 26 currently known members of the human MMP 
family are classified into 5 different groups based on substrate specificity and 
structure 101. The non-membrane MMPs are secreted as zymogens (pro-MMPs) 
and are activated by cleavage of the amino-terminal propeptide domain by 
serine proteases 102.  
All cells in the myocardium can express MMPs and the members reported to 
contribute to myocardial remodelling are MMP1, MMP3, MMP8, MMP13, 
MMP2, MMP9, MMP12, MMP28 and MT1-MMP 5, 103, 104, 105.  
To prevent excessive degradation of ECM, MMP expression is tightly regulated 
by tissue inhibitors of metalloproteinases (TIMPs). There are 4 known members 
(TIMP 1 - 4) which bind to the active site of MMPs with a 1:1 stoichiometry, 
blocking access to substrates 102. In addition, TIMPs are able to bind to the 
latent forms of MMPs to prevent auto-activation 106. Though constitutively 
expressed, TIMPs are differentially expressed in various cells and tissues and 
TIMP4 is most predominantly expressed in human myocardial tissue 107, 108.  
Whilst growth factors and cytokines IL1β and TNFα can induce synthesis and 
activity of MMPs 109, 110, these 2 mediators have additionally been reported to 
induce expression of TIMP1 and TIMP2 111. Furthermore, in vitro studies have 
suggested that TIMP1 and TIMP2 may stimulate growth of fibroblasts 112.  
In humans, alterations in MMP and TIMP expression have been noted in 
different cardiac diseases, including HF. In patients with end-stage DCM, 
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decreased MMP1 alongside increased MMP3, MMP9, TIMP1 and TIMP2 was 
reported 113. It has been stated that TIMP1 levels were increased in diseased 
hearts 114 whilst hypertensive patients with pathological hypertrophy have 
reduced plasma levels of MMP1, MMP2 and MMP9, alongside elevated TIMP1 
expression 115, 116. Elevated levels of MMP2, MMP9 and TIMP1 have been 
detected in MI patients 117. Furthermore plasma MMP9 is recognised as a 
prognostic marker for the indication of late-onset HF 118. Thus, ECM remodelling 
mediated by MMP activity and TIMP expression is a crucial mediator for the 
pathogenesis of HF. 
 
1.3.2.2 Fibrosis 
After injury to the myocardium, ECM components are deposited by both 
fibroblasts and myofibroblasts to promote scar formation and maintain 
myocardial integrity. However, excessive deposition of ECM proteins and 
accumulation of fibroblasts, is perceived as scarring and is known as fibrosis 88.  
Cardiac fibrosis leads to distorted organ architecture, stiffness, impaired 
myocardial mechano-electrical coupling leading to systolic and diastolic 
dysfunction and increased risk of arrhythmias 119. It has also been reported that 
fibrosis induces pathological signalling leading to progressive HF 88. 
Hyperactive fibroblasts and failure to terminate the wound healing response are 
the predominant causes for the scarring and the unfavourable remodelling 
associated with fibrosis 100, 120, 121.   
Whilst TNFα and interferon gamma (IFNγ) are recognised as being anti-fibrotic, 
TGFβ, a profibrotic cytokine, is a vital contributor to the development of cardiac 
fibrosis 122, 123, 124. TGFβ has been demonstrated to stimulate transformation of 
fibroblasts to myofibroblasts and increase ECM protein synthesis 93, 122.  
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In HF patients, increases in collagen, fibronectin, laminin and vimentin have 
been detected 125. The extent of fibrosis negatively correlates with ejection 
fraction (EF) and altered myocardial structure 5, 88. Nonetheless, the amino- and 
carboxyl- terminal properties of collagen type 1 and collagen type 3, are 
considered biomarkers of collagen synthesis 126 and in hypertensive and HF 
patients, these markers have been associated with severity of fibrosis and 
contractile function 127, 128.  
 
1.3.3 Cell death 
Cell death is a prominent characteristic of various CVDs including MI and HF 
129, 130. Cardiomyocyte cell death occurs primarily by 2 recognised forms of cell 
death; programmed necrosis and apoptosis. Though, the characteristics and 
signal transduction of these pathways are distinct, there are some overlapping 
features. Both necrosis and apoptosis are activated through cell-surface 
receptors, referred to as the extrinsic pathway or by the intrinsic pathway, which 
primarily involves the mitochondria 130, 131.  
Apoptosis is defined as programmed cell death 129, 131. This regulated process is 
essential during embryonic development and for tissue homeostasis. 
Cytoplasmic shrinkage, plasma membrane blebbing, nuclear condensation and 
DNA fragmentation alongside the presence of membrane-enclosed apoptotic 
bodies are central features of apoptosis 132, 133. Phagocytosis of apoptotic cells 
by macrophages and neighbouring cells maintain an efficient clean-up process.  
Apoptosis is mediated by cysteine proteases, known as caspases, that are 
synthesised as zymogens (procaspase) and activated upon cleavage 134. 
Caspases are classed as either upstream initiator caspases (caspase -2, -8, -9, 
-10) or downstream caspases (caspase -3, -6, -7). Initiator caspases cleave and 
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activate downstream caspases, which subsequently amplify the pro-apoptotic 
signal by cleaving other apoptotic mediators and cutting many cellular structural 
and regulatory proteins 129. 
Stimulation of the extrinsic pathway is facilitated through death-ligands such as 
Fas ligand and TNFα (figure 1.4) 129, 131, 135. Activation of the receptor induces 
the formation of the death-inducing signalling complex (DISC). Fas-associated 
death domain (FADD) is recruited and binds procaspase -8 or -10 136. These 
caspases are activated through forced proximation 137 and released from the 
DISC to cleave and activate procaspase -3 and -7, which subsequently cleave 
cellular proteins. However, activation of the extrinsic pathway is insufficient for 
complete cell death and requires amplification from the intrinsic pathway 129.  
The intrinsic pathway is activated by inadequate nutrients/survival factors, 
hypoxia, oxidative stress, DNA damage and chemical and physical toxins 131 
(figure 1.4). This process is mediated by the Bcl-2 family of proteins 138, which 
induces permeabilisation of the outer mitochondrial membrane, known as 
mitochondrial permeability transition (MPT). MPT enables release of 
mitochondrial apoptogens, such as cytochrome c, second mitochondria-derived 
activator of caspases (Smac/DIABLO) and Omi/HtrA2 into the cytosol 129, 131. 
Cytochrome c along with ATP and apoptotic protease activating factor 1 (Apaf1) 
associate to form the apoptosome, which binds, cleaves and activates caspase-
9 which in turn, cleaves and activates downstream caspases 139. Both 
Smac/DIABLO and Omi/HtrA2 inhibit IAP (inhibitors of apoptosis) 140, 141 whilst 
DNA fragmentation, a feature of apoptosis, is mediated by apoptosis inducing 
factor and endonuclease G 142. Inadequate, excessive or inappropriate 





Figure 1.4 Apoptotic pathways in cardiomyocytes. 
Apoptosis is induced by intrinsic and extrinsic stimuli. The extrinsic pathway is 
facilitated through death receptors such as Fas and tumour necrosis factor 
receptors (TNF-R). Binding of the ligand enables binding of Fas-associated 
death domain (FADD) which binds procaspase -8 or -10. Activation of these 
caspases enables cleavage and activation of procaspase -3. The intrinsic 
pathway is stimulated by inadequate nutrients, oxidative stress, DNA damage 
and toxins and is mediated by the Bcl-2 family of proteins. Permeabilisation of 
the outer mitochondrial membrane (OMM) by Bax and Bak, allows release of 
mitochondrial apoptogens, including cytochrome c (Cyt c). Cyt c along with ATP 
and apoptotic protease activating factor 1 (Apaf1) form the apoptosome, which 
binds, cleaves and activates caspase-9 which in turn, cleaves and activates 
downstream caspases, leading to apoptosis. Adapted from 131. 
 
Necrosis is actively executed by cells 131 and features of this cell death pathway 
include depletion of cellular ATP and swelling of the cell and organelles, which 
leads to the collapse of cellular homoeostasis 129, 143. Loss of plasma membrane 
integrity enables the release of cellular contents into the extracellular space, 
evoking an inflammatory response (section 1.5.1). Therefore necrosis 





Figure 1.5 Necrotic pathways in cardiomyocytes 
Necrosis is induced by intrinsic and extrinsic stimuli. The extrinsic pathway is 
mediated through the tumour necrosis factor receptor (TNF-R). Binding of TNFα 
to TNF-R recruits TNF-R associated death domain (TRADD), receptor-
interacting protein 1 (RIP1), TNF-R-associated factor 2 (TRAF2), inhibitors of 
apoptosis 1 (IAP1) and IAP2, which collectively form complex 1. Dissociation of 
the multiprotein complex from the receptor, deubiquitination of RIP1 and 
recruitment of FADD, RIP3 and caspase-8 forms complex 2. This leads to 
activation of apoptosis via caspase-8 stimulation. Inhibition of caspase-8 
induces cross-phosphorylation of RIP1 and RIP3, which progresses to necrosis 
through mechanisms that are unclear. The intrinsic pathway activated by 
elevated matrix calcium concentration, ROS, or depletion of ATP opens the 
mitochondrial permeability transition pore (mPTP). Subsequent swelling of the 
mitochondria and loss of mitochondrial electrochemical gradient (mECG) across 
the membrane halts oxidative phosphorylation. Following this, the cell 
undergoes necrosis. Adapted from 131. 
 
Necrosis is triggered by nutrient stress, heat shock or exposure to harsh 
environments. The extrinsic pathway involves 2 complexes and is mediated 
through the TNF receptor (TNF-R) 144. Binding of the death ligand, TNFα to its 
receptor recruits TNF-R associated death domain (TRADD), receptor-
interacting protein 1 (RIP1), TNF-R-associated factor 2 (TRAF2), IAP1 and 
IAP2, which collectively form complex 1 (figure 1.5).  IAP1 and IAP2 
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ubiquitinate RIP1 145 which permits recruitment of TAK1 and through a series of 
phosphorylation steps enables translocation of nuclear factor kappa-light-chain-
enhancer of activated B cells (NFκB) into the nucleus to stimulate transcription 
of survival factors 146. Complex I transitions into complex II when the 
multiprotein complex dissociates from the receptor, undergoes endocytosis 
followed by deubiquitination of RIP1 and recruitment of FADD, RIP3 and 
caspase-8 131, 144. Cleavage and activation of caspase-8 stimulates apoptosis 
whereas inhibited caspase-8 leads to cross-phosphorylation of RIP1 and RIP3, 
which progresses to necrosis through mechanisms that are unclear 129, 131, 144.  
The intrinsic necrotic pathway is mediated by the opening of the mitochondrial 
permeability transition pore (mPTP) which is caused by necrotic stimuli, 
elevated matrix calcium or phosphate concentration, by reactive oxygen species 
(ROS) or depletion of ATP 131 (figure 1.5). This opening leads to mitochondrial 
swelling and loss of electrochemical gradient across the membrane, halting 
oxidative phosphorylation. Following this, the cell undergoes necrosis.  
 
1.3.3.1 Cell death in MI and HF  
In animal models to induce MI or I/R injury, apoptosis and necrosis of myocytes 
and non-myocytes have been detected in the ischemic area. It has been 
reported that apoptosis peaks 4.5 hours after permanent coronary occlusion 
whilst necrosis peaks at 24 hours 147. Upon reperfusion, the rate of apoptosis is 
increased (I/R injury) whilst aspects of I/R injury, including ROS and 
normalisation of intracellular acidosis (section 1.6.4.1), may trigger opening of 
the mPTP, leading to necrosis 129. 
Compared to the acute and potentially immense cell death post-MI, cell death in 
HF is a chronic process and is modestly elevated. Both apoptosis and necrosis 
39 
 
are upregulated in HF. The rates of apoptosis in patients with end-stage HF are 
0.12 – 0.70 % 148, which questions if this low percentage of apoptosis may 
contribute to the pathogenesis of HF. It has also been suggested that necrosis 
was more frequent than apoptosis in HF patients 149. Interestingly others have 
reported that in HF patients, cardiomyocyte death with autophagic features 
occurred at a rate of 0.03% compared to 0.002% for apoptosis 150. Clearly, 
further studies are required to understand myocardial cell death and its 
contribution to the pathogenesis of HF. 
 
1.4 Autophagy 
Autophagy is a highly conserved process that can be described as an 
intracellular recycling process in which organelles, proteins and lipids are 
catabolised by lysosomal degradation. Under basal conditions, low levels of 
autophagy sustain the turnover of organelles and regulate protein and organelle 
abundance and quality 151. Autophagy is considered as a cell survival 
mechanism and is activated upon nutrient deprivation, hypoxia and oxidative 
stress, to replenish initial constituents. 
Whilst there are 3 main forms of autophagy, macroautophagy is most prevalent. 
Macroautophagy is mediated through the formation of an invaginated, double-
membrane vesicle, known as an autophagosome, that encapsulates engulfed 
material (figure 1.6). Lysosomes containing degradative lysosomal enzymes 
fuse with an autophagosome to form an autophagolysosome and the contents 
are then degraded. 
Within the heart, autophagy is a cytoprotective mechanism that maintains 
cellular homeostasis and therefore inadequate autophagy may lead to an 
accumulation of harmful proteins, protein aggregates and damaged organelles 
152. However excessive self-degradation of essential cellular constituents 
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promotes cell death 153. As mentioned, autophagic structures have been 
observed in dying and dead cardiomyocytes 129, 150 and in the cardiomyocytes of 
animal models such as UM-7.1 cardiomyopathic hamsters 154. This process is 
not well understood, and it remains unknown whether autophagy is a sign of 













Figure 1.6 The formation of autophagosomes. 
The membrane elongates and encapsulates cytosolic constituents, including 
proteins and organelles in a double membrane vesicle, known as an 
autophagosome. Lysosomes containing lysosomal enzymes dock and fuse with 
autophagosome to form an autophagolysosome and the contents are degraded. 
Adapted from 155. 
 
Autophagy has been observed in pathological cardiac hypertrophy, MI and HF 
151. Interestingly, whilst total protein abundance increases during pathological 
hypertrophy, it was reported that autophagic activity was diminished after 
pressure overload 152, 156, 157. 
Under ischemic and/or hypoxic conditions autophagy is activated, although in 
models to induce MI or I/R injury, the underlying pathways and functional 
consequences differ. During ischemia, activation of adenosine monophosphate-
activated protein kinase (AMPK) leads to induction of autophagy whilst after 
reperfusion, autophagic activity is elevated and associated with Beclin-1 
abundance 158. Therefore it may be considered that autophagic activity during 
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ischemia is protective 159, whereas during reperfusion, autophagy is excessively 
stimulated, possibly leading to cell death.   
Autophagy is upregulated in HF and failing hearts exhibit an increased number 
of autophagosomes 150. Diminished expression of markers of autophagy after 
mechanical unloading of the failing human heart by LV assist devices 160 
suggested that autophagy may be an adaptive mechanism in the failing heart 
151. Whether this increase in autophagy in the pathogenesis of HF is protective 
and associated with cell-survival or deleterious and related to cell death 
mechanism remains unclear. 
 
1.5 Inflammation         
The immune system possesses a variety of strategies to defend the body 
against invasion and attack by pathogens and tumours161 alongside the 
capability to promote tissue repair after injury. Responses of the immune 
system can be partitioned into 2 categories: the acute, abrupt innate response 
and the slower, more specific adaptive immune response. Inflammation is a 
common, initial, fast-acting innate immune defence mechanism that removes 
injurious stimuli and initiates the healing process162. The inflammatory response 
facilitates matrix deposition, removal of dead cells and debris, granulation tissue 
formation and the secretion of cytokine and growth factors 163.  
Detection of foreign substances or injurious stimuli by the complement system 
or tissue-residing macrophages stimulates the release of chemokines, IL8 and 
proinflammatory cytokines, IL1 and TNFα. Complement activation triggers 
degranulation of mast cells, releasing histamine and prostaglandins into the 
extracellular space. The secretion of these mediators instigates dilation of local 
blood vessels and permeabilisation of capillaries, leading to the increased 
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recruitment and extravasation of leukocytes, mainly neutrophils and monocytes 
to the area164. These cells contribute to the inflammatory response by secreting 
inflammatory cytokines and chemokines and using their artillery of weapons to 
combat the invasive agent or phagocytose foreign material or dying cells. 
Inflammation persists until anti-inflammatory mediators suppress it. Excessive 
inflammation can result in damage to the host tissues and lead to 
neurodegenerative and autoimmune disorders164. Therefore, inflammation must 
be tightly regulated to maintain homeostasis and prevent additional tissue 
damage. 
Within the heart, macrophages reside near endothelial cells or within the 
interstitial space 165. While, there are a few dendritic cells and mast cells, there 
are no neutrophils. Cells of the myocardium (cardiomyocytes, endothelial cells, 
fibroblasts) in additional to inflammatory cells (leukocytes, platelets, 
macrophages) contribute to cardiac inflammation. However, the intricate 
mechanisms responsible for initiating and integrating inflammatory responses 
within the heart remain poorly defined. 
 
1.5.1 Toll-like receptors (TLRs) 
Macrophages and dendritic cells are important sensors for detecting infectious 
material. Infectious material is sensed by pattern recognition receptors (PRRs) 
located at the plasma membrane or intracellularly in the cytoplasm or within 
endosomes. Binding of the ligand to the receptors triggers a signalling cascade 
to mediate a co-ordinated and well-orchestrated inflammatory response. 
These PRRs recognise foreign, non-self pathogen-associated molecular 
patterns (PAMPs) as well as endogenous, host-derived danger-associated 
molecular patterns (DAMPs) such as heat shock proteins and mitochondrial 
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DNA (mtDNA) 103, 161. DAMPs are proposed to act as ‘danger’ signals and are 
released during cellular injury or death. A subset of PRRs includes the 
transmembrane (TM) proteins, Toll-like receptors (TLRs). There are 10 TLR 
members in humans, with each TLR specifically recognising a different PAMP 
or DAMP (TLR ligand). The leucine-rich regions (LRR) within structurally 
conserved TLRs mediate recognition of TLR ligands whilst the cytoplasmic-
facing Toll and IL1 receptor-like (TIR) domains associate with an assortment of 
signalling proteins to activate intracellular signalling upon receptor stimulation 
(figure 1.7). TLRs have cell-specific expression and are either expressed at the 
plasma membrane or on endosomal membranes166. Activation of TLRs 
instigates an intracellular signalling pathway with each TLR having a specific 
response, but all activate the inflammatory cascade167. The inflammatory 
response evoked by TLRs can be acute or chronic. However TLRs have been 
reported to possess pro- or anti- apoptotic features alongside the intriguing 








Figure 1.7 Structure of toll-like receptors (TLRs). 
Pattern-recognition receptors such as TLRs are transmembrane (TM) receptors 
that recognise exogenous pathogen associated molecular patterns and 
endogenous danger associated molecular patterns. This is mediated by the 
leucine rich region (LRR) within the N-terminal domain which activates an 





In addition to TLRs, other PRRs include C-type lectins, and cytosolic proteins 
retinoic acid-inducible gene (RIG)-like receptors and nucleotide-binding 
oligomerisation domain (NOD)-like receptors (NLRs) 169. NLRs associate with 
apoptosis-associated speck-like protein containing a caspases recruitment 
domain (ASC) and caspase-1 to form a cytosolic multiprotein complex, known 
as an inflammasome 170. Formation of this complex can be activated by a 
variety of stimuli including ATP, asbestos urate crystals, microbial entities, ROS 
and mtDNA and these complexes are vital defenses against pathogens. 
Inflammasomes are capable of cleaving pro-IL1β and pro-IL18 into active IL1β 
and IL18, using the protease action of caspase-1 171. Both these cytokines are 
crucial in the attack against pathogens, recruiting leukocytes and stimulating a 
powerful inflammatory response.  
   
1.5.2 TLR9 signalling 
Whilst TLRs are preferentially expressed in immune cells, TLRs 1-10 are also 
expressed within the myocardium, with TLR4, a lipopolysaccharide detector, 
most abundantly expressed 172.   In addition to TLR4, there are several reports 
regarding the role of TLR2 (lipoproteins sensor) and TLR3 (endosomal double 
stranded RNA detector) in models of cardiac-related injury. However it has 
previously been reported that TLR9 could potentially stimulate inflammation that 
may contribute to the pathogenesis of HF 173 (section 1.5.3.1). Several reports 
have demonstrated that TLR9 is expressed in cardiomyocytes, cardiac 
fibroblasts and tissue-residing macrophages 174, 175, 176. Therefore there is 
particular interest in TLR9, an endosomal receptor that recognises 
unmethylated DNA motifs in which cytosine triphosphate deoxynucleotide is 
followed by guanine triphosphate deoxynucleotide (CpG), which are found 
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within bacterial and viral DNA 166, 177. Though the human genome possesses 
CpG motifs, these are often methylated and are not recognised by TLR9. In 
contrast, unmethylated CpG motifs are capable of evoking a robust 
immunostimulatory response. TLR9 is also activated by the DAMP, mtDNA 178, 
which also possesses inflammogenic unmethylated CpG motifs.  
Unmethylated CpG motifs bind to the TLR9 receptor, leading to the recruitment 
of the adaptor protein MyD88 to the TIR domain (figure 1.8) 179. MyD88 recruits 
several other signalling intermediates to form a signalling complex, including 
serine/threonine kinase, IL1R-associated kinase (IRAK)-1, IRAK-4 and TRAF6 
179. From this signalling complex, the inhibitor of kappa B kinase (IKK) complex 
consisting of IKKα, IKKβ and IKKγ is activated which in turn phosphorylates 
inhibitor of kappa B (IκBα). This leads to ubiquitin-mediated degradation of IκBα 
and the liberation of the transcription factor, NFκB, which is now free to 
translocate into the nucleus. TRAF6 facilitates the entry of interferon regulatory 
factor (IRF)-5 into the nucleus 180 whilst IRF7 is translocated into the nucleus 
through association between TRAF3, IRAK1, IKKα	  and MyD88 167. NFκB, IRF5 
and IRF7 initiate transcription of proinflammatory cytokines such as IL1 and IL6 
and type 1 IFNs, IFNα and IFNβ	  181.	  The transcription and induction of cytokines 
is a vital step for commencing and maintaining an inflammatory response.  
The downstream signalling of the other TLRs are all MyD88-dependent, 
excluding TLR3 172. However other adaptor proteins and signalling 








Figure 1.8 Toll-like receptor 9 (TLR9) signalling. 
Endosomal located TLR9 recognises unmethylated CpG motifs on DNA. 
Activation of TLR9 leads to the recruitment of the adaptor protein MyD88, which 
forms a complex with IL-1R-associated kinase (IRAK)-4, E3 ubiquitin ligase 
(E3UL) and TNFR-associated factor 6 (TRAF6). E3 ligase ubiquitinates TRAF 6 
enabling regulatory proteins of TAK1, TAB2 and TAB3 to bind to the 
ubiquitinated sites of TRAF 6 (not shown). Activated TAK1 phosphorylates IκB 
kinase (IKK)-β within the IKK complex, which in turn phosphorylates the inhibitor 
of kappa B (IκBα). This phosphorylation leads to degradation of IκBα via the 
ubiquitin–proteasome system and the release of NFκB. NFκB translocates into 
the nucleus and activates the transcription of proinflammatory cytokine genes 
and type 1 interferons. TRAF6 activates interferon regulatory factor (IRF)-5 to 
enter into the nucleus and activate the transcription of proinflammatory cytokine 
genes. In addition, MyD88 also forms a signalling complex with TRAF3, IRAK1 
and IKKα. Phosphorylation of IRF7 by IRAK1 or IKKα enables entry of IRF7 into 






While, the inflammatory nature of TLR9 has been well-studied, evidence 
suggests that TLR9 does not instigate autoimmune or virus-induced myocarditis 
169, 182. Moreover, recent reports have proposed a novel role of TLR9 for 
modulating energy metabolism 183 through inhibition of sarcoendoplasmic 
reticulum calcium ATPase 2 (SERCA2) in cardiomyocytes as a protective 
mechanism against stress 184. In addition, downstream mediators of TLR9 
signalling, NFκB, TNFα and IL6 have multiple roles. Both NFκB and TNFα have 
been reported to be pro-survival and induce and mediate pathological 
hypertrophy responses 185, 186, 187, yet retain the capability to stimulate apoptotic 
and inflammatory effects. This demonstrates the range of actions of cytokines 
and transcription factors and the need to contemplate the initial stimuli as well 
as the immediate upstream and downstream signalling components of the 
inflammatory cascade. 
 
1.5.3 Inflammation in MI and HF  
Inflammation is a contributing factor to the pathophysiology of cardiac diseases 
and remodelling. Short-term activation of TLR signalling induces cytoprotective 
responses within the heart, whereas long-term TLR signalling is maladaptive 
leading to cell death, ECM degradation and fibrosis, which alter cardiac 
morphology and function 172. This highlights the double-edged nature of 
inflammation and the balance between insufficient and excessive inflammation.  
After myocardial injury such as MI, ECM degradation and cardiomyocyte death 
induce the release of mediators which activate innate immune sensors, 
instigating an inflammatory response. In addition, the release of DAMPs from 
necrotic cells leads to PRR and inflammasome activation, inflammation and 
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necrosis. These pro-inflammatory activities mediate the clearance of dead cells 
and debris and initiate the repair and remodelling responses. 
In chronic HF patients, increased levels of circulating proinflammatory 
cytokines, such as TNFα19, IL6 and IL1β20, 21 correlate with the progression and 
severity of the condition and could be considered as independent predictors of 
prognosis. Several studies have shown that β-blockers possess anti-
inflammatory properties 188, 189 emphasising the potential benefits of developing 
treatments to modulate inflammation within HF patients. Unfortunately, clinical 
trials that modulate the inflammatory response through anticytokine and 
immunomodulatory therapy in HF patients have been disappointing. Therapies 
designed to target TNFα include an anti-TNF antibody (infliximab) 190 and 
soluble TNF inhibitory receptors (etanercept) 191, both of which were promising 
in preclinical models, but were unsuccessful in clinical trials. Both thalidomide 
192, 193 and pentoxifylline 194, 195 (a xanthine derivative) have multiple modes of 
immunomodulatory actions including minimising the effects of TNFα. However 
clinical data have been mixed. Experimental studies targeting leukocyte-
mediated inflammation (activation, adhesion and extravasation) in reperfused 
myocardium were extremely successful, with marked reductions in infarct size 
and prevented extension of ischemic cardiomyocyte injury 196, 197. However in 
MI-patients, these treatments were unsuccessful 198. Though it remains 
unknown why these treatments failed in clinical trials, one possible reason why 
these therapies were unsuccessful could be the temporal and spatial aspects of 
inflammation. There are acute and chronic inflammatory responses with 
different types and numbers/levels of cells, cytokines and other inflammatory 
mediators observed during these diverse stages of an inflammatory response 20, 
172. An example includes the multi-phase inflammatory response observed after 
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MI (discussed in chapter 5). Furthermore, cytokines are reported to be 
temporally regulated by circadian regulations (mediated by circulating 
hormones) which also be another contributing factor 199. Also, different tissue 
compartments may yield differential immune responses, therefore a general and 
systemic approach to targeting myocardial inflammation may not be appropriate 
and a more targeted approach (in terms of specific timing and location) may be 
more successful in treating HF.  
Thus the ineffectiveness of these therapies demonstrates the need to 
understand the mechanisms of inflammation. An additional layer of complexity 
is added by the complicated and varied nature of inflammation and 
inflammatory mediators in injury and repair. It has been proposed that 
interactions of the immune system with the neurohormonal system may induce 
systemic inflammation observed in HF 21, amid one study suggesting that 
proinflammatory cytokines may uncouple β-ARs 200.  
 
1.5.3.1 Autophagy, TLR9 and HF 
Inflammation has been implicated with the pathogenesis of HF, yet exposure to 
infectious agents is unlikely to be the causative agent. Therefore the prospect of 
sterile inflammation or inflammation without a foreign component was 
suggested 20. Release of host cellular components including DAMPs into the 
extracellular environment from necrotic cells could be one form of sterile stimuli 
alongside mechanical trauma, ischemia and toxins. It has previously been 
reported that partially digested mtDNA arising from incomplete stress-induced 
autophagy triggered chronic myocardial inflammation and HF 173.  
Cardiac-specific deletion of deoxyribonuclease (DNase) II, an acidic DNase in 
the lysosome accumulated mitochondrial DNA within autophagosomes 
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provoked a robust inflammatory response after pressure overload.  
Interestingly, inhibition or genetic-ablation of TLR9 attenuated this cardiac 
inflammation and dysfunction associated with this model, indicating that this 
inflammatory response was mediated through TLR9 173. Therefore, these 
findings suggest that mtDNA that escapes autophagy induces TLR9-mediated 
inflammation and HF, suggesting a potential pathway for stress-induced sterile 
inflammation that may contribute to the pathogenesis of HF.  
The role of TLR9 within the myocardium is an avenue of current interest.  
Pressure overload induced myocardial inflammation and cardiac remodelling is 
mediated by TLR9 173. TLR9-deficient mice subjected to pressure overload, 
displayed reduced cardiac dilatation, hypertrophy, fibrosis and pulmonary 
congestion together with improved cardiac function compared to WT mice.  
Synthetic oligonucleotides (ODN) containing CpG motifs are used to study the 
effects of TLR9 stimulation. Priming or administering (before or after induction 
of hypertrophy) mice with CpG-ODN attenuated the development of hypertrophy 
and HF 174, 201. Furthermore in a septic model, it was reported that bacterial 
DNA induced myocardial inflammation and reduced cardiomyocyte contractility 
202 and that in vivo inhibition of TLR9 ablated that dysfunction 203. Therefore 
TLR9 may be an important sensor within the healthy and stressed myocardium 
and its potential role within sterile inflammation may contribute to HF.  
An alternative mechanism of sterile inflammation involves the inflammasome . 
Within the myocardium, NOD1 and NLRP3 have been shown to participate 
within inflammasomes 170.  mtDNA and ROS have been reported to activate the 
NLRP3 inflammasome and reports of activated NLRP3 inflammasome after 
ischemia and I/R injury indicate that this complex had adverse consequences 
on cardiac remodelling 169.  
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1.6 Mechanisms of HF 
As mentioned previously, there is an assortment of biochemical and mechanical 
abnormalities associated with HF. Besides cardiac remodelling, additional 
characteristics of HF include alterations in the expression and downstream 
signalling of the β-ARs, calcium handling, metabolism and oxidative stress 66, 
204, 205, 206, 207. These features are discussed below as well as their contributions 
to the progression of HF. 
 
1.6.1 β-AR signalling  
As a component of the neurohormonal system, the sympathetic nervous system 
interacts with the cardiovascular system through AR. This interaction occurs is 
mediated by the release of the neurotransmitters, epinephrine and 
norepinephrine to modulate myocardial performance 204.  
Within the human body, there are 2 types of AR– α and β 208, 209, with 3 different 
β-AR sub-types (β1, β2, β3). Though, α1- and β- ARs are expressed in the 
myocardium, 75% of β-ARs are β1-AR receptors 210. Since β1-AR is the most 
abundant sub-type within the myocardium, this section will focus on the 
signalling pathway downstream of this receptor. 
β-ARs are G-protein coupled receptors (GPCRs) possessing 7 TM helices that 
associate with an intracellular G-protein 208, 211. The heterotrimeric G-protein 
contains 3 polypeptides chains, α, β, γ, that form 2 distinct subunits: Gα and 
Gβγ 212. In the guanosine diphosphate (GDP)-bound state, Gα and Gβγ form a 
functionally inactive heterotrimer (figure 1.9). When the receptor is activated 
and undergoes a conformational change, the G-protein exchanges GDP for 
guanosine triphosphate (GTP). The G-protein dissociates into 2 subunits, Gα-
GTP and Gβγ, which subsequently activates downstream signalling molecules. 
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Both β1- and β2- ARs have a Gαs stimulatory subunit which activates adenylate 
cyclase upon receptor stimulation 204, 211. This leads to an increase in cyclic 
adenosine monophosphate (cAMP) levels and activation of protein kinase A 
(PKA). This serine/threonine kinase targets many proteins including metabolic 
enzymes, ion channels and transcription factors.  
 
 
Figure 1.9 β-adrenergic receptor (β-AR) signalling.  
In the inactive state, guanosine diphosphate (GDP) is bound to the G-protein 
(Gαs/Gβγ). However, binding of the ligand to the β-AR leads to nucleotide 
exchange to guanosine triphosphate (GTP) and dissociation of Gαs and Gβγ. 
The Gαs subunit activates adenylate cyclase (AC), increasing cyclic adenosine 
monophosphate (cAMP) levels. This subsequently stimulates protein kinase A 
(PKA) which phosphorylates the ryanodine receptor (RyR), phospholamban 
(PLN) and contractile proteins (troponin (Tpn) I), leading to positive inotropic 
and chronotropic effects. However PKA phosphorylates G-protein-coupled 
receptor kinases (GRKs), which can phosphorylate a ligand-bound β-AR that 
enable binding of β-arrestin to the third intracellular loop and the carboxyl tail of 
the receptor. This leads to the internalisation of the receptor into the cytosol, 
where the ligand and β-arrestin are removed and the receptor is returned to the 
plasma membrane (PM). Additionally, hydrolysis of GTP by GTPases enables 
reformation of the heterotrimeric G-protein and inactivates downstream 
signalling. Adenosine triphosphate (ATP), sarcoendoplasmic reticulum calcium 




Within cardiomyocytes, PKA phosphorylates L-type voltage-operated calcium 
channels (VOCC) at the plasma membrane, ryanodine receptors (RyR) and 
phospholamban (PLN) at the SR membrane, contractile proteins (Tpn I) and G-
protein-coupled receptor kinases (GRKs) 213, 214. Thus, activation of β1-ARs 
contributes to enhanced calcium activity within the cytosol, increased contractile 
force of the muscle (positive inotropic effect) and elevated HR (positive 
chronotropic effect), leading to increased CO 204, 214. In addition, the Gβγ 
subunit induces phosphorylation and activation of ERK1/2, which activates the 
cardiac hypertrophy response downstream of the β-AR 215. β2-ARs may also 
couple to Gαi, an inhibitory subunit which diminishes adenylate cyclase activity 
and has anti-apoptotic properties 216. Therefore, β-AR signalling is essential for 
maintaining cardiac function in response to stress, a condition which activates 
AR signalling.  
High levels of catecholamines are toxic to cardiomyocytes as enhanced calcium 
activity may induce apoptosis through calcineurin activation 217. Therefore, β-AR 
activation is tightly regulated. Feedback mechanisms downstream of ARs 
include receptor phosphorylation by several kinases including PKA and protein 
kinase C (PKC), but is largely executed by serine/threonine targeting GRKs 213. 
GRK2 (β-ARK1) is predominantly expressed in the myocardium, alongside 
GRK3 (β-ARK2), GRK5 and GRK6 218. Phosphorylation of activated ARs 
enables binding of β-arrestin to the receptor, preventing the coupling of Gαs to 
the receptor 204, 214, 219. This loss of functional β-AR signalling is known as short-
term desensitisation. Long-term desensitisation involves internalisation of the 
receptor and regulated gene expression of the receptor and downstream 
signalling proteins 204.  
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1.6.1.1 β-AR signalling in HF 
β-AR signalling is dramatically changed during HF. Initial strain on the heart 
decreases CO, triggering the release of epinephrine and levels of circulating 
catecholamines are increased in HF patients 17, 18. Activation of the β-ARs 
stimulates myocyte contractility and HR to maintain CO, as part of a 
compensatory mechanism 220. This initially is favourable, however long term β-
AR stimulation leads to β-AR decoupling, β-AR desensitisation and 
internalisation of β-ARs from the plasma membrane of cardiomyocytes 183. 
Thus, interactions between the sympathetic nervous system and the 
myocardium are minimised, with a direct impact on myocardial performance in 
terms of calcium handling and cardiomyocyte contractility 204, 214, 219. Calcium 
mishandling and the subsequent activation of apoptosis contribute to the 
progression of HF 204, 214, 219. At a molecular level, the expression of β1-AR 
declines whilst β2-AR expression is maintained changing the ratio of β1-ARs : 
β2-ARs from 70:30 to 50:50 210. In addition, myocardial GRK2 221, 222 and Gαi 223  
levels are significantly elevated in human HF, which may contribute to the loss 
of β-AR responsiveness observed in this condition. In addition, several in vitro 
studies have shown immunomodulatory effects of β-AR activation, linking 
immune modulation, excessive catecholamine stimulation and β-AR signalling 
224, 225. Thus, β-AR signalling is thoroughly compromised in HF.  
 
1.6.2 Calcium handling  
Calcium is a critical regulator of cardiomyocyte contractile function, connecting 
the electrochemical signals that saturate the heart to the overall contraction of 
the myocardium. The major participants of calcium homeostasis and handling 
include RyRs, VOCCs and calcium pumps and transporters 205, 225.  
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As a wave of electrical excitation spreads across the heart, the plasma 
membrane of cardiomyocytes becomes depolarised. L-type VOCC, located 
within the T-tubules open to admit a small amount of calcium into the cytosol 
that binds to the cytosolic face of the RyR 226 (figure 1.10). This causes RyRs 
to open, leading to an influx of calcium into the cytosol from the SR, referred to 
as calcium-induced calcium release (CICR) 227. Additionally, a small amount of 
calcium is imported from extracellular sources. Cytoplasmic calcium 
concentration increases 100-fold and binds to the contractile protein, Tpn C 
stimulating myocardial contraction.  
Relaxation is mediated by the closure of calcium entry channels and calcium is 
rapidly imported into the SR by SERCA or exported into the extracellular space 
by sodium calcium exchanger (NCX) 205, 225. Therefore, the amplitude and 
duration of a calcium transient can modulate the rate, magnitude and duration 







Figure 1.10 Calcium handling. 
Upon cellular depolarisation, L-type voltage-operated calcium channels 
(VOCC), located within the T-tubules open to admit a small amount of calcium 
into the cytosol. This calcium binds to the cytosolic face of the RyR, causing the 
channel to open and an influx of calcium into the cytosol from the SR, known as 
calcium induced calcium release (CICR). An increase of 100-fold in calcium 
cytosolic concentration enables myocardial contraction though association with 
Troponin C (TpnC). Upon relaxation, calcium is quickly transported into the SR 
by ATP-dependent function of sarcoendoplasmic reticulum calcium ATPase 





The opening of L-type VOCC upon membrane depolarisation is vital for the 
initial entry of calcium, which acts as the trigger for SR calcium release. PKA-
dependent phosphorylation increases channel activity 228 whilst the effects of 
PKC phosphorylation remain unknown. Inactivation of the L-type VOCC is 
mediated by membrane repolarisation and calcium dependent inactivation 
controlled by calmodulin (CaM) and CaMKII 229.  
The RyR are located close to T-tubules to facilitate CICR. RyR2 is the prevalent 
cardiac isoform that associates to form a tetrameric complex with each 
monomer weighing 500 kDa. In addition, RyR2 acts as a scaffolding protein with 
a multitude of accessory proteins. The structure of the RyR was recently 
published 230, 231 and the mechanism of CICR may soon be established. 
Currently it is hypothesised that the initial binding of calcium causes 
conformational changes, twisting the TM region to open the ion pore, to allow 
influx of calcium into cytosol from SR 232.   
RyR2 activity is tightly regulated by several mechanisms. Whilst PKA and 
CaMKII phosphorylation increases RyR activity, protein phosphatases PP1 and 
PP2 decrease calcium activity 233, 234. Both the calcium-binding proteins, 
calsequestrin and calmodulin, are capable of binding to RyR2, decreasing 
calcium efflux through these channels 229.  
Uptake of calcium into the SR is mediated by SERCA using energy from ATP 
hydrolysis. Though 3 isoforms of SERCA have been identified, SERCA2 is the 
major form expressed in cardiomyocytes 235. SERCA activity directly influences 
cytosolic calcium content and the rate of myocardial relaxation. SERCA activity 
is regulated by the 52 amino acid TM protein, PLN 229. Unphosphorylated 
monomers of PLN associate with SERCA2 diminishing the affinity of SERCA2 
for calcium. However, phosphorylation of PLN induces formation of a pentamer 
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and relieves inhibition of SERCA2, leading to increased SERCA2 activity and 
SR calcium accumulation. Phosphorylation of PLN is mediated by CaMKII or 
cAMP dependent kinases at Serine-16 (PKA) or at Threonine-17 (PKC) 236. 
Modulation of PLN-mediated SERCA inhibition is a major mechanism for acute 
enhancement of cardiac function following β-AR activation.  
The NCX located on the plasma membrane uses the electrochemical gradient 
to expel 1 calcium ion whilst importing 3 sodium ions. The NCX can be reversed 
following depolarisation, leading to calcium entry and sodium efflux 229. 
Although phosphorylation of NCX by PKC and PKA has been described 237, 238, 
the effects remain unknown, though it is established that interactions with TM 
protein, phospholemman inhibits NCX activity 239. 
Subtle modifications in calcium regulatory and handling proteins as a result of 
mutation, disease or chronic changes in haemodynamic demand have profound 
consequences for cardiomyocyte function. During adaptive hypertrophy, 
increases in the amplitude of calcium transients and sparks as well as 
enhanced SR store loading have been reported 2, 70, 229. Elevated SERCA2 
activity is proposed to be caused by increased SERCA expression, decreased 
PLN expression and increased PLN phosphorylation. In addition, a decrease in 
NCX current and an increase in RyR activity have been noted in this adaptive 
phase 208.  
As the heart progresses to failure, further changes in calcium handling are 
observed and a general decrease in the amplitude of calcium transient has 
been noted 205. The density of the L-type VOCC is reduced in HF samples, 
though the calcium current is maintained by PKA-mediated phosphorylation of 
the channels 240. In addition, it has been proposed that abnormal RyR2 function 
is involved in dysregulated calcium handling in HF, with hyperphosphorylation of 
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RyR2 triggering spontaneous RyR2-mediated SR calcium leakage. This leads 
to depressed SR calcium content and delayed myocardial contraction which 
may contribute to the development of ventricular tachycardia 205, 241.  
Most studies have found that SERCA activity is reduced in HF, which increases 
diastolic calcium levels (associated with diastolic dysfunction), prolongs 
myocyte relaxation and reduces SR calcium content (reduced systolic 
performance) 205, 229, 242, 243. This could be due to the abundance of PLN, 
reduced phosphorylation of PLN and the expression of SERCA, which have all 
been detected in failing heart samples. 
Further, the abundance and activity of the NCX is increased in HF 205, 244 and its 
activity to remove cytoplasmic calcium is increased, which is likely to be due to 
the impaired SERCA2 activity. Also, reverse-mode NCX activity has been 
reported which may contribute to diastolic dysfunction 244.  
Thus calcium handling is essential to maintaining cardiomyocyte function and 
alterations in the expression, activity and post-translational modifications of the 
proteins involved greatly influence the progression of HF.  
   	    
1.6.3 Metabolism 
Due to the contractile nature of the myocardium, cardiomyocytes require a 
constant supply of ATP. Therefore ATP consumption in myocardial tissue is 
very high and turnover is rapid. However a low intracellular content means that 
ATP can be completely consumed within seconds if ATP production is 
interrupted. As myocardial contraction directly correlates with the rate of ATP 
generation, impairments in ATP generation may induce contractile dysfunction. 
Under normoxic conditions, oxidative phosphorylation in the mitochondria of a 
healthy heart generates more than 95% of cardiac ATP 245. The remaining 5% 
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is obtained from glycolysis and to a lesser extent, the tricarboxylic (TCA) cycle. 
Electrons power oxidative phosphorylation, which are derived from 
dehydrogenation reactions that occur during β-oxidation, TCA cycle, glycolysis 
and pyruvate decarboxylation (figure 1.11). The electron-carrying 
intermediates, nicotinamide adenine dinucleotide (NADH) and flavin adenine 
dinucleotide (FADH2), acquire electrons from carbon fuels and transfer them to 
the oxidative phosphorylation machinery. In a healthy heart, β-oxidation of fatty 
acids (FAs) is the dominant source of electrons, providing 60-90% of cardiac 
ATP whilst the remaining proportion is derived from carbohydrates, (glucose, 
pyruvate and lactate), amino acids and ketones 246, 247. The metabolic flexibility 
to utilise different carbon sources permits changes to substrate utilisation in 
response to altered substrate availability or altered regulation of metabolic 
pathways. 
As mentioned above, FAs are crucial for ATP generation 248. Free FAs are 
transported into the cytosol by transporter proteins, where they are esterified 
into fatty acyl-coenzyme A (CoA) 249 (figure 1.11). This is then transported 
across the mitochondrial membrane by carnitine palmitoyltransferase 1 (CPT1) 
and CPT2 250. Once inside the mitochondria, Acyl-CoA undergoes β-oxidation, 
generating acetyl-CoA, NADH and FADH2. Acetyl-CoA feeds into the TCA cycle 
whilst NADH and FADH2 fuel mitochondrial oxidative phosphorylation.  
Aside from FAs, the other major carbon source utilised within the myocardium is 
glucose, which can be derived from glycogen stores. However the majority of 
glucose is absorbed from the blood, facilitated by insulin-independent glucose 
transporters 1 (GLUT1) and insulin-sensitive GLUT4 251 (figure 1.11). Once in 





Figure 1.11 Metabolic pathways in cardiomyocytes. 
Both glucose and fatty acids (FAs) are metabolic sources of electrons used to 
power the electron transport chain to generate ATP. The majority of cardiac 
metabolism is mediated by FA oxidation. FAs enter the cytosol by FA 
transporter (FAT) proteins and esterified into fatty acyl-coenzyme A (CoA). Fatty 
acyl-CoA is transported across the mitochondrial membrane by carnitine 
palmitoyltransferase 1 (CPT1) and CPT2 and undergoes β-oxidation of FAs, 
generating acetyl-CoA. Acetyl-CoA is also generated from glucose, which is 
transported into the cytosol by glucose transporters (GLUT) and directly 
phosphorylated to glucose-6-phosphate (G6P). G6P can be used for glycogen 
synthesis and the pentose phosphate pathway (PPP) but the majority is 
directed towards glycolysis, which yields pyruvate. Pyruvate is either converted 
to lactate which is exported from the cell by monocarboxylate transporter (MCT) 
or pyruvate is transported into the mitochondria by the mitochondrial pyruvate 
carrier (MPC) to undergo pyruvate decarboxylation by pyruvate dehydrogenase 
(PDH) producing acetyl-CoA. Generation of acetyl-CoA is used to fuel the TCA 
cycle. Electrons from nicotinamide adenine dinucleotide (NADH) and flavin 
adenine dinucleotide (FADH2) are imparted to the electron transport chain, 
which generates an electrochemical gradient to power ATPase, yielding ATP. 
IMS = intermitochondrial space. Adapted from 248. 
 
G6P can be further used in a multitude of pathways, such as glycogen 
synthesis and the pentose phosphate pathway (PPP). Usually, G6P undergoes 
glycolysis, yielding pyruvate, NADH and small amount of ATP. This ATP is 
thought to be used for calcium uptake into the SR by SERCA activity and 
61 
 
diastolic relaxation 248, 251. The pyruvate is then either converted to lactate by 
LDH (anaerobic metabolism) or transported into the mitochondria to undergo 
oxidation to acetyl-CoA.  
As mentioned, both β-oxidation of FAs and pyruvate decarboxylation yield 
acetyl-CoA, which is consumed by the TCA cycle to provide additional sources 
of electrons. In addition, the carbon intermediates of the TCA cycle are 
replenished by anaplerosis, a crucial process in the heart 252.  
Thus, the regulation of myocardial metabolism is linked to carbon substrate 
concentration, hormones, coronary flow, inotropic state and the nutritional 
status of tissue.  
 
1.6.3.1 Metabolism in HF  
Many studies have proposed that impaired substrate metabolism contributes to 
contractile dysfunction and progressive LV remodelling 2, 66, 206, 251. However, 
metabolic phenotypes differ between HF of different causes and at different 
stage of HF. During compensated hypertrophy, glycolysis modestly increases 
253. When hypertrophy becomes maladaptive and systolic dysfunction occurs, 
the myocardium switches to a preference for carbohydrate sources 206, 245, 248, 
251. The foetal heart preferentially utilises carbohydrates sources, which is also 
observed during cardiac hypertrophy, consistent with re-expression of foetal 
genes. In addition, there is accelerated glycolysis and a higher rate of glucose 
uptake but surprisingly no changes in expression of glycolytic enzymes 254. 
However there are no changes in glucose oxidation, although increased activity 
of LDH has been reported alongside elevated efflux of lactate from the 
myocardium 251.  
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Conversely, FA uptake and oxidation are reduced in HF 248. The expression of 
enzymes involved in these processes such as, long chain acyl CoA 
dehydrogenase, medium chain acyl CoA dehydrogenase as well as FA 
transporter, CPT1b, are reduced in compensated hypertrophied hearts and 
dysfunctional hearts though no changes in CPT1a are seen 255, 256. Changes in 
FA oxidation have been suggested to be caused by reduced expression of 
peroxisome proliferator-activated receptor alpha (PPARα) 257. This nuclear 
receptor is upregulated by FA levels and promotes FA uptake and oxidation and 
reduced expression of PPARα has been reported in HF 258. Additionally, studies 
in HF patients exhibit diminished ATP content, increased ADP levels and 
reduced activity of the oxidative phosphorylation machinery 245, 259, 260 alongside 
transcriptional regulation of genes involved in mitochondrial oxidative 
metabolism 257. Commonly the change in substrate preference from FAs to 
glucose does not occur until end-stage HF, but is dependent upon the aetiology 
of the condition 245, 248. 
 
1.6.4 Redox signalling and oxidative stress 
Redox signalling involves the oxidation or reduction of cellular signalling 
pathway components by reactive species. This process is involved in 
electrochemical coupling and cell differentiation and is further associated with 
pathological processes such as adaptation to hypoxia/ischemia, cardiac 
remodelling (fibrosis, hypertrophy, cell death), calcium dysregulation and 
contractile dysfunction 207. 
Oxidative stress occurs when the production of reactive species exceed the 
capacity of antioxidant defence. Reactive species include ROS, which 
encompasses both highly reactive, unstable, free radicals (superoxide and 
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hydroxyl radicals) and less reactive, more stable non-radical forms (hydrogen 
peroxide) 261.  
ROS are by-products of aerobic metabolism, therefore highly metabolising 
tissues, such as the myocardium, are abundant with ROS. In the myocardium, 
sources of ROS include NADPH oxidases, xanthine oxidase and the electron 
transport chain 207, 261. However, minimal levels of ROS are maintained by the 
presence of antioxidant mediators and the enzymes, superoxide dismutases, 
catalases and peroxidases.  
Oxidative stress is an intrinsic mechanism in cardiac remodelling and in the 
development of cardiac hypertrophy and HF, contributing to the structural and 
functional changes associated with these conditions 2, 66, 261. Increased oxidative 
stress leads to oxidation and damage of macromolecules (DNA, lipids and 
proteins), membranes and enzymes involved in cellular structure, function and 
homeostasis 262, 263. In addition, ROS regulate growth and hypertrophic 
pathways, thereby promoting cardiomyocyte remodelling 207, 261. Both collagen 
synthesis and MMP activity are regulated by oxidative stress 207, 264, 265. ROS 
can initiate apoptosis and necrosis whilst other studies suggest that ROS alter 
calcium transients and electrochemical coupling by increasing the activity of 
NCX leading to calcium overload 266. Thus oxidative stress and increased ROS 
production may have adverse effects on cardiac remodelling. 
Systemic and myocardial oxidative stress have been noted in HF patients. 
These include increases in lipid peroxidation, circulating levels of 
myeloperoxidase and 8-isoprostanes in addition to increased oxidation of 
glycoproteins, protein and DNA 267, 268, 269, 270. Therefore measurements of 
markers of oxidative stress such as pentosidine, 8-oxo-2’-deoxyguanosine (8-




Myocardial ischemia occurs when there is an inadequate supply of blood to the 
heart. This is commonly caused by blocked or reduced blood flow, halting 
oxidative phosphorylation within cardiomyocytes. Cellular ATP is depleted 
which has disastrous ramifications on cardiomyocytes in terms of relaxation of 
myofilaments. In addition, reduction in glycogen stocks, disruption of the ionic 
equilibrium and cellular swelling are consequences of ischemia and diminished 
ATP levels. Ischemia is prominent during cardiac remodelling and evokes LV 
dysfunction, enhanced levels of catecholamines, apoptosis and stunning / 
hibernation of cardiomyocytes 274 (figure 1.12a). 
Due to cessation of aerobic respiration, there is a shift towards anaerobic 
respiration, depleting glycogen stores and an accumulation of hydrogen ions, 
inducing tissue acidosis 263, 275. To counteract the acidosis, the sodium-
hydrogen exchanger is activated, with an efflux of hydrogen ions balanced by 
the influx of sodium ions. However the increasing cytosolic sodium 
concentration stimulates the reverse action of the NCX, leading to an influx of 
calcium into the cytoplasm 263. Due to ATP depletion, SERCA activity is 
unavailable, leading to a build-up of calcium ions in the cytoplasm, which 
activates numerous intracellular degradative enzymes that damage cellular 
structures and can lead to cell death. Calcium is passively imported into the 
mitochondrial matrix by the mitochondrial calcium uniporter and mitochondrial 
calcium overload is a stimuli for MPT, leading to apoptosis 130, 276 (figure 1.12a). 
If the ischemia is severe and ionic imbalances are sustained, this cytosolic and 
mitochondrial calcium overload will induce irreversible cellular injury.  
Reperfusion of an ischemic tissue may reverse these effects and restore normal 
myocyte contractile function, if the duration of ischemia is brief. However, it was 
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demonstrated that reperfused myocardium displayed greater pathological 
injuries, such as myocyte swelling, plasma membrane disruption and dense 
mitochondrial bodies compared to non-reperfused myocardium that was 
subjected to the same ischemic duration 277. Thus the concept of I/R injury was 
established in which reperfusion itself, triggers myocardial injury beyond that 
caused by ischemia. Prime mediators of I/R injury include the rapid correction of 
intracellular acidosis, myocyte calcium overload and oxidative stress 278 (figure 
1.12b). Under ischemia, acidosis reduces the reverse activity of NCX, inhibits 
MPT and prevents the activation of cytoskeletal-degrading calcium-dependent 
proteases, known as calpains 279. However upon reperfusion, the washout of 
hydrogen ions alleviates acidotic inhibition, inducing injury of reperfused 
myocytes. Upon reperfusion, myocyte calcium overload after ischemia is not 
amended, but is further exacerbated 263.  The washout of hydrogen ions favours 
sodium-hydrogen exchanger activity, with an influx of sodium ions, which 
activates the reverse action of the NCX. The resulting elevated cytosolic 
calcium levels lead to cytosolic and mitochondrial calcium overload, inducing 
cardiomyocyte injury by MPT induction, activation of calpains and myocyte 
hypercontracture 278. Additionally, reperfusion of ischemic tissue results in a 
sudden burst of ROS which overwhelms the capacity of the cell to scavenge 
these intermediates, evoking a state of oxidative stress 274, 280.  ROS are 
capable of inducing MPT which enables the release of additional free radicals 
that can trigger MPT in other mitochondria, termed ‘ROS-induced ROS release’ 
281. Moreover, ROS damage calcium handling proteins, lipids and DNA thereby 
contributing to calcium overload, lipid peroxidation, protein cross-linkage and 
DNA oxidation. There are multiple sources of increased ROS in the reperfused 
cardiomyocyte. A major contributor of ROS after reperfusion is xanthine oxidase 
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as well as the electron transport chain as a result of incomplete reduction of 
oxygen 280. Additionally, I/R injury results in the influx of leukocytes which 
















Figure 1.12 Damaging pathways of ischemia and ischemia-reperfusion 
(I/R) injury 
A, Ischemia leads to neurohormonal activation and anaerobic metabolism, of 
which the latter induces acidosis, which activates sodium-hydrogen exchanger 
(importing sodium and exporting protons) and the reverse action of the sodium-
calcium exchanger (importing calcium and exporting sodium) which 
subsequently leads to calcium overload. This results in myocardial stunning and 
induction of mitochondrial permeability transition (MPT), leading to apoptosis 
and activation of calpains, which degrade cellular structural and functional 
proteins. B, Reperfusion of an ischemic tissue leads to correction of intracellular 
pH and ROS generation inducing a state of oxidative stress. These ROS 
damage membranes and induce MPT. In addition reperfusion enhances 
calcium overload, by favouring sodium-hydrogen exchanger activity which 
further increase intracellular calcium levels, by the reverse action of the sodium-
calcium exchanger. Increased calcium levels lead to MPT induction, activation 




1.7 Animal models of HF 
Despite advancements in understanding the molecular processes that 
contribute to the pathogenesis and progression of HF, prognosis remains poor 
with current treatments. However, with the incidence of HF anticipated to 
increase, it is necessary to comprehend the mechanisms of this syndrome to 
develop novel therapies for treatment. In this context, animal models have a 
major role in devising potential therapeutic strategies.  
A wide variety of animals, including dogs, rabbits and rats, have been used to 
model a wide variety of cardiac-related diseases. However the popularity of the 
mouse has leapt in the last two decades since its genome was successfully 
sequenced, which has enabled researchers to manipulate the murine genome, 
generating mice of different genetic backgrounds (knockouts, overexpression, 
knockins). This technology has enabled researchers to further understand the 
role of particular proteins within the healthy and injured (using models 
discussed below) heart. Several pre-clinical hypertrophy and HF models have 
been established in mice including transverse aortic constriction (TAC), 
coronary artery ligation to induce MI and catecholamine infusion 282, 283, 284. 
Disadvantages of using mice include the ethical dilemma of using animals as 
well as the initiating cause and speed at which hypertrophy and HF develop. In 
humans, these conditions may progress naturally over months to years, 
whereas in mice these conditions (hypertension, pressure overload) are 
synthetically orchestrated to occur over a period of days to weeks.  Other 
disadvantages of using mice include the differences in HR (human = 60 - 100 
bpm, mouse = 500 - 600 bpm) and lifespan (human = 70 years, mouse = 2 - 3 
years). However, compared to other animal species, mice have large litters, 
short gestation times, low maintenance and housing expenses and recent 
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technological advancements to measure haemodynamic parameters in small 
animals have prevailed. Thus, alongside the ability to manipulate the murine 
genome, the mouse has become a popular choice for studying the 
pathogenesis of HF and models using mice have provided much knowledge 
about the heart and the mechanisms by which the heart progresses to failure. 
 
1.7.1 Model of pressure overload-induced remodelling 
Hypertensive patients develop hypertrophy as a result of perpetually increased 
afterload. In these situations, the LV elevates the systolic BP to eject an 
adequate SV, known as pressure overload. Banding of the ascending, 
transverse or descending aorta is established as a preclinical model of pressure 
overload 285 and can be used to study the progression of hypertrophy to HF. 
Additionally, the tightness of banding can be modified to derive different HF 
phenotypes (compensatory hypertrophy, decompensated hypertrophy, acute 
HF) with different timecourses 286. Low mortality and cardiac remodelling are 
associated with this model 287. 
 
1.7.2 Model of volume overload-induced remodelling 
Patients with chronic mitral or atrial regurgitation acquire a constantly elevated 
LV cavity volume, known as volume overload.  Under these conditions, CO is 
maintained by elevated SV, which is sustained by an increase in preload. Over 
time, the myocardium dilates and end-diastolic volume increases. In mice, to 
mimic the progression of volume overload to HF, an aortocaval shunt can be 
created between the abdominal aorta and inferior vena cava 288. This model 
induces eccentric cardiac hypertrophy, developing into cardiac dilatation and 




1.7.3  Models of MI and I/R injury 
MI is a unique stress of the myocardium associated with increased preload, 
increased afterload and cardiac remodelling. Ligation of the left anterior 
descending (LAD) coronary artery can be used to investigate the remodelling 
after MI 289, and its pathogenesis to HF. Wall thinning, infarct development and 
activation of wound repair responses are attributes of this model, alongside the 
haemodynamic changes seen in MI patients.  
Research into the mechanisms that induce I/R injury is an area of active interest 
due to the poor recovery of ischemic tissue. Models of reperfusion after 
ischemia have been established to study the mechanisms of I/R and myocardial 
stunning 290, 291. I/R injury can be performed in vivo with ligation executed as 
described above with a small tube present to ease relief of the occlusion and 
enable reperfusion. This model is associated with the typical features of I/R 
injury including infiltration of inflammatory cells, attenuated fibrotic remodelling 
and enhanced neovascularisation 292. Additionally, I/R injury can be examined 
ex vivo using the Langendorf system 293. The heart is explanted and mounted 
onto a perfusion system and supplied with nutrients to maintain cellular 
energetics. This system is capable of evaluating the pathophysiological and 
electrophysiological consequences of I/R injury. 
 
1.7.4 Neurohormonal models 
As mentioned previously, enhanced activation of the sympathetic nervous 
system is commonly observed in HF patients and is proposed to contribute to 
cardiac dysfunction. Elevated levels of catecholamines are observed in these 




Catecholamines are an organic chemical group, which encompasses 
endogenous signalling hormones, epinephrine and dopamine as well as 
synthetic entities such as isoproterenol (Iso). Within the body, catecholamines 
act as signalling molecules that bind to ARs to prepare the body for physical 
action. As mentioned in section 1.6.1, the adrenergic signalling cascade plays 
a fundamental role in hypertrophy and its development to HF.  
In addition to Ang II or insulin-like growth factor 1 infusion, Iso is commonly 
used to investigate pathological ventricular remodelling associated with 
hypertrophy 282. Although Iso is structurally similar to epinephrine, it has a 
higher affinity for the β-AR than epinephrine and norepinephrine 294. Over the 
past sixty years, Iso infusion has been implemented as a successful model of 
hypertrophy with infusion inducing LV hypertrophy, fibrosis and cell death in rats 
and dogs  295, 296, 297, 298.  
As a β-AR stimulant (β-stimulant), Iso binds to β-ARs and activates intracellular 
signalling pathways downstream of these receptors. However, chronic infusion 
of catecholamines impairs the β-AR signalling pathway with reports of 
desensitised adrenergic receptors and calcium mishandling 299, 300. 
Furthermore, increased proinflammatory cytokine expression, lipid peroxidation 
and diminished FA and glucose metabolism have all been detected after Iso 
treatment 224, 301, 302. Thus infusion of Iso has multiple effects on the 
myocardium.  
Although, infusion of Iso is frequently used to model hypertrophy, several 
studies have used Iso to induce HF 303, 304. Iso can be administered by 
intraperitoneal injection or by implantation of an osmotic minipump and may 
therefore be considered less invasive than the methods described above. This 
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model provides a platform to study the effects of catecholamines and the β-AR 
signalling pathway in the development of hypertrophy and its progression to HF.  
 
1.8 Study rationale 
Sterile inflammation has been reported to contribute to the pathogenesis and 
progression of HF 20, 169, yet the processes that initiate and execute myocardial 
inflammation remain unknown. The endosomal immune sensor, TLR9 is 
reported to be involved in pressure overload-induced myocardial inflammation 
and cardiac remodelling 173. However, the mechanisms and interactions by 
which TLR9 induces these responses after pressure overload remain unstudied.  
Various cellular pathways are activated after pressure overload, including the β-
AR signalling cascade, which is impaired in HF and has immunomodulatory 
roles 224, 225. Therefore TLR9 may potentially interact with the β-AR signalling 
cascade to induce myocardial inflammation and may also impact other cardiac 
remodelling processes such as fibrosis, hypertrophy and cardiac function. 
Another common trigger of HF is MI, in which a robust inflammatory is observed 
and is reported to play a crucial role during LV remodelling post-MI by aiding the 
clearance of dead cells and promoting tissue repair. However, as mentioned, 
the processes that initiate and execute myocardial inflammation remain 
unknown. Although, the impact of TLR9 stimulation on LV remodelling after MI 
has not yet been studied, increased levels of circulating mtDNA have been 
detected in acute MI patients 305. This finding suggests a stimuli that could 
potentially activate a TLR9-dependant inflammatory response post-MI and 





Therefore, the overall aim of this thesis was to investigate the role of the 
immune sensor, TLR9 in the pathogenesis of HF and its contribution to the 
associated inflammatory response. This thesis focussed upon TLR9-mediated 
inflammation in the context of β-AR signalling cascade and post-MI using 
mouse models. 
Therefore the general hypothesis for this thesis is that TLR9-mediated 
inflammation contributes to myocardial inflammation observed in Iso-induced 
HF and MI-induced HF. 
Chapter 3 focuses on possible associations between TLR9-mediated 
inflammation and the β-AR signalling cascade, using a β-stimulant infusion 
model. Further characterisation of this model is performed in chapter 4, in which 
alterations in oxidative stress, mitochondrial morphology and function and 
metabolism are investigated. Finally, chapter 5 examines the contribution of 
TLR9-associated inflammation in the aftermath of MI. Collectively these 
chapters aim to increase the understanding of inflammatory processes within 





2.1 Animal work 
All procedures were performed in accordance with the Guidance on the 
Operation of the Animals (Scientific Procedures) Act, 1986 (UK Home Office). 
Global TLR9-deficient (TLR9KO) mice were kindly provided by Professor 
Shizuo Akira (Osaka University, Japan) 177. In these mice, a 1 kb genomic DNA 
sequence that encoded for the LRR of murine TLR9 was replaced with a 
neomycin cassette (figure 2.1). These mice had previously been backcrossed 
with C57Bl/6 mice for more than 5 generations, so C57BL/6 mice could be used 
as wild-type (WT) controls. C57Bl/6 mice, hereafter referred to as WT mice, 
were ordered from Harlan Laboratories whilst TLR9KO mice were bred and 
housed on site. Mice were accommodated in a temperature and humidity 
controlled animal facility, with 12-hour light/dark cycles and were given 
unrestricted access to water and standard laboratory chow.  
For Isoprenaline (Iso) related experiments in chapters 3 and 4, 10 – 11-week-
old, 24 – 27 g WT and TLR9KO male mice were used whilst MI-related 
experiments in chapter 5 were performed with 8 – 10-week-old WT and 
TLR9KO male mice. All experiments were performed in a blinded manner using 
a coding system to minimise bias. Mice were coded prior to treatment, therefore 
it was unknown to the experimental operator during the experiment the genetic 
background and treatment for each mice / sample. The treatment and genetic 
background was disclosed upon conclusion of the physiological, biochemical or 






















Figure 2.1 Targeted disruption of the murine gene encoding Tlr9 used to 
generate a conventional TLR9-deficient mouse line. 
Figure taken from Hemmi et al (2000) 177. A, Maps of the TLR9 genome, the 
targeting vector and the predicted disrupted gene. In the targeting vector, 1 kbp 
of the coding exon (closed box) was replaced with a neomycin cassette and 
novel restriction enzyme sites : B, BamHI; S, ScaI. B, Southern blot analysis of 
offspring from the heterozygote intercrosses. Extracted DNA was digested with 
ScaI and hybridised with the radiolabelled probe indicated in A. Wild-type (WT) 
mice (+/+) gave a single 3 kbp band, a 10 kbp band for TLR9KO mice (-/-) and 
both bands for heterozygous mice (+/-). C, Northern blot analysis of splenocytes 
from WT (+/+) and TLR9KO (-/-) mice. Samples were hybridised using a probe 
targeting the TLR9 N-terminal or C-terminal portions. The N-terminal probe 
bound to WT samples but did not bind to TLR9KO samples, confirming 
recombination of the Tlr9 encoding allele. D, Comparison of the predicted 
amino-acid sequences between WT (+/+) and TLR9KO (-/-) cDNA highlight the 
introduction of a new stop codon in TLR9KO cDNA to cause premature 
translational termination to generate a shorter form of TLR9. The numbers 





Figure 2.2 Genotyping procedure of TLR9KO mice. 
A, Steps performed to genotype TLR9KO mice. B, PCR (polymerase chain 
reaction) programme. On ice, extracted DNA was combined with AmpliTaq 
Gold Buffer, deoxynucleotide triphosphates (dNTPs), magnesium chloride 
(MgCl2), dimethyl sulphoxide (DMSO), primers (Table 2.1), autoclaved water 
and AmpliTaq Gold DNA polymerase. Samples were heated to 94oC for 10 
minutes, then 35 cycles of 94 oC for 30 seconds, cooling to 67oC for 1 minute 
and heating to 72oC for 1 minute. After the repeated cycles, the samples were 
held at 72oC for 10 minutes. 
 
2.1.1 Genotyping of TLR9KO mice 
The breeding strategy to produce TLR9KO mice was designed so that only 
TLR9KO mice were generated. Homozygous knockout (TLR9KO) mice were 
bred with TLR9KO mice, to yield only TLR9KO mice (see figure 3.5). Ear 
biopsies were taken from mice before surgery and after harvesting to confirm 
the genotype of the mouse. An outline of the procedure used to genotype these 
mice is presented in figure 2.2a.  
 
2.1.1.1 DNA extraction 
Ear biopsies were added to coded tubes containing 10 µM NaOH (Sigma 
Aldrich, S8045), vortexed and left to incubate at 95°C for 30 minutes to lyse 
samples.  Next, 0.1 M Tris-HCl (pH 8.0) (Trizma base, Sigma Aldrich, T1503; 
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36% hydrochloric acid, Alfa Aesar, L13091) was added and the samples were 
vortexed and centrifuged at 13,400 g for 10 minutes at room temperature (RT). 
The supernatant containing genomic DNA was isolated and put into a new tube. 
To increase the purity of the genomic DNA for polymerase chain reaction 
(PCR), double the volume of Tris- Ethylenediaminetetraacetic acid (EDTA) 
buffer (TE) (10 mM Tris, 1 mM EDTA (Sigma Aldrich, ED2SS)) was added to 
the DNA extracted from ear biopsies. Next, phenol (Sigma Aldrich, P4557) and 
chloroform : isoamyl alcohol (IAA) were added (chloroform : IAA, 24 : 1, Sigma 
Aldrich, CO549) and the samples were vortexed for 30 seconds followed by 
centrifugation for 5 minutes at 15,700 g at 4oC. The top phase of the solution 
was transferred to a new tube and chloroform : IAA was added. The vortex and 
centrifugation steps were repeated. The top phase of the solution was 
transferred to a new tube and 3 M sodium acetate (1/10 of the volume) (Sigma 
Aldrich, S2889) and 100% ethanol (2.5 x the volume) (Fisher Scientific, 
E/0650DF/17) was added. The tube was mixed gently and left at -20oC for 30 
minutes. The solution was subjected to centrifugation for 30 minutes at 15,700 g 
at 4oC and the resulting pellet was resuspended in 20 µl TE buffer to obtain 
pure genomic DNA. 
 
2.1.1.2 PCR and agarose gel electrophoresis 
Extracted genomic DNA (purified by phenol chloroform extraction) was diluted 
10-fold and 0.5 µl was added to the PCR mixture. This PCR mixture consisted 
of 1 x AmpliTaq Gold Buffer (Life Technologies, 4398781), 200 µM 
deoxynucleotide triphosphates (dNTPs) (Life Technologies, 1405147), 2.5 mM 
MgCl2 (Life Technologies, 4486224), 2.5% dimethyl sulphoxide (DMSO) (Sigma 
Aldrich, W387520), 0.5 µM of each primer (forward and reverse), autoclaved 
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water and 2.5 U of AmpliTaq Gold DNA polymerase (Life Technologies, 
4311814).  
Two mastermixes were prepared; 1 mastermix included primers for WT mice 
(WT and Extra) and another mastermix contained primers for TLR9KO mice 
(TLR9KO and extra) (table 2.1). The tubes were loaded onto the PCR machine 
(Veriti thermocycler, Applied Biosystems) and heated to 94oC for 10 minutes 
and then 35 cycles of heating to 94oC for 30 seconds, cooling to 67oC for 1 
minute and heating to 72oC for 1 minute (figure 2.2b). After the repeated 
cycles, the samples remained at 72oC for 10 minutes. Next, PCR samples were 
diluted 6 times with DNA loading buffer and applied to a 1.5% agarose gel (1.5 
g in 100 ml Tris-Borate-EDTA (TBE) (900 mM Tris, 900 mM boric acid (Sigma 
Aldrich, B7660, 20 mM EDTA))) with a 100 bp ladder (Promega, G2101). 
Electrophoresis was performed for 30 minutes at 150 V with TBE. Following 
this, the gel was stained in 0.5 µg/ml ethidium bromide (Sigma Aldrich, E1510) 
and developed using the gel imager, BioSpectrum AC Imaging System (UVP). 
Samples were decoded to identify the mice from which the sample was 
obtained. 
 
Table 2.1 Sequences of primers used to genotype TLR9KO mice. 
To confirm the genotype of TLR9KO mice, polymerase chain reactions were 
performed with DNA extracted from ear biopsies using 2 different primer sets. 
The first primer set (WT and Extra primers) would only amplify DNA from WT 
mice whilst the other primer set (TLR9KO and Extra primers) would only amplify 







WT  5’-GAAGGTTCTGG GCTCAATGGTCATGTG-3’ 
Extra 5’-GCAA TGGAAAGGACTGTCCACTTTGTG-3’ 




2.1.2.1 Preparation and implantation of minipumps 
Osmotic minipumps (model 2004, Alzet) infusing 75 mg/kg/day Iso (isoprenaline 
hydrochloride, Sigma Aldrich, I5627), 50 mg/kg/day Iso or saline solutions 
(AquaPharm, XVD587) were primed and implanted as previously described 306. 
40 hours before implantation, minipumps were prepared under sterile conditions 
and stored in saline at 37oC for priming. The concentration of the Iso solution 
loaded into the minipumps was calculated to account for the flow rate of the 
minipumps and body weight of the mice (figure 2.3). 
Figure 2.3 Equations used to determine the concentration of Iso solution 
required for minipumps. 
A, Equations used to calculate the concentration of Iso needed for each 
experiment. B, Use of the equations to determine the concentration of Iso 
solution required to deliver 50 mg/kg/day Iso to a 25 g mouse using minipumps 
with a flow rate of 0.25 µL/hour. 
 
Once the solutions were prepared and filtered, the solutions were loaded into 
the minipumps according to the manufacturer’s protocol using a syringe and the 
filling tube provided with the minipumps. Once the minipumps were filled with 
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solution, the filling tube was removed and the flow moderator (provided with the 
minipumps) was fully inserted into the minipump.  
Surgery was performed in a blinded manner to minimise bias. The surgeon 
(myself) was unaware of which minipump was inserted (saline or Iso) and the 
genetic background of the mice. Mice were given an intra-peritoneal (IP) 
injection (6 ml/kg) containing an anaesthetic cocktail (9.3% ketamine (Pfizer, 
Vetalar) and 9.8% medetimidine (Orion, Domitor)) and analgesia reagents. Hair 
was shaved from the posterior of the mice above the tail and the skin was 
cleansed using povidine-iodine (VetaSept) and chlorhexidine (VetaSept).  
Loss of the pedal toe reflex ensured that mice were sufficiently anaesthetised. 
An incision was made subcutaneously (SC) on the back of the mouse close to 
the tail and a pocket was created for the minipump by inserting jaws of surgical 
scissors into the incision and performing a spreading motion by opening and 
closing the jaws. The minipump was implanted and the incision was closed 
using 5-0 suture (Ethilon, Ethicon). IP injection of the anaesthetic reversal 
reagent (10% atipamezole (Orion, Antisedan)) was applied to the mouse and 
mice were left to recover in a warm chamber before returning to their cages.  
 
2.1.2.2  Left anterior descending (LAD) artery ligation  
Ligation of the LAD artery was performed by Dr Shigemiki Omiya (King’s 
College London) as previously described 156. Mice were anaesthetised by IP 
injection containing an anaesthetic cocktail (6 ml/kg) and also given analgesia. 
Hair was shaved from the neck area and the left side of the ribcage and the skin 
was disinfected using povidine-iodine and chlorhexidine. Mice were maintained 
in supine position and after ensuring that mice were adequately anaesthetised, 
mice were intubated at 150 strokes per minute (SV 150 µl) using a Type 845 
80 
 
ventilator (MiniVent). A left-sided thoracotomy was performed, carefully pulling 
aside the pectoralis minor and pectoralis major. Using forceps, an incision was 
made in the 3rd intercostal space (between the 3rd and 4th rib). The thorax was 
opened carefully and the LAD coronary artery was located and completely 
ligated with 1 stitch of 8-0 suture (Ethilon, Ethicon). After ligation, the muscles 
were carefully repositioned and the skin was closed using 5-0 suture (Ethilon, 
Ethicon). Anaesthetic reversal reagent was administered to the mice by IP 
injection and mice were left to recover in a warm chamber before returning to 
their cages. 
 
2.1.2.2.1 Evans Blue staining 
Evans Blue staining was performed by Dr Shigemiki Omiya (King’s College 
London). Directly after LAD ligation, mice were injected with 2% Evan’s Blue 
reagent (Sigma Aldrich, 206334) in saline into the inferior vena cava. 
Immediately, several organs, including the heart turned blue.  The mice were 
left for 30 seconds to allow complete staining of the myocardium and then the 
heart was extracted and frozen. Hearts were transversely cut into 6 slices and 
imaged using a camera (G15, Canon). 
 
2.1.3 In vivo and ex vivo measurements 
2.1.3.1 Echocardiography and BP measurements 
Echocardiography using Vevo 2100 Imaging System (Visualsonics) attached to 
MicroScan transducer (Visualsonics, MS250) was used to study in vivo cardiac 
morphology and function. Echocardiography was either performed using 
anaesthetised mice using 0.5 - 2% isoflurane (Abbot, 13506) by myself or using 
conscious mice by Dr Manabu Taneike or Dr Shigemiki Omiya (both from King’s 
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College London). As the mice were coded, the genetic background and 
treatment for each mouse was unknown to the operator and echocardiography 
was performed in a blinded manner. 
 
Figure 2.4 Analysis of echocardiographic images and formulas used to 
calculate cardiac parameters. 
Vevo 2100 Workstation Software (Visualsonics) was used to analyse short-axis 
M-mode echocardiographic images. A, The user was able to measure cardiac 
parameters. End-diastolic measurements are shown in red: Interventricular 
septal wall thickness (IVSd), Left ventricle internal dimension (LVIDd), Left 
ventricular posterior wall thickness (LVPWd). End-systolic measurements are 
shown in green: Interventricular septal wall thickness (IVSs), Left ventricle 
internal dimension (LVIDs), Left ventricular posterior wall thickness (LVPWs). 
Heart rate (HR) (blue) was drawn with every contraction cycle. B-D, 
Measurements from echocardiographic images were used to calculate the 
ejection fraction (B), fractional shortening (C) and LV mass (D). LVEDV = left 




Preceding echocardiography, hair was removed from the chest using a topical 
depilatory agent. Under anaesthesia, the body temperature of the mice was 
maintained at 36.5oC ± 1oC and the respiratory rate kept above 100 breaths per 
minute. Using Vevo 2100 Workstation Software (Version 1.6.0, Visualsonics), 2 
short axis M-mode images were acquired for each animal and each image was 
analysed during 2 different heartbeats as described in figure 2.4. 
Non-invasive BP measurements (Kent Scientific, CODA) were performed on 
pre-warmed conscious mice in a blinded manner (figure 2.5). Mice were trained 
3 times before taking valid BP measurements. Using the CODA software (Kent 
Scientific), 3 or more accepted readings (out of 20) were required to calculate 









2.1.3.2 Cardiac magnetic resonance imaging (MRI) 
Cardiac MRI, 7 Tesla horizontal MR scanner (Varian) was performed by Dr 
Andrea Protti (King’s College London) as previously described 307, 308. The 
operator was blinded to the genetic background of the mice and mice were 
anaethetised with 1.5% isoflurane, maintained at 37oC and set in the prone 
Figure 2.5 Blood pressure (BP) measurements 
Mice were warmed to dilate blood vessels and a tail cuff was applied to the 
mouse, that was linked to a laptop that recorded the BP readings. 
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position. 30 µl bolus of 0.5 mmol/kg gadolinium-diethylenetriaminepentaacetic 
acid (Gd-DPTA) (Magnevist, Schering Healthcare) was injected IP into the 
mice. 2 metallic needles were placed SC in the front paws to monitor the 
electrocardiogram.  
Acquired images were analysed using a semiautomated in-house-developed 
cardiac preclinical computer software program 307, 308 to calculate cardiac 
functional parameters and infarct size (figure 2.6). Using ImageJ software 




Figure 2.6 Equations used to analyse cardiac MRI images. 
Semiautomated in-house-developed cardiac preclinical computer software 
program was used to analyse cardiac MRI images 307, 308. Equations used to 
measure the (A) infarct size. Areainf = End-diastolic infarct area, Areatot = End-
diastolic total LV area. (B) Stroke volume and (C) LV mass. γ = specific gravity 
of the myocardium (1.055 g/cm2). 
 
  
2.1.3.3 Gravimetric data collection 
Animals were culled by cervical dislocation. Promptly, the chest was opened 
and the hearts was harvested and washed in ice-cold phosphate buffered saline 
(PBS) (Sigma Aldrich, P4417). The heart was weighed and segmented for 
further analyses (figure 2.7). In addition measurements of lung weight, liver 










Figure 2.7 Segmentation of a murine heart.  
Upon harvesting,  the heart was excised from the body, washed in ice-cold 
PBS, and sliced horizontally in the middle and the top half was submitted for 
histological analyses. The right ventricle was removed from the residual heart 
piece (bottom half) and the remaining left ventricle was cut into two from an 
aerial view, with both halves containing septal and lateral walls. Only samples of 
left ventricles were submitted for biochemical analyses. 
 
2.2 Histological analysis 
After harvesting, coded heart samples for paraffin embedding were fixed in 4% 
paraformaldehyde (PFA) (Sigma Aldrich, P6148) overnight at 4oC. Next day, the 
heart samples were washed 3 times with PBS. The hearts were stored in 70% 
ethanol at 4oC and submitted for processing. After processing, the heart 
samples were embedded in paraffin and 6 µm sections were cut using the 
microtome (Leica, RM2125). The sections were heated to 42oC for 5 minutes in 
a water-bath (RA Lamb, E65), collected using Superfrost Plus slides (Thermo 
Scientific, 10149870) and heated to 40oC for 30 minutes (RA Lamb, E18.1) and 
left at RT overnight. Prior to staining, the paraffin embedded heart sections 
were deparaffinised in xylene (Scientific Laboratory Supplies, 534056) twice 
and rehydrated using decreasing concentrations of ethanol (100% twice, 95%, 
80%, 70%) and distilled H2O (dH2O) with each incubation lasting 5 minutes.  
The heart tissue reserved for cryosections were stored in Shandon Cryomatrix 
compound (Thermo Scientific, 6769006) after harvesting and frozen using 
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isopropanol (Sigma Aldrich, I9516) and dry ice. The coded samples were 
sectioned using the cryostat (Thermo Scientific, HM560) at a thickness of 6 µm 
and stored at -80oC. Prior to staining, the sections were dried at RT for 30 
minutes, fixed in acetone (Sigma Aldrich, 34850) for 15 minutes at 4oC and 
washed with PBS 3 times for 5 minutes. Slides were decoded upon termination 
of the experiment to disclose the genetic background and treatment for each 
sample. 
 
2.2.1 Haematoxylin and Eosin (H & E) staining 
H & E staining was performed using paraffin-embedded and cryo- sections. 
After being prepared as described in section 2.2, the sections were treated with 
haematoxylin (Thermo Scientific, LAMB-230-D) for 3 minutes and rinsed with 
tap water. Sections were dipped 12 times in acid ethanol (1:400 concentrated 
HCl in 70% ethanol) and rinsed in dH2O. Eosin (Thermo Scientific, LAMB-100-
D) was used as a counterstain for 30 seconds, before dehydrating with 3 
washes of 5 minutes using 95% and 100% ethanol. Slides were treated with 
xylene twice for 15 minutes and mounted with coverslips (Fisher, 12373128) 
using DPX mountant (Sigma Aldrich, 06522) and left to dry overnight. The 
slides were imaged using a brightfield microscope (Zeiss, Axioskop 2) at 50 x 
and 200 x magnification. 
 
2.2.2 Wheat Germ Agglutinin (WGA) staining 
After fixing the cryosections (section 2.2), slides were washed using tap water 
for 5 minutes. After drawing a circle around the specimen using a PAP pen (Life 
Technologies, 00-8899), the sections were incubated with 0.1% bovine serum 
albumin (BSA) (Sigma Aldrich, A7906) in PBS for 5 minutes. Once the BSA 
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solution was removed, the section was incubated with FITC-lectin conjugate 
(diluted 100-fold with 0.1% BSA solution) (Sigma Aldrich, L4895) at RT for 1 
hour. Sections were washed 3 times with 0.1% BSA solution for 5 minutes and 
finally rinsed with PBS. The slides were mounted using Vectashield mounting 
medium for fluorescence with DAPI (Vector Laboratories, H-1200) and sealed 
using nail polish. 5 images per heart section were acquired using Volocity 
software (version 6.3, Perkin Elmer) on the fluorescent microscope (IX81, 
Olympus) at 200 x magnification. Using ImageJ, the cardiomyocyte cross-
sectional area (CSA) of 20 cells per image was measured. Cardiomyocytes that 








2.2.3 Immunohistochemistry (IHC) 
After myocardial cryosections were fixed (section 2.2), a circle was drawn 
around the specimen using a PAP pen and the sections were blocked with 3% 
skimmed milk powder reagent (Biorad, 170-6404) diluted in PBS for 30 minutes 
at RT. This was followed by an overnight incubation at 4oC with the primary 
antibody (table 2.4), diluted in blocking reagent. The next day, slides were 
Figure 2.8 Analysis of wheat germ agglutinin (WGA) staining to measure 
cardiomyocyte cross-sectional area (CSA). 
Images of WGA staining to illustrate the round shape (red) and central position 
of the nuclei within cardiomyocytes (left) selected for analysis to measure the 
cardiomyocyte CSA (right). Scale bar = 30 µm. Green signal (FITC, lectin), blue 
signal (DAPI, DNA). 
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washed in PBS 3 times for 5 minutes and endogenous peroxidases were 
deactivated using 0.3% H2O2 in methanol (Pedrogen, Sigma Aldrich, 31642; 
Methanol, Fisher Scientific, M/3900/17) for 30 minutes at RT. A 15 minutes 
wash with PBS was followed by incubation with the secondary antibody (table 
2.5) in blocking reagent at RT for 30 minutes. Sections were washed 3 times for 
5 minutes using PBS and then incubated with ABC reagent (Vector, PK-6101) 
at RT for 20 minutes. Slides were washed twice for 5 minutes in PBS and 
incubated with 3,3’-diaminobenzidine (DAB) (Vector, DAB SK-4100). Washing 
in PBS halted the reaction and slides were counterstained with haematoxylin for 
3 minutes. Slides were washed in pre-warmed dH2O for 10 minutes, dehydrated 
and mounted using DPX. Slides were left to dry overnight and were imaged on 
the brightfield microscope at 200 x and 400 x magnification. The number of 
DAB-positive cells were calculated from 5 images per section and expressed as 
cells per mm2. Negative controls were performed without any primary antibody 
to confirm the specificity of antibody. 
 
2.2.4 Masson’s Trichrome (MT) staining 
MT kit (Polysciences Inc, 25088-1) was used for this procedure and followed 
according to the manufacturers instructions. Slides were mounted with DPX 
mountant and left to dry overnight. Slides were viewed on the brightfield 
microscope and images were taken at 200 x magnification. Analysis of 5 
images per heart section was performed using ImageJ software to determine 





2.2.5 Picrosirius Red staining 
Paraffin-embedded heart sections were prepared as described in section 2.2. 
Slides were subjected to 0.2% phosphomolybdic acid (Sigma Aldrich, 79560) 
for 2 minutes, rinsed and incubated in 0.1% picrosirius red diluted in saturated 
picric acid (Direct Red 80, Sigma Aldrich, 43665; saturated picric acid, Sigma 
Aldrich, 80456) for 2 hours at RT. The slides were washed twice with acidified 
water (1:200 dilution of acetic acid (Scientific Laboratory Supplies, CHE1016)), 
dehydrated using 95% ethanol twice and 100% ethanol twice. Slides were 
cleared with xylene twice for 15 minutes and mounted using DPX and left 
overnight to dry. Brightfield images were acquired using the IX81 microscope 
(Olympus) at 50 x magnification. Using the tilestitch feature, an image was 
formed of the entire heart section. ImageJ software was used to analyse the 
amount of fibrosis, by splitting the image into different colour channels. The 
fibrotic area and the total area of the heart section were measured and the 
fibrotic area was expressed as a percentage of the total area of the heart. 
 
2.2.6 TUNEL staining 
After deparaffinising and hydrating paraffin-embedded sections (section 2.2), 
slides were incubated with 50 µg/ml proteinase K (Sigma Aldrich, P2308) 
diluted in PBS, for 30 minutes at RT. Myocardial cryosections were fixed using 
4% PFA for 1 hour at RT and were permeabilised using 0.25% Triton X-100  
(Sigma Aldrich, X100) for 20 minutes. Both paraffin-embedded- and cryo- 
sections were washed twice in PBS and incubated with α-sarcomeric actin 
antibody (diluted 1:500 in 1% BSA with 0.1% Triton X-100 in PBS) (Sigma 
Aldrich, A2172) at RT. After 50 minutes incubation, the samples were washed 4 
times with PBS and each section was incubated with 5 µl Texas RED Anti-
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mouse IgM (Vector Laboratories, TI-2020), 45 µl labeling safe buffer and 5 µl 
TdT enzyme (both from In Situ Apoptosis Detection Kit, Clontech, MK500). This 
incubation was performed at 37oC in a light-shielded humidity chamber for 1 
hour and then washed 4 times with PBS. The slides were mounted with DAPI 
containing mounting media and sealed using nail varnish. For the positive 
control, the section was incubated with 300 U/ml Dnase I (Sigma Aldrich, 
DN25), diluted in 1 mg/ml BSA in 50 mM Tris-HCl (pH7.5) for 30 minutes at RT, 
prior to incubation with anti-α-sarcomeric actin. Slides were viewed using the 
fluorescent microscope. Images were taken in 5 random regions of the section 
at 200 x magnification and the number of DAPI nuclei per image was calculated 
using Volocity. The number of TUNEL-positive cells was counted in the whole 
heart section and expressed at number of TUNEL-positive cells per 105 cells. 
   
2.2.7 Oil Red O staining 
Frozen cryosections were warmed to RT whilst Oil Red O stock solution (0.3% 
in isopropanol; Sigma Aldrich, O0625) was diluted 6:4 with dH2O (Oil Red O 
working solution). This solution was vortexed, left for 10 minutes and filtered. 
After air-drying the slides, the sections were fixed with 10% formaldehyde (FA) 
(Sigma Aldrich, F8775) for 10 minutes on ice. Following this, the samples were 
washed twice for 5 minutes with dH2O. Slides were then stained with the Oil 
Red O working solution for 10 minutes and washed in running tap water for 10 
minutes.  Slides were counterstained with haematoxylin for 5 minutes and 
washed again with running tap water for 10 minutes. Slides were mounted using 
DPX. 5 brightfield images were attained per section at 200 x magnification. 
Images were analysed using ImageJ software by splitting the image into 
different colour channels. Lipid deposition (marked in red) was calculated and 
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the total area of the heart section was measured and the lipid deposition was 
expressed as a percentage. 
 
2.2.8 Immunofluorescence (IF) staining 
After cryosections were defrosted and fixed (section 2.2), a circle was drawn 
around the section using a PAP pen. Sections were blocked with 2% skimmed 
milk diluted in PBS, for 30 minutes at RT. Next the samples were left in primary 
antibody (table 2.4) diluted in the blocking reagent overnight at 4oC. Next day, 
the slides were washed 3 times in PBS for 5 minutes. Subsequently, sections 
were incubated with secondary antibody (table 2.5) diluted in blocking reagent 
at RT for 1 hour under light-shielded conditions. Sections were washed 3 times 
in PBS for 5 minutes and mounted using ProLong Gold Antifade Reagent with 
DAPI (Life Technologies, P36935) and left in a dark place overnight. 5 images 
per heart section were acquired using the fluorescent microscope at 200 x 
magnification. The number of α-SMA and double positive (α-SMA and Ki67) 
cells were counted per image using Volocity and expressed as positive cells per 
mm2. 
 
2.3 RNA extraction and quantitative-real-time PCR (qRT-PCR)  
2.3.1 RNA extraction 
Frozen heart tissue were coded (to minimise bias) and homogenised at 25 Hz 
for 1 minute with 1 ml TRIzol (Life Technologies, 15596) using MM400 
homogeniser  (Retsch).  The solution was pipetted into a clean tube and 
incubated RT for 5 minutes. Chloroform (200 µl) (Sigma Aldrich, C2432) was 
added and shaken vigorously for 15 seconds. The solution was left at RT for 5 
minutes, followed by centrifugation at 12,000 g for 15 minutes at 4 oC. The 
upper aqueous phase was placed into a clean labelled tube and 500 µl 
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isopropanol was added and the tube was inverted several times. After 10 
minutes incubation at RT, the tubes were centrifuged at 12,000 g for 10 minutes 
at 4oC. The supernatant was discarded and the pellet was washed with 1 ml 
70% ethanol. The tubes were briefly vortexed and centrifuged at 7,500 g for 5 
minutes at 4oC. The supernatant was removed and the pellet was left to airdry. 
The pellet was resuspended in 30 µl RNase / DNase free H2O (Gibco, 10977-
035) and incubated at 55oC for 10 minutes.  
 
2.3.2 Complementary DNA (cDNA) synthesis and qRT-PCR 
Total RNA concentration was measured using Nanodrop 2000 (Thermo 
Scienitifc). Total RNA (500 ng) was incubated with 100 ng random primers (Life 
Technologies, 48190-011), 0.5 mM dNTPs (Life Technologies, N8080260) and 
dH2O and heated to 65oC for 5 minutes. Samples were chilled on ice whilst 5 x 
first strand buffer (Life Technologies, y02321) and 0.01 M dithiothreitol (Life 
Technologies, y00147) was added. Samples were incubated at 25oC for 2 
minutes. After adding 100 U Superscript II reverse transcriptase (Life 
Technologies, 18064), samples were incubated at 25oC for 10 minutes, 42oC for 
50 minutes and 70oC for 15 minutes using Veriti thermocycler (Applied 
Biosystems) (figure 2.9). 
cDNA samples were diluted 10-fold. For standards, 2 µl of each sample was 
combined in another tube and diluted accordingly (1 x, 4 x, 16 x and 64 x).  
cDNA was submitted for qRT-PCR analysis using 2 x Power SyBr Green 
Mastermix (Life Technologies, 4367660), 0.5 µM forward and reverse primers 
and dH2O in a 96 well plate. The plate was sealed and qRT-PCR was 
performed on StepOnePlus machine (Applied Biosystems) with the programme 
set at 95oC for 10 minutes, then 40 cycles of 95oC for 15 seconds and 60oC for 
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1 minute (figure 2.10). Samples were decoded to identify the mouse genotype 




Figure 2.9 Reverse Transcription (RT) programme using Superscript II. 
Total RNA (500 ng) was mixed with random primers, deoxynucleotide 
triphosphates (dNTPs) and dH2O. After heating to 65oC for 5 minutes, 5x First 
Strand (FS) Buffer and dithiothreitol (DTT) were added on ice. Samples were 
heated to at 25oC for 2 minutes. Superscript II Reverse Transcriptase (SSII RT) 
was added and the samples were incubated at 25oC for 10 minutes, 42oC for 50 








Figure 2.10 qRT-PCR programme.  
Ten-fold diluted cDNA was mixed with Power SyBr Green Mastermix, 0.5 µM 
forward and reverse primers and dH2O. This solution was heated to 95oC for 10 







2.4 SDS-PAGE and Western blotting 
Protease inhibitors (PI) (Sigma Aldrich, P8340) were diluted 100 x in lysis buffer 
(table 2.3). Lysis buffer with PI was added to tubes containing frozen harvested 
LV samples. Samples were homogenised at 25 Hz for 1 minute and pipetted 
into a clean tube. 0.1% Triton X-100 in PBS (Sigma Aldrich, X-100) was added 
and samples were left on ice for 30 minutes, followed by 10 minutes 
centrifugation at 8,000 rpm at 4 oC. The supernatant was collected. 10 µl of the 
supernatant was diluted 10-fold and used for protein quantification using Pierce 
BCA assay kit (Thermo Scientific Pierce, 13276818). After measuring the 
protein concentration, 20 – 40 µg protein was mixed with 5 x sample buffer 
(table 2.3) with 5% 2-mercaptoethanol (Sigma Aldrich, M3148). Samples were 
either heated to 95oC for 5 minutes or left at RT for 30 minutes. Samples were 
loaded onto 5%, 10% and 15% SDS gels (table 2.3) with running buffer (table 
2.3) and Precision Plus Protein Dual Xtra Standards (Biorad, 161-0377) and 
SDS-PAGE was performed for 2 hours at 120 V. Proteins were transferred from 
SDS-PAGE onto nitrocellulose membrane (Fisher Scientific, 15269794) at 0.1 A 
for 100 minutes with transfer buffer (table 2.3) using the wet transfer method. 
After transfer, the membrane was rinsed twice with TBS (table 2.3) and blocked 
for 1 hour at RT using the Odyssey blocking buffer (LI-COR Biosciences, 927-
40000) or 5% milk powder. After blocking, membranes were washed with TBS-
T (table 2.3) 4 times, each wash lasting 5 minutes. This was followed by 
overnight incubation at 4oC with the primary antibody diluted in the blocking 
reagent. Next day, the membranes were washed as described earlier, followed 
by secondary antibody incubation at RT for 1 hour. Membranes were washed 
as before and developed using the Odyssey Clx imager (LI-COR Biosciences). 
Image Studio Lite software (version 5.2, LI-COR Biosciences) was used to 
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analyse images and perform densimetric analysis. Primary and secondary 
antibodies used for Western blotting are listed in table 2.4 and 2.5. 
 
2.5 Transmission electron microscopy (TEM) 
Mice were given an IP injection containing 75 IU heparin. After 20 minutes, mice 
were anaesthetised using an IP injection of sodium pentobarbital (50 mg/kg 
body weight) (Animalcare Ltd, Pentoject). Once the mice were adequately 
anaesthetised (with loss of the pedal toe reflex), the chest was opened. The 
apex of the LV was punctured by a needle that was connected to the PHD2000 
pump (Harvard Apparatus) delivering wash solution (100 mM piperazine-N,N′-
bis (2-ethanesulfonic acid (PIPES)) at 90 - 100 mmHg (flow rate 5 ml/min). 
Immediately after starting perfusion, the right atrium was snipped to allow 
blood/perfusate to leave the circulation. After 2 minutes, the fixative (0.1% 
sodium nitrate, 2% PFA, 2% glutaraldehyde, 100 mM PIPES) was perfused 
through the animal for 5 minutes. Following this, the heart was excised and 
sliced transversally. Slices were kept in buffer overnight and next morning, the 
hearts were washed with 100 mM PIPES 3 times. Samples were taken to the 
Centre of Ultrasound Imaging (King’s College London) and Dr Gema Vizcay 
and Ms Leanne Glover kindly dehydrated, sectioned and stained the samples 
as well as providing the fixative and wash buffer. Images were taken on TEM 
(H7650, Hitachi). 
 
2.6 Phospholamban overexpression studies 
2.6.1 Bacterial transformation 
Whilst the DNA plasmid solution was chilled on ice, DH5α competent cells 
(Invitrogen, 18258) were also thawed on ice. Once thawed, the cells were 
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added to the DNA solution (1,000 ng) and mixed by gentle pipetting. The 
mixture was left on ice for 30 minutes and then heat-shocked at 42oC for 45 
seconds. Immediately after, the samples were placed on ice for 2 minutes and 1 
ml of SOC (SOB media with 20 mM magnesium and 20 mM glucose) was 
added. The samples were incubated at 37oC for 1 hour, followed by 
centrifugation at 5,900 g for 1 minute. The majority of the supernatant was 
removed, leaving approximately 100 µl which was used to resuspend the pellet. 
This solution was placed onto RT antibiotic-containing agar plates (ampicillin 
(10 mg / 100 ml) (Sigma Aldrich, A9393) or chloramphenicol (1.25 mg / 100 ml) 
(Sigma Aldrich, C0378)) (Bacto Agar, BD Biosciences, 214010; LB Broth Merck, 
VM1540485) and spread across the surface. The plates were left to incubate at 
37oC overnight.  
 
2.6.2 Miniprep and DNA sequencing  
The day after transformation, colonies were picked using sterile toothpicks and 
incubated in individual tubes containing LB Broth with antibiotic ((ampicillin (10 
mg / 100 ml) or chloramphenicol (1.25 mg / 100 ml)) and left to grow overnight 
at 37oC. Next day, plasmid DNA was isolated from the cloudy LB Broth solution 
by using the QIAprep Spin Miniprep Kit (Qiagen, 27106). The protocol from the 
kit was followed and the DNA was eluted in 30 µl dH2O. The DNA concentration 
and the 260/280 ratio was determined by the Nanodrop 2000. For DNA 
sequencing, samples were diluted to 100 ng/µl and dispatched to Source 




2.6.3 Enzyme digestion and ligation 
Buffers (NEB) for enzyme digestion was selected according to NEBuffer 
performance chart for restriction enzymes (NEB). 2 µl buffer, 250 µg DNA and 
1,000 units of each restriction enzyme for double digestion was combined and 
made up to 20 µl with RNase/DNase free H2O and left for 1 hour at 37oC. After 
digestion, 6 x DNA loading buffer was added to the samples and loaded onto a 
1% agarose gel (1 g agarose in 100 ml TBE) and subjected to electrophoresis 
for 30 minutes at 150 V in TBE. After gel electrophoresis, samples were stained 
with ethidium bromide. Digested bands were observed using a transilluminator 
(UVP) and were excised from the gel. The digested DNA was isolated from the 
agarose gel using QIAquick gel extraction kit (Qiagen, 28706) and the DNA was 
eluted in 30 µl dH2O.  
Ligation of digested products was performed using the Mighty Mix DNA ligation 
kit (Clontech, 6023).  Eluted DNA (vector) was diluted at 1:3 ratio with the eluted 
DNA (insert) and 2 x ligation mix was added (final volume 20 µl) and the 
solution was left at 16oC overnight. The next day, 1 µl of the ligation mixture 
was transformed into DH5α cells. 
 
2.6.4 Cell Culture 
Human embryonic kidney (HEK)-293A cells (American Type Culture Collection) 
were kindly provided by Mr Francesco Nicolini (King’s College London). Cells 
were cultured in 75 cm2 flasks (Thermo Scientific, 178905) with DMEM medium 
(Sigma Aldrich, D6546) containing 10% foetal bovine serum (Gibco, 10270-106) 
and 1% penicillin-streptomycin-glutamine (Sigma Aldrich, G1146). Cells were 
incubated at 37oC with 5% CO2. 
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When cells reached approximately 80% confluency, cells were passaged. 
Media was aspirated off the cells and 5 ml PBS (Sigma Aldrich, D8637) was 
used to rinse the cells. 5 ml 0.5 M EDTA was added to the cells and left for 5 
minutes at 37oC. 5 ml culture media was added and the suspended cell solution 
was centrifuged at 100 g for 5 minutes. The supernatant was discarded and the 
pellet (cells) was resuspended with 1 ml of pre-warmed culture media. This cell 
mixture was diluted 20 x in 20 ml of culture media and seeded into a new flask. 
 
2.6.5 Transfection 
HEK293A cells were seeded at 2.5 x 105 cells per well in 6-well plates (in 3ml 
culture media) and left to incubate for 24 hours. Next day, cells were transfected 
with FuGENE HD (Promega, E2311) and plasmid DNA (3 µg) (ratio of 
transfection reagent : DNA plasmid was 3:1). Cells were harvested for 24 and 
48 hours after transfection and the protein was isolated. Wells were aspirated, 
leaving 1 ml that was used to scrape the cells. The cell suspension was pipetted 
into clean tubes and centrifuged at 15,700 g for 5 minutes at 4oC. The 
supernatant was discarded and the pellet was resuspended in 50 µl ice-cold 
lysis buffer containing PI (diluted 100 x). Immediately samples were sonicated 
for 10 seconds, followed by centrifugation at 15,700 g for 5 minutes at 4oC. The 
pellet was discarded and the protein concentration of the supernatant was 
determined and Western blotting was performed as described in section 2.4. 
 
2.7 Statistical analysis 
Results are shown as the mean  ±   standard error mean (SEM) and the data 
were analysed using Graph Pad Prism (Graph Pad Software Inc, version 5.0). 
Paired data was assessed using Student’s t-test analysis. Comparing 3 sets of 
data were analysed using one-way analysis of variance (ANOVA) with the 
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Bonferroni post hoc test whereas two-way ANOVA with the Bonferroni post-hoc 
test was used for comparing 4 sets of data made up of 2 distinct groups (for 
example WT and KO, with Saline and Iso treatments). Repeated measures 
analysis was used on results in experiments in which parameters were 
measured at 2 different time points using the same samples. A value of p<0.05 






















Table 2.2 qRT-PCR primers. 
Forward and reverse primer sequences that were used in this thesis to study 
the mRNA expression of various markers. 
 
Gene of interest Direction of primer Sequence 
Acaca F GAGAGGGGTCAAGTCCTTCC 
 R CTGCTGCCGTCATAAGACAA 
Acacb F GGGCTCCCTGGATGACAAC 
 R GCTCTTCCGGGAGGAGTTCT 
Adrb1 F GTCATGGGATTGCTGGTGGT 
 R GCAAACTCTGGTAGCGAAAGG 
Adrb2 F GACAGCGACTTCTTGCTGG 
 R CGTCCCGTTCCTGAGTGAC 
Atp2a2 F TCGACCAGTCAATTCTTACAGG 
 R CAGGGACAGGGTCAGTATGC 
Ccl2 F CCACTCACCTGCTGCTACTCAT 
 R TGGTGATCCTCTTGTAGCTCTCC 
Ccl5 F GCTGCTTTGCCTACCTCTCC 
 R TCGAGTGACAAACACGACTGC 
Col1a2 F ACGCGGACTCTGTTGCTGCT 
 R GCGGGACCCCTTTGTCCACG 
Col3a1 F CCCGGGTGCTCCTGGACAGA 
 R CACCCTGAGGACCAGGCGGA 
Cpt1 F GTGACTGGTGGGAGGAATAC 
 R GAGCATCTCCATGGCGTAG 
Cpt2 F CAGTGCACAGAAGCCTCTCTTG 
 R CTTCCCAATGCCGTTCTCAA 
Crat F TGCTGCCAGAACCGTGGT 
 R TCCAGGGATTGCTGAAGTGG 
Fasn F TTGCTGGCACTACAGAATGC 
 R AACAGCCTCAGAGCGACAAT 
Hif1a F CCCATTCCTCATCCGTCAA 
 R CCGGCTCATAACCCATCAA 
Hmox1 F CAGGATTTGTCAGAGGCCCTGAAGG 
 R TGTGGTACAGGGAGGCCATCACC 
Ifnb1 F CTTCTCCGTCATCTCCATAGGG 
 R CACAGCCCTCTCCATCAACT 
Ifny F CGGCACAGTCATTGAAAGCCTA 
 R GTTGCTGATGGCCTGATTGTC 
Il1b F AAGAGCTTCAGGCAGGCAGTATCA 
 R TAATGGGAACGTCACACACCAGCA 
Il6 F ACAACCACGGCCTTCCCTACTT 
 R CACGATTTCCCAGAGAACATGTG 
Il10 F CGGCACAGTCATTGAAAGCCTA 
 R GTTGCTGATGGCCTGATTGTC 
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Gene of interest Direction of primer Sequence 
Il12b F AGACATGGAGTCATAGGCTCTG 
 R CCATTTTCCTTCTTGTGGAGCA 
Gapdh F CATGGCCTTCCGTGTTCCTA 
 R CCTGCTTCACCACCTTCTTGAT 
Gclc F GTTATGGCTTTGAGTGCTGCAT 
 R ATCACTCCCCAGCGACAATC 
Gsta2 F CAGAGTCCGGAAGATTTGGA 
 R GAGGCTGCTGATTCTGCTCT 
Ldha F GGCACTGACGCAGACAAG 
 R AGCTTGATCACCTCGTAGGC 
Mmp2 F GATAACCTGGATGCCGTCGTG 
 R CTTCACGCTCTTGAGACTTTGGTTC 
Mmp9 F GAAGGCAAACCCTGTGTGTT 
 R AGAGTACTGCTTGCCCAGGA 
Myh7 F ATGTGCCGGACCTTGGAAG 
 R CCTCGGGTTAGCTGAGAGATCA 
Nppa F TCGTCTTGGCCTTTTGGCT 
 R TCCAGGTGGTCTAGCAGGTTCT 
Nppb F AAGTCCTAGCCAGTCTCCAGA 
 R GAGCTGTCTCTGGGCCATTTC 
Pdha1 F TGTGACCTTCATCGGCTAGAA 
 R TGATCCGCCTTTAGCTCCATC 
Pdk1 F GGACTTCGGGTCAGTGAATGC 
 R TCCTGAGAAGATTGTCGGGGA 
Pdk4 F CCGCTTAGTGAACACTCCTTC 
 R TGACCAGCGTGTCTACAAACT 
Ppargc1a F AATCAGACCTGACACAACGC 
 R GCATTCCTCAATTTCACCAA 
Slc2a1 F ATGGATCCCAGCAGCAAG 
 R CCAGTGTTATAGCCGAACTGC 
Slc2a4 F GACGGACACTCCATCTGTTG 
 R GCCACGATCGAGACATAGC 
Sod2 F GTGTCTGTGGGAGTCCAAGG 
 R AGCGGAATAAGGCCTGTTGT 
Tgfb1 F CTCCCGTGGCTTCTAGTGC 
 R GCCTTAGTTTGGACAGGATCTG 
Tgfb2 F TGGCTTCACCACAAACAGAG 
 R GTGCCATCAATACCTGCAAA 
Timp1 F GTAAGGCCTGTAGCTGTGCC 
 R GTCTCGTTGATTTCTGGGGA 
Timp2 F CACAGACTTCAGCGAATGGA 
 R CTTGGGAAGCTTGAGAGTGG 
Timp3 F CAGCCCTGTGATACTTGGGT 








































Gene of interest Direction of primer Sequence 
Timp4 F ACCTCCGGAAGGAGTACGTT 
 R TTATCTGGCAGCAACACAGC 
Tnfa F TCCCAGGTTCTCTTCAAGGGA 
 R GGTGAGGAGCACGTAGTCGG 
Txnrd1 F GGTCCTATGACTTCGACCTG 
 R AGTCGGTGTGACAAAATCCAAG 
Buffer Ingredients 
Lysis buffer  
(100 ml) 
5 ml 1 M Tris-Cl (pH 7.4), 15 ml 1 M NaCl, 200 µl 0.5 
M EDTA, 1 ml 0.1 M EGTA, 500 µl 0.5 M Na-
orthovanadate, 500 µl 0.5 M Na-pyrophosphate, 500 
µl 0.2 M β-glycerophosphate 
Sample Buffer  
(100 ml) 
10 ml 0.1% bromophenol blue, 5 ml 1 M sodium 
phosphate buffer (pH 7.0), 50 ml glycerol, 2%  SDS 
SDS-PAGE buffer (1 
L) 3 g Tris, 14.5 g glycine, 1 g powdered SDS 
Transfer buffer  
(1 L) 2.9 g Tris, 14.5 g glycine, 200 ml methanol 
TBS  
(1L) 2.42 g Tris, 8 g NaCl, pH to 7.4 using HCl 
TBST  
(1 L) TBS with 0.1% Tween 
  
5% SDS-PAGE 
resolving gel (6 ml) 
1 ml 30% acrylamide/bis, 1.5 ml 1.5 M Tris HCl (pH 
8.8), 30 µl 20% SDS, 45 µl 10% ammonium 
persulphate, 15 µl TEMED 
10% SDS-PAGE 
resolving gel (6 ml) 
2 ml 30% acrylamide/bis, 1.5 ml 1.5 M Tris HCl (pH 
8.8), 30 µl 20% SDS, 45 µl 10% ammonium 
persulphate, 15 µl TEMED 
15% SDS-PAGE 
resolving gel (6 ml) 
3 ml 30% acrylamide/bis, 1.5 ml 1.5 M Tris HCl (pH 
8.8), 30 µl 20% SDS, 45 µl 10% ammonium 
persulphate, 15 µl TEMED 
Stacking gel (6 ml) 
0.9 ml 30% acrylamide/bis, 1.5 ml 0.5 M Tris HCl (pH 
6.8), 30 µl 20% SDS, 45 µl 10% ammonium 
persulphate, 20 µl TEMED 
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Table 2.4 List of primary antibodies used in this study 
These antibodies were used for immunohistochemical (IHC), 
immunofluorescence (IF) and western blotting (WB) experiments. Markers used 
for IHC include : CD3 = T-cell marker, CD45 = leukocyte marker, CD68 = 
macrophage marker, FSP1 (fibroblast specific protein 1)= fibroblast marker, 
Ly6G/C= neutrophil marker. Markers used for IF include : α-SMA (α-smooth 
muscle actin) = myofibroblast marker, Ki67 = proliferation marker. AMPK = 
adenosine monophosphate-activated protein kinase, Iκb = inhibitor of kappa b, 




Antibody Dilution Company and catalogue number 
 
IHC Rabbit anti-mouse CD3 1:100 Abcam, ab16669 
Rat anti-mouse CD45 1:100 R&D Systems, MAB114 
Rat anti-mouse CD68 1:100 AbD Serotec, MCA1957GA 
Rabbit anti-mouse FSP1 1:2000 Abcam, ab27957 
Rat anti-mouse Ly6G and Ly6C 1:50 BD Pharmigen, 550291 
  
IF Goat anti-mouse α-SMA 1:50 Abcam, ab21027 
Rabbit anti-mouse Ki67 1:500 Abcam, ab15580 
  
WB Mouse anti-mouse α-actinin 1:1000 Sigma, A5044 
Rabbit anti-mouse pAMPKα (Thr172) 1:1000 CST, 2535 
Rabbit anti-mouse AMPKα 1:1000 CST, 2532 
Rabbit anti-mouse Caspase-3 1:1000 CST, 9665 
Mouse anti-mouse Desmin 1:100 Dako, M0760 
Mouse anti-mouse pIκb 1:1000 CST, 9246 
Rabbit anti-mouse Iκb 1:1000 CST, 9242 
Mouse anti-mouse PLN 1:500 Thermo Scientific, MA3-922 
Goat anti-mouse pPLN 1:500 Santa Cruz, sc-12963 
Goat anti-mouse SERCA2 1:1000 Santa Cruz, sc-8094 
Mouse anti-mouse α-tubulin 1:5000 CST, 3873 
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 Antibody Dilution Company and catalogue number 
 
IHC Biotinylated goat anti-rabbit IgG 1:200 
Vector Laboratories,  
PK-6101 
Mouse adsorbed biotinylated rabbit 
anti-rat IgG 3:200 





Alexa Fluor® 568 donkey anti-goat, 
orange-red 10 µg/ml 
Thermo Scientific,  
A-11057 
Alexa Fluor® 488 chicken anti-
rabbit, green  10 µg/ml 




WB IR dye 700 goat anti-mouse 1:15000 
LI-COR,  
926-68020 
IR dye 800 goat anti-rabbit 1:15000 LI-COR,  926-32211 
IR dye 800 donkey anti-goat 1:15000 LI-COR,  926-32214 
IR dye 800 donkey anti-mouse 1:15000 LI-COR,  926-32212 
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3 Cardiac effects of TLR9 after chronic β-AR stimulation 
3.1 Introduction 
The pathogenesis and progression of HF is associated with increased levels of 
pro-inflammatory cytokines 19, 20, impaired β-AR signalling 22, 210 and increased 
levels of circulating catecholamines 18, 309. However, the processes that initiate 
inflammatory responses within the heart remain undefined 20. As mentioned, 
one investigation demonstrated that mtDNA binds to the immune sensor and 
inflammatory instigator, TLR9, within cardiomyocytes, inducing myocarditis and 
dilated cardiomyopathy 173. Furthermore, the same study reported that TLR9KO 
mice, subjected to TAC, exhibited reduced cardiac dilatation, cardiac 
hypertrophy, fibrosis, inflammation and pulmonary congestion together with 
improved cardiac function compared to control mice. Together, these 2 findings 
propose a potential role of TLR9 in the pathogenesis of HF, although the 
intricate mechanisms by which TLR9-mediated inflammation provoke 
deterioration of the failing heart remains unanswered.  
In both clinical HF cases and preclinical models, cardiomyocyte overload 
instigates various cellular responses, through the activation of several signalling 
pathways, including the clinically vital, neurohormonal β-AR signalling cascade. 
Currently, inhibition of this signalling pathway by β-blockers remains a prevalent 
treatment for HF, emphasising the influence of this pathway in the pathogenesis 
of HF. Thorough examination of this pathway has identified chronotropic and 
inotropic responses after β-AR stimulation and several studies have 
demonstrated that β-AR signalling possesses immunomodulatory effects 
alongside the reported anti-inflammatory properties of β-blockers 224, 225, 310. 
These reports indicate a potential relationship between inflammation and the β-
AR signalling cascade, which may contribute to the pathogenesis of HF. With 
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the accumulating evidence discussed above, advocating that TLR9 contributes 
to the advancement of HF, it was hypothesised that the immune sensor, TLR9, 
potentially interacts with the β-AR signalling cascade, leading to myocardial 
inflammation and DCM.  
The aim of this study was to develop a murine model of HF, induced by Iso 
infusion, to explore the relationship between TLR9-mediated inflammation and 
the β-AR signalling pathway, in the pathogenesis of HF. Differences in the 
cardiac phenotype of WT and TLR9KO mice, subjected to this model would 
thereby inform on this association. 
 
3.2 Results 
3.2.1 Conception of an Iso infusion model 
Infusion of the β-stimulant Iso has frequently been used as a model of cardiac 
hypertrophy and cardiac dysfunction 299, 306, 311. With its reported capability to 
induce myocardial inflammation 224, Iso was considered an appropriate model 
for investigating the association between the β-AR signalling cascade and 
TLR9-mediated inflammation. Various doses of Iso between 5-30 mg/kg/day for 
1 day up to 2 weeks 312, 313, 314 have been utilised as models of hypertrophy. 
However, previous data from my laboratory group demonstrated that in WT 
mice (Capns1+/+), 50 mg/kg/day Iso for 2 weeks increased posterior wall 
thickness whilst maintaining cardiac function (figure 3.1), suggesting that these 
WT mice were in the compensated phase of cardiac hypertrophy which had not 
yet progressed to HF 306. Other doses of Iso was used by my laboratory prior to 
this study to determine the optimal Iso dose to induce hypertrophy (data not 




Figure 3.1 Mild cardiac hypertrophy observed in WT (Capsn1+/+) mice after 
2 weeks infusion of 50 mg/kg/day Iso. 
Data taken from Taneike et al (2011) 306.  A, Transthoracic M-mode 
echocardiography after 2 weeks infusion of Iso in calpain small 1 (Capsn1) 
genetically modified mice. Scale bars = 0.2 s and 5 mm, respectively. B, 
Echocardiographic and physiological parameters show increased end-diastolic 
posterior wall thickness (LVPWd) in Capsn1+/+ (WT) mice, though no changes 
were observed in left ventricular fractional shortening (LVFS) or heart weight / 
body weight (HW/BW) ratio. This indicates the initiation of the early stages of 
pathological hypertrophy in these WT (Capsn1+/+) mice after 2 weeks infusion of 
50 mg/kg/day Iso. Values expressed as mean ± S.E.M (n = 4 per group); Saline 
(open bars), Iso (closed bars). *p<0.05 versus the corresponding saline-treated 
group; †, p<0.05 versus Iso-treated Capns1+/+ mice. IVSd = End-diastolic 
interventricular septal wall thickness; LVPWd = LV posterior wall thickness; 
LVIDd = End-diastolic LV internal dimension; LVIDs = End-systolic LV internal 
dimension; LVFS = LV fractional shortening. 
 
As cardiac hypertrophy typically progresses to HF 80, it was anticipated that a 
higher and prolonged dose of Iso, compared to this previous study using 50 
mg/kg/day Iso for 2 weeks conducted by my laboratory group (figure 3.1), 
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would result in HF. Therefore, taking these previous findings from my laboratory 
into account, 10 - 11 week-old C57Bl/6 male mice were implanted with osmotic 
minipumps infusing 75 mg/kg/day Iso, 50 mg/kg/day Iso or saline (as control) for 
4 weeks to determine a suitable dose and duration of Iso infusion to induce HF 
(figure 3.2). For this series of experiments, cardiac morphology and function 
was assessed by echocardiography 2 and 4 weeks after minipump implantation. 
Mice were sacrificed 4 weeks after minipump implantation, to obtain 
physiological measurements. 
 
Figure 3.2 Timeline of in vivo procedures for the pilot study. 
To determine a suitable timecourse and concentration of Iso infusion for a 
model of heart failure, 10 – 11-week old WT male mice were implanted with 
minipumps infusing 75 mg/kg/day Iso, 50 mg/kg/day Iso or saline. Mice were 
subjected to echocardiography (echo) 2 and 4 weeks post-implantation. The 
mice were sacrificed on day 29. 
 
 
3.2.1.1 4 weeks treatment of 50 and 75 mg/kg/day Iso induced cardiac 
dilatation and dysfunction. 
Study of cardiac structure and function in vivo was facilitated by M-mode 
echocardiography, which was performed on conscious mice using the LV short 
axis view (refer to section 2.1.3.1). Minor changes in echocardiographic 
parameters were observed 2 weeks after Iso infusion at both doses compared 
to saline-infused mice (figure 3.3). Nonetheless, 4 weeks after Iso infusion, 
end-diastolic and end-systolic measurements of the LV chamber (LVIDd and 
LVIDs) were increased, compared with saline treatment, indicative of LV cardiac 
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chamber dilatation (figure 3.3c). No significant changes were observed in end-
diastolic and end-systolic septal or posterior wall thickness (IVSd, IVSs, LVPWd 
and LVPWs) after 4 weeks of Iso infusion (figure 3.3a-b). Cardiac function, 
depicted by EF* and fractional shortening (FS)†, deteriorated 4 weeks after Iso 
infusion (figure 3.3d) compared with mice treated with saline. In addition, LV 
mass was increased after 4 weeks of Iso treatment compared to saline-treated 
mice (figure 3.3f). Most surprisingly, the heart rate (HR) remained unchanged 
at both doses of Iso compared to saline-infused mice, at all timepoints (figure 
3.3e).  
No differences in echocardiographic parameters were noted between mice 
treated with 50 mg/kg/day Iso and those administered with 75 mg/kg/day Iso, 
after 4 weeks of minipump infusion (figure 3.3), suggesting both doses of Iso 
induce chamber dilatation and cardiac dysfunction to a similar extent.  
 
3.2.1.2 50 mg/kg/day Iso increased heart weight and lung weight.  
After 4 weeks of infusion of 75 mg/kg day Iso, 50 mg/kg/day Iso or saline, the 
mice were sacrificed and the heart, lung and liver tissues were harvested and 
weighed and the tibia lengths were recorded in order to determine any 
physiological variations induced by Iso treatment. Mice infused with 50 
mg/kg/day Iso gained body weight compared with saline-treated mice (figure 
3.4a), though there were no significant differences in the tibia lengths between 
all groups (figure 3.4b). Therefore, all parameters were standardised to tibia 
length to account for the size of the mouse. 
                                            
* Compared to saline-treated mice, EF decreased by 25.47% and 26.65% in 
mice treated with 50 mg/kg/day Iso and 75 mg/kg/day Iso, respectively. 
† FS decreased by 20.50% and 21.94 % in mice treated with 50 mg/kg/day Iso 




Figure 3.3 4 weeks infusion of Iso induced dilated cardiomyopathy.  
Echocardiographic measurements of conscious WT mice 2 and 4 weeks after 
implantation with minipumps infusing 75 mg/kg/day Iso (green), 50 mg/kg/day 
Iso (blue) or saline (white). A, IVSd = End-diastolic interventricular septal wall 
thickness, IVSs = End-systolic interventricular septal wall thickness. B, LVPWd 
= End-diastolic left ventricular posterior wall thickness, LVPWs = End-systolic 
left ventricular posterior wall thickness. C, LVIDd = End-diastolic left ventricle 
internal dimension, LVIDs = End-systolic left ventricle internal dimension. D, EF 
= Ejection fraction, FS = Fractional shortening. E, HR = Heart rate. F = LV 
mass. No changes in echocardiographic parameters were observed after 2 
weeks infusion, however after 4 weeks infusion, Iso induced chamber dilatation 
and cardiac dysfunction. Saline n= 4; 50 mg/kg/day Iso n= 7; 75 mg/kg/day Iso, 
n= 4. Data were analysed by two-way ANOVA with bonferroni’s post-hoc test. 






Figure 3.4 Physiological analysis revealed that 50 mg/kg/day Iso increased 
heart weight and lung weight.  
Mice fitted with minipumps infusing 75 mg/kg/day Iso, 50 mg/kg/day Iso or 
saline were harvested 29 days after implantation and physiological parameters 
were examined. A, Body weight. B, Tibia length (TL). C, Heart weight and heart 
weight / TL. D, Lung weight and lung weight / TL. E, Liver weight and liver 
weight / TL. Mice treated with 50 mg/kg day Iso increased body weight, heart 
weight / TL and lung weight / TL compared to saline-treated mice, whereas no 
difference was seen with mice infused with 75 mg/kg day Iso. Saline (white), n= 
4; 50 mg/kg/day Iso (blue) n= 7; 75 mg/kg/day Iso (green) n= 4. Data were 







Increased heart weight and increased heart weight / tibia length was noted in 
the mice infused with 50 mg/kg/day Iso compared to saline, implying induction 
of cardiac hypertrophy in these mice (figure 3.4c). Lung weight / tibia length 
was significantly increased in mice treated with 50 mg/kg/day Iso mice 
compared to saline-treated mice (figure 3.4d), indicating pulmonary congestion, 
a common feature of left-sided HF. No differences in liver weight or liver weight 
/ tibia length were observed after 4 weeks of Iso infusion, compared to saline-
treated mice (figure 3.4e). No significant alterations were detected in the 
physiological parameters, between mice treated for 4 weeks with saline and 75 
mg/kg day Iso or between mice infused with 75 mg/kg day Iso and 50 
mg/kg/day Iso for 4 weeks (figure 3.4). 
 
3.2.1.3 Summary of pilot study. 
The aim of the pilot study was to determine a suitable dose and timecourse of 
Iso that could be employed as a model of HF for further investigations. From 
preceding studies, it was anticipated that 4 weeks infusion of Iso would lead to 
tachycardia, cardiac hypertrophy, chamber dilatation, body weight gain, 
pulmonary congestion alongside excessive cardiac dysfunction as previously 
reported 80, 295, 313, 315, 316, 317, 318.  
In the pilot study, the echocardiographic data displayed no significant changes 
in the cardiac morphology and function after 2 weeks infusion of Iso at both 
doses compared to saline-infused mice. Whilst, 4 weeks treatment of Iso at both 
doses was sufficient to induce LV chamber dilatation, cardiac dysfunction and 
increased LV mass compared to saline controls, the wall thicknesses and HR 
after 4 weeks of Iso treatment was unexpectedly comparable to saline treated-
mice (table 3.1, see section 3.3.1 for further discussion).  
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Table 3.1 Summary table of pilot study. 
Table to show differences in echocardiographic and physiological parameters 
between 2 different doses of Iso, 50 and 75 mg/kg/day detailed in figures 3.3 
and 3.4. 50 mg/kg/day Iso-infused mice induced more physiological changes 
over 4 weeks than mice treated with 75 mg/kg/day Iso. ✓ = significant difference 
compared to saline-treated mice, X = no difference compared to saline-infused 
mice. PI = pump implantation, LVIDd = End-diastolic left ventricle internal 
dimension, LVIDs = End-systolic left ventricle internal dimension, EF = Ejection 
fraction, FS = Fractional shortening, IVSd = End-diastolic interventricular septal 
wall thickness, LVPWd = End-diastolic left ventricular posterior wall thickness, 
W = Weight, TL = Tibia length. 
 
Phenotype 50 mg/kg/day Iso 75 mg/kg/day Iso 
Chamber dilatation  








4 weeks after PI 
Cardiac dysfunction  








4 weeks after PI 
Cardiac hypertrophy  
Increased IVSd and LVPWd  
Increased LV mass 







4 weeks after PI 







4 weeks after PI 
Body weight  



















Increased body weight, increased heart weight and pulmonary congestion were 
indicated by the physiological data obtained from mice infused for 4 weeks with 
50 mg/kg/day Iso compared with saline (table 3.1). However, no significant 
difference was observed in the physiological parameters between mice infused 
with 75 mg/kg day Iso and mice treated with saline. These surprising findings 
suggest that 50 mg/kg/day Iso induced more significant physiological alterations 
than 75 mg/kg/day Iso infusion, although there were no significant differences 
between mice infused with 50 mg/kg/day Iso or 75 mg/kg/day Iso in all 
echocardiographic and physiological parameters (table 3.1). As it was 
hypothesised that a higher dose of Iso infusion would result in a stronger 
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dysfunctional phenotype, this finding is highly unexpected and is discussed 
further in section 3.3.1.  
Also the measurements of cardiac hypertrophy remain inconclusive as no 
changes to wall thickness was observed by echocardiography, although 
increased heart weight was noted. Further molecular analyses are required to 
determine the induction of cardiac hypertrophy. Although pulmonary congestion 
was observed after Iso infusion, the extent of cardiac dysfunction after Iso 
infusion within this model was not severe enough to induce HF 11, 23, 319, 320, 
suggesting that this model is representative of mild cardiac dysfunction with 
pulmonary congestion.  
Collectively, the pilot study found that 50 mg/kg/day Iso for 4 weeks induced 
more physiological changes than 75 mg/kg/day Iso. Although severe cardiac 
dysfunction and HF was not observed in this model, 50 mg/kg/day Iso (referred 
to as Iso) for 4 weeks was chosen to evaluate the association between TLR9 
and β-AR-signalling as it may provide an insight on the impact of excessive and 
chronic β-AR signalling that may contribute to the progression to HF. Therefore, 
the condition induced by Iso (chamber dilatation, cardiac dysfunction, increased 
heart weight, weight gain and pulmonary congestion) was referred to as β–
stimulant-induced cardiomyopathy.  
A limitation of the pilot study was the lack of echocardiographic data preceding 
minipump implantation. Therefore pre-implantation echocardiography was 
performed in all future experiments to verify no differences between mice prior 
to surgery. Furthermore, as the HR was unchanged between saline- and Iso- 
infused hearts, BP was assessed to monitor the physiological effects of Iso in 




3.2.2 Investigation of the affiliation between TLR9-mediated inflammation 
and β-AR signalling. 
To explore the potential relationship between TLR9-medaited inflammation and 
the β-AR signalling pathway, the experimental model of β–stimulant-induced 
cardiomyopathy devised in the pilot study was implemented to global TLR9KO 
mice, kindly provided by Professor Shizuo Akira (Osaka University, Japan) 177.  
 
3.2.2.1 Genotyping of WT and TLR9KO mice. 
As mentioned in section 2.1.1 TLR9KO mice were previously backcrossed with 
C57Bl/6 mice, warranting the use of C57BL/6 mice as WT controls. The 
breeding strategy intercrossed homozygous knockout (TLR9KO) mice with 
TLR9KO mice to yield only TLR9KO mice (figure 3.5).  
Figure 3.5 Breeding strategy for TLR9KO mice. 
TLR9KO mice that were backcrossed with C57Bl/6 mice were kindly donated by 
Professor Shizuo Akira (Osaka University, Japan). Due to demand for TLR9KO 
(TLR9-/-) mice, TLR9KO were bred with TLR9KO to produce only TLR9KO mice. 




To confirm the genotype of the WT and TLR9KO mice utilised in these 
experiments, DNA was extracted from ear biopsies of the mice and submitted 
for PCR with 2 separate primer combinations. The first primer assortment (WT) 
recognised the WT DNA sequence whilst the other primer set (TLR9KO) 
targeted the neomycin cassette within TLR9KO mice (table 2.1).  The 
genotyping results of WT and TLR9KO mice utilised in this series of 
experiments are displayed in figure 3.6.
 
Figure 3.6 Genotyping results of WT (C57Bl/6) and TLR9KO mice. 
PCR was performed using WT primers or TLR9KO primers (table 2.1) on DNA 
extracted from ear biopsies from WT and TLR9KO mice. Samples were loaded 
onto a 1.5% agarose gel. WT primers amplified a 1.2 kbp region from WT DNA, 
which was not amplified using DNA from TLR9KO mice. Conversely, the 
TLR9KO primers targeted a 1.2 kbp region in the genome of TLR9KO mice, 
whereas no amplification was seen using WT DNA. If mice were heterozygous, 
then both WT and TLR9KO primer sets would amplify the DNA. Therefore, 
samples (S) 1 - 4 have a 1.2 kbp band using WT primers and no band using the 
Neo primers indicating that these mice are WT. Samples 5 - 8 display a 1.2 kbp 
band amplified with the TLR9KO primers, but no band using the WT primers 
indicating that these are TLR9KO mice. M= marker (100 bp ladder), X= empty 
well, P = positive control, N = negative control 
 
3.2.2.2 WT and TLR9KO mice displayed no differences in 
echocardiographic and physiological parameters at baseline. 
To compare the cardiac structure and function between WT and TLR9KO mice 
at baseline, 10 - 11 week-old male mice were subjected to anaesthetised 
echocardiography using 1.5% isoflurane. The following day, mice were 
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harvested for physiological analyses. No significant differences in cardiac 
structure and function relayed by the echocardiographic data or physiological 
measurements were observed between WT and TLR9KO mice at baseline 
(table 3.2 and 3.3).  
 
Table 3.2 No differences in echocardiographic parameters at baseline 
between WT and TLR9KO mice.  
Anaesthetised echocardiography was performed on 10-week-old WT and 
TLR9KO mice to assess cardiac morphology and performance. No differences 
were observed in all echocardiographic parameters at baseline. Data were 
analysed by t-test. IVSd = End-diastolic interventricular septal wall thickness, 
LVPWd = End-diastolic left ventricular posterior wall thickness, LVIDd = End-
diastolic left ventricle internal dimension, IVSs = End-systolic interventricular 
septal wall thickness, LVPWs = End-systolic left ventricular posterior wall 
thickness, LVIDs = End-systolic left ventricle internal dimension, EF = Ejection 






P value Sig. 
(n= 6) (n= 6) 
IVSd (mm) 0.70 ± 0.01 0.70 ± 0.01 0.99 n.s 
IVSs (mm) 1.00 ± 0.02 1.03 ± 0.02 0.20 n.s 
LVIDd (mm) 3.90 ± 0.02 3.85 ± 0.03 0.26 n.s 
LVIDs (mm) 2.69 ± 0.02 2.64 ± 0.03 0.25 n.s 
LVPWd (mm) 0.82 ± 0.02 0.81 ± 0.03 0.91 n.s 
LVPWs (mm) 1.08 ± 0.04 1.02 ± 0.01 0.19 n.s 
     
EF (%) 59.49 ± 0.54 60.03 ± 0.57 0.50 n.s 
FS (%) 31.10 ± 0.37 31.45 ± 0.38 0.53 n.s 
HR (BPM) 447.83 ± 9.80 464.00 ± 22.42 0.52 n.s 










Table 3.3 Physiological parameters were similar between WT and TLR9KO 
mice at baseline. 
Physiological parameters were measured from 10-week-old WT and TLR9KO 
mice, demonstrating no differences between the 2 groups of mice at baseline. 
Data were analysed by student t-test. BP = blood pressure, Sig. = significance, 




P value Sig. 
(n= 6) (n= 6) 
Body weight (g) 25.75 ± 0.42 26.00 ± 0.39 0.67 n.s 
Systolic BP (mmHg) 95.01 ± 3.49 96.94 ± 3.86 0.72 n.s 
 Diastolic BP (mmHg) 68.14 ± 3.02 69.50 ± 3.02 0.76 n.s 
     
Heart weight (mg) 142.88 ± 4.29 141.12 ± 4.98 0.79 n.s 
Lung weight (mg) 146.07 ± 2.92 152.67 ± 4.78 0.27 n.s 
Liver weight (mg) 1231.62 ± 22.25 1339.17 ± 76.25 0.21 n.s 
Tibia length (mm) 17.57 ± 0.22 17.76 ± 0.12 0.46 n.s 
     Heart weight / Body 
weight ratio (mg/g) 5.67 ± 0.19 5.31 ± 0.19 0.21 n.s 
Heart weight / Tibia length 
ratio (mg/mm) 8.15 ± 0.33 7.95 ± 0.28 0.65 n.s 
Lung weight / Body 
weight ratio (mg/g) 5.80 ± 0.16 5.62 ± 0.08 0.33 n.s 
Lung weight / Tibia length 
ratio (mg/mm) 8.32 ± 0.17 8.59 ± 0.24 0.37 n.s 
Liver weight / Body 
weight ratio (mg/g) 48.94 ± 1.50 49.54 ± 3.24 0.87 n.s 
Liver weight / Tibia length 
ratio (mg/mm) 70.17 ± 1.54 75.43 ± 4.27 0.27 n.s 
 
 
3.2.2.3 Cardiac function was modestly salvaged in TLR9KO mice after Iso 
infusion. 
Prior to minipump implantation, echocardiography and BP measurements were 
performed on WT and TLR9KO mice (figure 3.7), followed by implantation of 
minipumps to infuse either 50 mg/kg/day Iso or saline. Echocardiography was 
performed under anaesthesia using 1.5% isoflurane whilst BP measurements 
were performed on conscious mice. 4 weeks after implantation, mice were 





Figure 3.7 Timeline of in vivo procedures.  
10-11-week-old WT and TLR9KO male mice (24 - 27 g) were subjected to 
echocardiography (echo) and blood pressure (BP) measurements pre-
implantation. The mice were fitted with minipumps infusing 50 mg/kg/day Iso or 
saline. 4 weeks later, echo and BP measurements were performed and the 
mice were sacrificed the day after. 
 
 
Figure 3.8 No differences in physiological parameters pre-implantation 
between WT and TLR9KO mice. 
The body weight and blood pressure (BP) measurements showed no difference 
prior to implantation. WT saline (white), WT Iso (light blue), TLR9KO saline 
(grey), TLR9KO Iso (dark blue); n= 8 for all groups.  Data were analysed by 
two-way ANOVA with bonferroni’s post-hoc test.  
 
 
Figure 3.9 Transthoracic M-mode echocardiography pre-implantation 
showed no differences in cardiac morphology between WT and TLR9KO 
mice. 
Transthoracic M-mode echocardiography pre-implantation displayed no 
difference in cardiac morphology and function between WT and TLR9KO mice. 
n= 8 for all groups. Scale bars = 0.2 s and 5 mm respectively. 
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Figure 3.10 No difference in echocardiographic parameters pre-
implantation.  
Anaesthetised echocardiography was performed on WT and TLR9KO prior to 
minipump implantation. A, IVSd = End-diastolic interventricular septal wall 
thickness, IVSs = End-systolic interventricular septal wall thickness. B, LVPWd 
= End-diastolic left ventricular posterior wall thickness, LVPWs = End-systolic 
left ventricular posterior wall thickness. C, LVIDd = End-diastolic left ventricle 
internal dimension, LVIDs = End-systolic left ventricle internal dimension. D, EF 
= Ejection fraction, FS = Fractional shortening. E, HR = Heart rate. F = LV 
mass. No differences were observed in cardiac structural and functional 
parameters. WT saline (white), WT Iso (light blue), TLR9KO saline (grey), 
TLR9KO Iso (dark blue); n= 8 for all groups. Data were analysed by two-way 





As expected, there were no differences in echocardiographic, body weight or 
BP parameters pre-implantation between WT and TLR9KO mice (figures 3.8, 
3.9 and 3.10). Moreover, 4 weeks after minipump implantation, systolic BP, 
diastolic BP and body weight were significantly increased in WT mice after Iso 
infusion, compared to saline-treated mice (figure 3.11), indicating hypertension 
and weight gain. Additionally, these changes were also observed in TLR9KO 
mice with the same treatment, though there were no differences in these 
parameters between Iso-infused WT and TLR9KO mice. Tachycardia with an 
elevated HR of approximately 190 bpm was observed in Iso-infused WT mice 
compared to saline-treated mice, which was additionally observed in TLR9KO 
mice after Iso infusion (figure 3.12 and 3.13e). There was also a significant 
increase in the LVPWd in WT mice after Iso infusion, compared to saline 
treated mice, but no difference between saline- and Iso- treated TLR9KO mice 
(figure 3.13b). Considering that echocardiographic parameters are HR 
dependent alongside elevation of the HR by 44% in both WT and TLR9KO Iso-
infused mice, compared to saline-treated mice, it was technically challenging to 
compare and interpret the data between saline- and Iso- infused mice. 
 
Figure 3.11 Iso induced physiological changes after 4 weeks infusion in 
WT and TLR9KO mice. 
After 4 weeks infusion of Iso, the body weight and BP were increased in WT 
and TLR9KO mice. WT saline (white), WT Iso (light blue), TLR9KO saline 
(grey), TLR9KO Iso (dark blue); n= 8 for all groups. Data were analysed by two-





Figure 3.12 Transthoracic M-mode echocardiography indicated 
tachycardia in mice subjected to Iso treatment. 
Transthoracic M-mode echocardiography after 4 weeks infusion of Iso in WT 
and TLR9KO mice revealed increased heart rate in mice treated with Iso. Scale 
bars = 0.2 s and 5 mm respectively. n= 8 for all groups. 
 
Therefore, echocardiography was also performed using different percentages of 
isoflurane (ISF) to achieve heart rates within a range of 450 – 550 BPM (figure 
3.14). Using this method, Iso infusion in WT mice increased LVPWd, LVIDd, 
LVIDs and LV mass and reduced EF and FS, compared to saline-treated mice 
which suggested induction of cardiac hypertrophy, chamber dilatation and 
cardiac dysfunction after Iso infusion in WT mice (figure 3.15). Whilst Iso 
infusion in TLR9KO mice exhibited chamber dilatation (figure 3.15c), 
comparable to WT mice after Iso infusion, LVPWd or LV mass were not 
increased compared to saline-treated TLR9KO mice (figure 3.15b, f). 
Additionally, the cardiac function was modestly improved in the Iso-infused 
TLR9KO mice compared with WT mice infused with Iso (figure 3.15d). These 
exciting findings insinuate that Iso-induced cardiac dysfunction and thickened 
walls were partially blunted in TLR9KO mice, compared to WT mice suggesting 
that TLR9 may influence cardiac function and potentially cardiac hypertrophy 







Figure 3.13 Tachycardia was observed in Iso- infused WT and TLR9KO 
mice. 
Echocardiographic measurements were performed under anaesthesia using 
1.5% isoflurane on WT and TLR9KO mice after 4 weeks infusion of Iso. A, IVSd 
= End-diastolic interventricular septal wall thickness, IVSs = End-systolic 
interventricular septal wall thickness. B, LVPWd = End-diastolic left ventricular 
posterior wall thickness, LVPWs = End-systolic left ventricular posterior wall 
thickness. C, LVIDd = End-diastolic left ventricle internal dimension, LVIDs = 
End-systolic left ventricle internal dimension. D, EF = Ejection fraction, FS = 
Fractional shortening. E, HR = Heart rate. F = LV mass. HR was increased by 
approximately 190 BPM in WT and TLR9KO Iso-infused mice compared to 
saline-infused mice. WT saline (white), WT Iso (light blue), TLR9KO saline 
(grey), TLR9KO Iso (dark blue); n= 8 for all groups. Data were analysed by two-







Figure 3.14 Transthoracic M-mode echocardiography using 
echocardiographic method 2 exhibited dilated cardiomyopathy after Iso 
infusion in WT and TLR9KO mice. 
Transthoracic M-mode echocardiography after 4 weeks infusion of Iso or saline 
in WT and TLR9KO mice. Anaesthetised echocardiography was performed 
using different percentages of isoflurane to bring heart rates to between 450 





Figure 3.15 Performing echocardiography to match heart rates (HRs) 
revealed a rescue of cardiac function in TLR9KO mice after Iso infusion. 
Anaesthetised echocardiography was performed using different percentages of 
isoflurane to bring HRs to between 450 and 550 bpm. A, IVSd = End-diastolic 
interventricular septal wall thickness, IVSs = End-systolic interventricular septal 
wall thickness. B, LVPWd = End-diastolic left ventricular posterior wall 
thickness, LVPWs = End-systolic left ventricular posterior wall thickness. C, 
LVIDd = End-diastolic left ventricle internal dimension, LVIDs = End-systolic left 
ventricle internal dimension. D, EF = Ejection fraction, FS = Fractional 
shortening. E, HR. F = LV mass. Though chamber dilatation and cardiac 
dysfunction were observed in WT and TLR9KO Iso infused mice, there was 
partial recovery of LVPWd thickness and cardiac function after Iso infusion in 
TLR9KO mice compared with WT mice. WT saline (white), WT Iso (light blue), 
TLR9KO saline (grey), TLR9KO Iso (dark blue); n= 8 for all groups. Data were 




3.2.2.4 Blunted gain of heart weight after Iso infusion in TLR9KO mice. 
After 4 weeks of saline or Iso infusion, WT and TLR9KO mice were sacrificed 
and their organs were harvested for physiological analyses. Compared to 
saline-treated mice, Iso infusion in WT mice induced body weight gain, yet did 
not affect the tibia length (figure 3.16a-b). Heart, lung and liver weights 
normalised to tibia length were significantly upregulated in Iso-infused WT mice 
compared to saline-treated mice (figure 3.16c-e), indicative of cardiac 
hypertrophy, pulmonary congestion and systemic congestion.  
TLR9KO mice presented similar changes in physiological parameters as WT 
mice after Iso treatment. The heart weight / tibia length was increased in both 
WT and TLR9KO mice after Iso infusion, however, most intriguingly the 
increase in this parameter was significantly less in Iso-infused TLR9KO mice 
compared to WT Iso- infused mice (figure 3.16c). Therefore these findings 
suggest that after Iso infusion, both WT and TLR9KO mice induce body weight 
gain, pulmonary congestion and systemic congestion to a similar extent, yet 
TLR9KO mice were less susceptible to Iso-induced heart weight gain than WT 
mice. These exciting findings suggest that TLR9 may influence the progression 






Figure 3.16 Less gain in heart weight in TLR9KO mice infused with 50 
mg/kg/day Iso for 4 weeks compared with WT mice. 
Physiological parameters were measured in WT and TLR9KO mice after 4 
weeks Iso infusion. A, Body weight. B, Tibia length (TL). C, Heart weight and 
heart weight / TL. D, Lung weight and lung weight / TL. E, Liver weight and liver 
weight / TL. WT and TLR9KO mice subjected to Iso infusion gained weight and 
the mass of the heart, liver and lungs were increased compared with saline-
treated mice. However, the gain in heart weight was reduced in TLR9KO-Iso 
infused mice compared with WT Iso-treated mice. WT saline (white), WT Iso 
(light blue), TLR9KO saline (grey), TLR9KO Iso (dark blue); n= 8 for all groups. 
Data were analysed by two-way ANOVA with bonferroni’s post-hoc test. 






3.2.2.5 Investigation of the hypertrophic response after Iso infusion in WT 
and TLR9KO mice  
Several preceding studies demonstrated that Iso induces cardiac hypertrophy 
295, 296, 311. At the cellular level, this is characterised by increased cardiomyocyte 
CSA, re-expression of foetal genes and elevated protein synthesis. Moreover, 
these changes are also detected in the failing heart. Thus, to study if the 
hypertrophic response was activated after Iso infusion in WT and TLR9KO 
mice, staining with H & E and WGA was performed to measure cardiomyocyte 
CSA, alongside qRT-PCR to monitor changes in foetal gene expression. 
 
3.2.2.5.1 Increased cardiomyocyte CSA after Iso infusion in WT mice. 
Samples for histological analysis were harvested from WT and TLR9KO mice 
after Iso infusion. Initially, these heart samples were embedded in paraffin, 
sectioned and stained with H & E. Unfortunately in all of the paraffin-embedded 
sections, large spaces between cardiomyocytes were observed (figure 3.17a), 
that were speculated to be a consequence of artefacts in the fixation or 
embedding procedures. In an attempt to optimise the paraffin-embedding 
protocol, different fixation protocols were performed, modifying the 
concentration of fixatives  (PFA or FA), the period of fixation (4 or 24 hours) and 
temperatures (4oC or RT). Despite these adjustments, the gaps between 






Figure 3.17 Optimising the fixation conditions for paraffin embedding did 
not resolve the breaching of cardiomyocytes. 
A, Hematoxylin and Eosin (H & E) staining on paraffin embedded heart sections 
from WT and TLR9KO mice infused for 4 weeks with 50 mg/kg/day Iso or saline 
revealed gaps between cardiomyocytes. B, Heart sections using different 
fixation conditions (fixatives, temperatures and durations) were subjected to H & 
E staining. PFA= paraformaldehyde. Images taken at 200x magnification, scale 
bar = 30 µm. 
 
As paraffin-embedded samples were unsuitable for staining, H & E staining was 
performed on cryosections of hearts of WT and TLR9KO mice after Iso infusion. 
The staining suggests there was an increase in the CSA after Iso infusion in 
both WT and TLR9KO mice (figure 3.18) (data not quantified). To quantitate 
the changes in cardiomyocyte CSA after Iso treatment, WGA staining was 
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performed and the CSA of 100 cardiomyocytes per section was measured using 
Image J software. Analysis of CSA measurements exhibited a significant 
increase in the cardiomyocyte CSA after Iso infusion in WT mice, compared to 
saline-treated mice, indicative of cardiac hypertrophy (figure 3.19). In contrast, 
no differences were observed between saline- and Iso- infused TLR9KO mice 
or between Iso-treated WT and TLR9KO mice. Although these current findings 
suggests a blunted cardiac hypertrophic response in TLR9KO mice subjected to 
Iso, compared to WT mice, further samples are required to confirm this finding 
as the p value for TLR9KO subjected to saline and Iso treatment is close to 












Figure 3.18 Haematoxylin & Eosin (H & E) staining using cryosections of 
hearts from WT and TLR9KO mice infused with Iso for 4 weeks. 
H & E staining on cryosections of heart tissue from WT and TLR9KO mice 
infused for 4 weeks with 50 mg/kg/day Iso or saline. Cardiomyocyte cross-
sectional area (CSA) appears to be increased in Iso infused mice. n = 5 for all 





Figure 3.19 Wheat germ agglutinin (WGA) staining presented an increase 
in cardiomyocyte cross-sectional area (CSA) in WT mice infused with Iso, 
but no difference in the TLR9KO mice. 
A, WGA staining was performed on cryosections on myocardium harvested 
from WT and TLR9KO mice after 4 weeks of Iso infusion. Scale bar = 30 µm. B, 
Quantification of cardiomyocyte CSA revealed an increase in WT mice treated 
with Iso compared with saline treated mice, which was not observed with the 
TLR9KO mice infused with Iso. Green signal (FITC, lectin), blue signal (DAPI, 
DNA). WT saline (white), WT Iso (light blue), TLR9KO saline (grey), TLR9KO 
Iso (dark blue); n= 5 for all groups. Values expressed as mean ± SEM. Data 
were analysed by two-way ANOVA with bonferroni’s post-hoc test. *p<0.05. p 
value for TLR9KO saline versus TLR9KO iso is 0.079. 
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3.2.2.5.2 Iso infusion did not induce expression of foetal genes. 
The mRNA levels of foetal genes, natriuretic peptide A (Nppa), Nppb and 
myosin heavy chain 7 beta (Myh7) were evaluated by qRT-PCR using LV 
samples of WT and TLR9KO mice after Iso infusion. Most unexpectedly, Nppa 
expression was significantly reduced after Iso infusion in WT mice, compared to 
saline-treated mice (figure 3.20). However this surprising change was not 
observed between TLR9 saline- and Iso- treated mice. Furthermore, no 
differences in Nppb and Myh7 expression were detected between saline- and 
Iso- treated WT mice, which was analogous to TLR9KO mice after Iso infusion.  
 
 
Figure 3.20 Foetal genes were not induced in the myocardium of WT and 
TLR9KO mice after Iso infusion. 
qRT-PCR analysis was performed on left ventricular cDNA samples of WT and 
TLR9KO mice subjected to 4 weeks treatment of Iso. Levels of natriuretic 
peptide A (Nppa) were reduced in WT iso-infused mice compared with WT 
saline-infused mice, whereas no difference was seen in TLR9KO mice. 
Expression of Nppb and myosin heavy chain 7 beta (Myh7) remained indifferent 
after Iso infusion in WT and TLR9KO mice. Glyceraldehyde 3-phosphate 
dehydrogenase (Gapdh) was used as a housekeeping gene. Values expressed 
as mean ± SEM. WT saline (white), WT Iso (light blue), TLR9KO saline (grey), 
TLR9KO Iso (dark blue); n= 5 for all groups. Data were analysed by two-way 






3.2.2.5.3 Primers targeting natriuretic peptide A were validated. 
As the qRT-PCR results regarding Nppa expression were unexpected, the 
primers were validated. Firstly, the quality and purity of the RNA was re-
assessed and was adequate for experiments.  The reverse transcription and 
qRT-PCR reaction were repeated, yielding similar results as before. Next, the 
specificity of the primers used for qRT-PCR was assessed by melt curve 
analysis. These primers exhibited 1 peak, indicating that the primers amplify a 
single PCR product (figure 3.21). Therefore qRT-PCR was performed using 
primers targeting Nppa and LV homogenates harvested from WT mice 
subjected to TAC, kindly provided by Dr Manabu Taneike (King’s College 
London) (figure 3.22a). As expected, a significant increase was observed in 
Nppa levels, confirming the specificity of these primers. Finally, a Taqman 
assay for Nppa and Gapdh was used on samples from WT and TLR9KO mice 
infused for 4 weeks with Iso or saline, which also demonstrated similar results 
to the initial data (figure 3.22b).  Together, these results indicate that Nppa 









Figure 3.21 Melt curve of natriuretic peptide A targeting primers.  
Natriuretic peptide A (Nppa) primers were subjected to a melt curve analysis, 
rendering 1 peak. This confirms that the primers amplify 1 product from DNA 




One explanation for the lack of upregulated hypertrophic markers might be the 
timepoint at which these samples were harvested.  Therefore to determine the 
expression of foetal genes at an earlier timepoint, mice were infused with saline 
or 50 mg/kg/day Iso for 2 weeks. Although the numbers of experimental 
replicates were too low to analyse the data statistically, the data from these 
samples indicate that even at an earlier timepoint, there was no induction of 
foetal gene expression after Iso infusion (figure 3.23e-f). It was also 
contemplated that the Iso concentration may be excessive. Therefore heart 
samples were obtained from mice infused for 2 weeks with 30 mg/kg/day Iso, 
kindly provided by Dr James Clark (King’s College London). Although cardiac 
dysfunction was observed in these mice after Iso infusion (figure 3.23j), there 
was again no difference observed in the expression of hypertrophic markers 
after Iso infusion (figure 3.23k-l). In summary, the findings presented in this 
section detected no upregulation of hypertrophic markers in samples using 
different concentrations of Iso for different infusion periods.  
Figure 3.22 Verification of primers targeting natriuretic peptide A.  
A, qRT-PCR was performed on cDNA using cardiac homogenates of WT mice 
subjected to transverse aortic constriction (TAC) from Dr Manabu Taneike 
(King’s College London) using primers targeting natriuretic peptide A (Nppa). 
Nppa was induced after pressure overload. Sham (open) and TAC (orange). n= 
3. B, qRT-PCR was performed using a Taqman assay for Nppa on samples 
from left ventricular samples of WT and TLR9KO mice subjected to 4 weeks 
treatment of Iso. No difference was observed in all groups. n= 5. Values 
expressed as mean ± SEM. Glyceraldehyde 3-phosphate dehydrogenase 





Figure 3.23 Foetal genes expression was not elevated in models using 
different doses and timecourses of Iso. 
The mRNA levels of natriuretic peptide A (Nppa) and natriuretic peptide B 
(Nppb) were measured in different models of Iso known to induce hypertrophy. 
A-F, Data from WT mice subjected to 2 weeks infusion of saline (open bars, n= 
1) or 50 mg/kg/day Iso (pink bars, n= 2). A - D, Echocardiographic parameters. 
A, IVSd = End-diastolic interventricular septal wall thickness. B, LVPWd = End-
diastolic left ventricular posterior wall thickness. C, LVIDd = End-diastolic left 
ventricle internal dimension. D, FS = Fractional shortening. E and F, mRNA 
expression of Nppa and Nppb from cardiac tissue. G - L, Murine heart samples 
donated by Dr James Clark (King’s College London) after 2 weeks infusion of 
saline (open bars, n= 3) or 30 mg/kg/day Iso (red bars, n= 4). Data were 
analysed by student’s t-test. G - J, Echocardiographic parameters. K and L, 




3.2.2.6 Examination of the inflammatory response of WT and TLR9KO 
mice after Iso infusion.  
To determine whether TLR9-mediated inflammation contributed to the 
detrimental role of TLR9 on heart function and weight, the inflammatory 
response after Iso infusion was examined between WT and TLR9KO mice. IHC 
staining to detect cell surface markers of inflammatory cells was performed 
alongside qRT-PCR analyses of the expression of chemokines and pro-
inflammatory cytokines.  
 
3.2.2.6.1 No changes in the number of inflammatory cells after Iso 
treatment in WT and TLR9KO mice. 
IHC staining was executed on cryosections of the myocardium obtained from 
WT and TLR9KO mice infused with saline or Iso for 4 weeks. Expression of 
CD45, a leukocyte marker that relays information about the general immune 
response 321 was examined, alongside more specific markers which included 
CD68, a macrophage marker 322, Ly6G/C, a neutrophil marker 323 and CD3, a T 
cell marker 324 (figure 3.24). To determine if there were any modest changes in 
the number of infiltrating cells, the number of CD45-positive, CD68-positive, 
Ly6G/C-positive and CD3-positive cells were quantified from 5 random images 
acquired per section. However no significant differences in the number of 
CD45-, CD68-, Ly6G/C- or CD3- positive inflammatory cells were observed 
between saline- and Iso- treated WT mice (figure 3.25). Moreover, the number 
of these cells was similar between WT and TLR9KO mice treated with saline or 
Iso. As this data stands, these findings suggest that an inflammatory response 
was not activated after Iso infusion. However, there are tendencies within the 
data to suggest that Iso increases the recruitment of CD45-, CD68-, or CD3- 
136 
 
positive inflammatory cells, therefore increasing the number of samples would 
either prove or disprove this potential trend. 
 
 
Figure 3.24 Immunohistochemical (IHC) staining suggests no differences 
in the number of inflammatory cells in the myocardium in WT and TLR9KO 
mice after Iso treatment. 
IHC staining for inflammatory cell markers was performed on cryosections of 
myocardium harvested from WT and TLR9KO after 4 weeks of Iso infusion. 
Images acquired at 400x magnification, Scale bar = 30 µm. Staining was 
performed to detect cells expressing CD45 = leukocytes, CD68 = macrophages, 
Ly6G/C = neutrophils and CD3 = T-cells. There was no obvious difference in 
the infiltration of inflammatory cells into the myocardium of WT and TLR9KO 





















3.2.2.6.2 mRNA levels of cytokines and chemokines remained unchanged 
after Iso infusion. 
mRNA levels of the pro-inflammatory cytokines, tumour necrosis factor (Tnf)-a, 
interleukin (Il)-1b, Il6, Il10, Il12b, interferon (Ifn)-b1 and Ifng and chemokines, 
chemokine C-C motif ligand (Ccl)-2 and Ccl5 were evaluated by qRT-PCR 
using LV homogenates harvested from WT and TLR9KO mice infused with Iso. 
 
Figure 3.25 No quantifiable changes in the infiltration of inflammatory 
cells into myocardial tissue after Iso infusion in WT and TLR9KO mice. 
To study the infiltration of inflammatory cell markers into the myocardium of WT 
and TLR9KO after 4 weeks of Iso infusion, IHC staining was performed. The 
number of 3,3'-Diaminobenzidine (DAB)-positive cells after each stain were 
counted from 5 images per heart at 400 x magnification and expressed as cells 
per mm2. A, CD45 = leukocytes. B, CD68 = macrophages. C, Ly6G/C = 
neutrophils. D, CD3 = T-cells. No changes were observed in myocardial 
inflammatory cell infiltration after Iso infusion in WT and TLR9KO mice. WT 
saline (white), WT Iso (light blue), TLR9KO saline (grey), TLR9KO Iso (dark 
blue); n= 3 for all groups. Values expressed as mean ± SEM. Data were 





Figure 3.26 mRNA expression of chemokines and cytokines was not 
upregulated in WT and TLR9KO mice after infusion with Iso. 
qRT-PCR analysis was performed on LV samples of WT and TLR9KO mice 
after 4 weeks of Iso infusion. A, mRNA expression of chemokines. Ccl5 = 
chemokine (C-C motif) ligand 5 and Ccl2. B - D, Cytokine mRNA expression. B, 
Tnfa = tumour necrosis factor α. C, Ifnb = interferon β. D, Il1b = interleukin 1β, 
Il6 and Il12b. Gapdh (Glyceraldehyde 3-phosphate dehydrogenase) was used 
as a housekeeping gene. No difference in the expression levels of chemokines 
and cytokines after 4 weeks Iso treatment was observed in WT and TLR9KO 
mice.  Il10 and Ifny were undetectable. Values expressed as mean ± SEM.  WT 
saline (white), WT Iso (light blue), TLR9KO saline (grey), TLR9KO Iso (dark 
blue); n= 5 for all groups. Data were analysed by two-way ANOVA with 
bonferroni’s post-hoc test. 
 
Analysis of these samples determined no differences in the expression of 
chemokines, Ccl2 and Ccl5 (figure 3.26a) and cytokines, Tnfa, Il1b, Il6, Il12b, 
and Ifnb between WT mice infused with saline and Iso (figure 3.26 b-d). 
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Additionally, there were no differences in the expression of these markers 
between WT and TLR9KO mice after saline or Iso treatment. Il10 and Ifng were 
undetectable in all samples (not shown). There were tendencies within the data 
to suggest that Iso increases the mRNA expression of chemokines, Ccl2 and 
Ccl5 and decreases the expression of cytokines, Tnfa, Il6, Il12b, and Ifnb. Also 
there may a decreasing trend in mRNA expression of these cytokines (Tnfa, Il6, 
Il12b, and Ifnb) between WT and TLR9KO mice subjected to saline treatment.  
Therefore as the data stands, the findings of the IHC staining in section 
3.2.2.6.1 and the results presented here indicate that an inflammatory response 
was not stimulated after Iso infusion and inflammation is unlikely to contribute to 
TLR9-mediated heart weight gain and dysfunction. However, there are several 
trends observed within the data (discussed above), therefore more samples are 
required to prove / disprove these tendencies.  
 
3.2.2.7 Study of the fibrotic response after Iso infusion in WT and TLR9KO 
mice. 
Several reports have demonstrated increased fibrosis after Iso infusion 296, 325, 
326, therefore it was questioned whether fibrosis contributes to TLR9-mediated 
cardiac dysfunction and heart weight gain. Levels of fibrosis were assessed by 
MT staining and qRT-PCR to determine the mRNA levels of fibrotic markers 
using samples harvested from WT and TLR9KO mice after Iso infusion. 
 
3.2.2.7.1 MT staining and Picrosirius Red staining indicated no fibrosis 
after Iso infusion. 
MT staining was performed on myocardial cryosections harvested from WT and 
TLR9KO mice after Iso infusion. Images displayed in figure 3.27a surprisingly 
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suggested no obvious difference in the extent of fibrosis between all groups. 
Therefore the fibrotic staining was quantified using Image J software to 
determine any variations. These analyses similarly indicated no differences in 
the levels of fibrosis between saline- and Iso- treated WT mice (figure 3.27b), 
which was uniform with TLR9KO mice after saline or Iso infusion.  
 
Figure 3.27 Masson’s Trichrome staining revealed no difference in cardiac 
fibrosis in WT and TLR9KO mice after Iso infusion for 4 weeks 
No difference in fibrosis was detected in WT and TLR9KO mice after treatment 
of Iso for 1 month. A, Images of Masson’s Trichrome staining. Scale bar = 30 
µm. B, Quantification of fibrotic area. Five images per section were analysed 
using Image J software. Values expressed as mean ± SEM. n= 3 per group. 




As MT staining detected little fibrosis, a more sensitive method, Picrosirius Red 
staining, was performed to assess the extent of fibrosis between WT saline- and 
WT Iso- infused mice (figure 3.28). Picrosirius Red staining found no significant 
difference in fibrosis between WT saline and WT Iso-infused hearts, suggesting 
no induction of fibrosis after Iso infusion. However, both figures 3.27b and 
3.28b display a trend towards increased levels of fibrosis after Iso infusion in 
WT mice and TLR9KO mice, therefore more samples are required to confirm 
this trend. 
  
Figure 3.28 Picrosirius Red staining confirmed no changes in fibrosis 
after Iso infusion in WT mice. 
A, Picrosirius Red staining was performed on heart sections of WT mice, 
showing no difference in fibrosis between saline and Iso-infused animals, 
corroborating the findings in figure 3.27. Scale bar = 500 µm. B, Quantification 
of fibrotic area. Values expressed as mean ± SEM. Saline = open bars, Iso = 




3.2.2.7.2 Col1a2 and Col3a1 mRNA levels were not upregulated after Iso 
infusion. 
The mRNA levels of fibrotic markers, collagen type 1 alpha 2 (Col1a2) and 
collagen type 3 alpha 1 (Col3a1) were measured by qRT-PCR using LV 
homogenates from WT and TLR9KO mice infused with Iso. However there was 
no significant difference in the expression of the different markers between 
saline and Iso WT mice, which was comparable with TLR9KO mice after the 
same treatment (figure 3.29). However, figure 3.29 suggests a trend towards 
increased expression of fibrotic markers after Iso infusion in WT mice and 








This unexpected, uniform expression of fibrotic markers after Iso infusion 
questioned the accuracy of the primers, therefore qRT-PCR was performed 
using primers targeting Col1a2 and Col3a1 on mRNA isolated from the LV of 
mice subjected to TAC, kindly provided by Manabu Taneike (King’s College 
Figure 3.29 No difference in the mRNA levels of fibrotic markers in WT 
and TLR9KO mice after 4 weeks of Iso treatment. 
LV samples of WT and TLR9KO mice subjected to 4 weeks infusion of Iso were 
used to analyse fibrotic markers by qRT-PCR analysis. Levels of collagen type 
1 alpha 2 (Col1a2) and Col3a1 were indifferent between WT and TLR9KO mice 
after Iso infusion. Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) was 
used as a housekeeper. Values expressed as mean ± SEM. WT saline (white), 
WT Iso (light blue), TLR9KO saline (grey), TLR9KO Iso (dark blue); n= 5 for all 
groups. Data were analysed by two-way ANOVA. 
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London). An increase in Col1a2 and Col3a1 expression was detected in WT 
mice subjected to TAC compared to sham-operated mice, validating these 
primers (figure 3.30). Hence, these current findings suggest that there was 
surprisingly no induction of fibrosis after Iso treatment in both WT and TLR9KO 







Figure 3.30 Mice subjected to transverse aortic constriction exhibited 
elevated levels of fibrotic markers, 
The effectiveness of the primers targeting fibrotic markers were evaluated using 
cardiac tissue from WT mice subjected to transverse aortic constriction (TAC) 
from Dr Manabu Taneike (King’s College London) using primers targeting 
collagen type 1 alpha 2 (Col1a2) and Col3a1. An increase in the expression of 
fibrotic markers was observed in TAC operated mice compared with Sham, 




3.2.2.8 Study of apoptosis after Iso infusion in WT and TLR9KO mice.  
Cell death by apoptosis is another reported consequence of Iso infusion 295. 
Therefore to determine whether apoptosis contributed to TLR9-mediated 
cardiac dysfunction after Iso infusion, terminal deoxynucleotidyl transferase 
(TdT)-deoxyuridine triphosphate (dUTP) nick end labeling (TUNEL) staining and 






3.2.2.8.1 TUNEL staining indicated no difference in apoptosis after Iso 
infusion. 
Fragmented DNA with nicked ends is a characteristic feature of apoptosis 327. 
TUNEL staining uses TdT enzymes to label these nicked ends with dUTP 
conjugated to fluorophores, thereby signalling activation of cellular apoptosis. 
TUNEL staining using paraffin-embedded sections was established in my 
laboratory group 156, 328. However, cryosections were utilised for histological 
experiments, due to the issues with paraffin-embedded sections described in 
figure 3.17. Fortunately, the kit used for TUNEL staining provided a protocol for 
the use of cryosections. The sections were fixed in acetone at 4oC for 15 
minutes followed by incubation with the permeabilisation buffer provided with 
the kit. However there was poor detection of the FITC and DAPI signal using 
the cryosections compared with the paraffin-embedded sections (figure 3.31a). 
It was speculated that the permeabilisation was inadequate, therefore the 
sections were permeabilised with 0.25% Triton for 20 minutes (figure 3.31b). 
However this did not improve the signal. Next, the fixation conditions were 
altered by utilising 4% PFA for 1 hour at RT, followed by permeabilisation in 
0.25% Triton for 20 minutes.  These conditions proved to be successful (figure 
3.31b) and were used in subsequent TUNEL staining experiments.  
TUNEL staining was performed on cryosections of hearts from WT and 
TLR9KO mice infused with 50 mg/kg/day Iso or saline for 4 weeks, using the 
optimised protocol described above. Images of TUNEL-positive cells are 
displayed in figure 3.32a. TUNEL-positive cells were defined as bright FITC 
signal, which overlapped with the DAPI signal (confirming that this signal was 
coming from DNA) and also overlay with the TRITC signal, indicating that these 




Figure 3.31 Optimisation of TUNEL staining enhanced the DAPI signal. 
A, TUNEL staining performed on cryosections did not reveal any DAPI signal, 
whereas paraffin embedded sections showed strong DAPI signal. DAPI (DNA), 
FITC (TUNEL-positive nuclei), TRITC (α-sarcomeric actin for cardiomyocytes). 
Scale bar = 30 µm. Thus different fixation and permeabilisation conditions were 
tested, with protocol 2 being successful. B, DAPI staining was performed on 
spare cryosections using different fixation and permeabilisation methods. 
Protocol 1; sections were fixed using acetone for 15 minutes at 4oC and 
permeabilised using 0.25% Triton X-100, followed by DAPI staining. Protocol 2; 
4% PFA for an hour at room temperature and then sections were permeabilised 
using 0.25% Triton for 20 minutes and stained with DAPI. 
 
The number of TUNEL-positive cardiomyocytes in the entire heart section were 
counted and expressed as a proportion of the number of TUNEL-positive cells 
per 105 nuclei of cardiomyocytes (figure 3.32b). No significant differences in 
the number of TUNEL-positive cells were observed between WT and TLR9KO 
mice after Iso infusion, suggesting no stimulation of apoptotic pathways. A 
tendency towards more TUNEL-positive cells after Iso infusion in WT mice 
could be suggested from figure 3.32b, however more samples are required to 
confirm this trend. 
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Figure 3.32 TUNEL staining identified no difference in apoptosis in the 
myocardium of WT and TLR9KO mice infused with Iso.  
A, TUNEL staining performed on cryosections of hearts revealed no difference 
in the number of TUNEL-positive nuclei (white arrows) in the hearts of WT and 
TLR9KO mice treated with Iso. DAPI (DNA), FITC (TUNEL-positive nuclei), 
TRITC (α-sarcomeric actin for cardiomyocytes). Positive control section was 
incubated with DNase I prior to TUNEL staining. Scale bar = 30 µm. B, 
Quantification of TUNEL-positive cells per 105 nuclei, expressed as mean ± 
SEM. WT saline (white), WT Iso (light blue), TLR9KO saline (grey), TLR9KO Iso 
(dark blue); n= 3 per group. Data were analysed by two-way ANOVA with 
bonferroni’s post-hoc test.   
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3.2.2.8.2 Cleaved caspase-3 expression was unchanged after Iso infusion. 
Upon activation of the apoptotic signalling cascade, initiator caspases cleave 
the effector caspase, procaspase-3, into its active form, which consequently 
cleaves cellular contents 129, 131. Thus the apoptotic response after Iso infusion 
in WT and TLR9KO mice was examined by Western blot analysis of 
procaspase-3 and its cleaved form using LV homogenates. There were no 
differences in the expression of procaspase-3 between WT and TLR9KO mice 
after Iso infusion (figure 3.33). Additionally, there was no detection of the 
cleaved form of procaspase-3 in all groups, suggesting very little apoptosis in 
these mice. However more samples are required to support these claims. 
 
Figure 3.33 No change in caspase-3 activation after Iso infusion in WT and 
TLR9KO mice. 
A, Western blot analysis showed no change in procaspase-3 and cleaved 
caspase-3 expression in LV homogenates between WT and TLR9KO mice 
subjected to Iso treatment. M = marker (values in kDa). Red arrows correspond 
to quantified bands. B, Densimetric analysis. Values displayed as mean ± SEM. 
WT saline (white), WT Iso (light blue), TLR9KO saline (grey), TLR9KO Iso (dark 
blue); n= 3 for all groups. Data were analysed by two-way ANOVA with 





Collectively, the most important results from this chapter demonstrate that TLR9 
induces cardiac dysfunction and heart weight gain, through an association with 
the β-AR signalling pathway. However, the current data displays that neither, 
fibrosis, apoptosis or inflammation were involved in TLR9-mediated cardiac 
dysfunction and heart weight gain. These findings propose a novel role of TLR9, 
independent of its inflammatory function, which influences cardiac function and 
heart weight and may prove to be detrimental during the progression of HF. In 
addition, this chapter has demonstrated that excessive, constant and chronic 
infusion of Iso does not induce typical HF, but mild cardiac dysfunction and was 
referred to as β-stimulant-induced cardiomyopathy (figure 3.34).  
 
 
Figure 3.34 Summary findings of this chapter. 
Excessive, constant and chronic β-adrenergic receptor (β-AR) stimulation 
caused β-stimulant-induced cardiomyopathy, which has multiple effects of 
cardiac function and structure, however, surprisingly did not induce fibrosis, 
apoptosis or foetal gene expression. The most exciting findings were identifying 




3.3.1 Iso treatment induced dilated cardiomyopathy. 
A pilot study was conducted to determine a suitable timecourse and 
concentration of Iso to induce HF. Based on previous studies from my research 
group discussed in section 3.2.1 306, 2 doses of Iso were used in this current 
study, with the expectation that the higher dose would induce a quicker and 
more robust HF phenotype. As mentioned, well-established traits of Iso infusion, 
tachycardia, cardiac hypertrophy, LV chamber dilatation, body weight gain, 
pulmonary congestion alongside cardiac dysfunction, were anticipated 
outcomes of Iso infusion in this current model 80, 295, 313, 315, 316, 317, 318.  
Although cardiac dilatation and dysfunction and increased LV mass were 
observed 4 weeks after Iso infusion at both doses (figure 3.3c, d, f), there were 
surprisingly no changes in HR or wall thickness (IVSd or LVPWd) parameters 
after 4 weeks of Iso infusion (figure 3.3b, e). For the pilot study, 
echocardiography was performed on conscious mice with HR between 700 - 
800 bpm. With physiological HR values between 500 to 600 bpm 329, it is 
plausible that the mice were stressed during echocardiography, increasing the 
levels of circulating catecholamines and elevating the HR. The HR may have 
reached its maximal value in both saline- and Iso- treated mice thus masking 
the effects of the Iso treatment. In addition, with such a high HR, there may be 
difficulties associated with accurately viewing the wall thickness by short axis M-
mode echocardiography. 
The physiological data from the pilot study indicated weight gain, heart weight 
gain and pulmonary congestion in mice infused with 50 mg/kg/day Iso for 4 
weeks compared to saline-infused mice (figure 3.4). However these 
physiological changes were not observed between mice infused with 75 
mg/kg/day Iso and saline, suggesting that 50 mg/kg/day Iso instigated a more 
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severe phenotype than 75 mg/kg/day Iso. For the 75 mg/kg/day Iso dose, Iso 
was dissolved at 313 mg/ml, which is close to the maximal solubility capacity of 
Iso reported by the datasheet (333 mg/ml). Therefore, it is possible that the Iso 
may have precipitated within the minipumps over the 4 weeks during which they 
were implanted, rendering the minipump inactive and reducing the 
concentration of Iso that was infused into the mouse. Therefore the blood 
concentration of Iso should have been measured in all mice to ensure that the 
minipumps were working effectively to deliver Iso at the proposed rate. 
In the pilot study, Dr Manabu Taneike and Dr Shigemiki Omiya (both from 
King’s College London) performed echocardiography using conscious mice 
(figure 3.3), whereas, in the main study I performed echocardiography on 
anaesthetised mice (figures 3.19, 3.10, 3.12 - 3.15). This alteration was due to 
different skillsets of the echocardiographic handlers. Nevertheless, the 
echocardiographic data from both studies yielded different findings and values. 
As mentioned, the mice were scruffed to perform conscious echocardiography 
in the pilot study, which may cause stress to the mice and conceal Iso-induced 
tachycardia. Using anaesthetised echocardiography, increased LVPWd and HR 
were observed after Iso infusion in WT mice (suggesting cardiac hypertrophy 
and tachycardia) and not in the pilot study. Although, anaesthesia suppresses 
cardiac function, the clarity of the images is improved which is used to define 
the wall thickness and avoids the effects of stress-induced HR changes. This 
may contribute to the differences seen in LVPWd and HR in the main 
investigation (section 6.4 for further discussion).  
However, due to Iso-induced tachycardia, it was difficult to interpret the 
echocardiographic data obtained under anaesthesia as differences in HR 
between saline and Iso treated mice were observed when performing 
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echocardiography using same ISF% and using different ISF% in an attempt to 
match HRs (section 6.4 for further discussion). Alternatively, HR 
independent indices could have been measured such as myocardial 
performance index (MPI), isovolumic contraction time (IVCT) and isovolumic 
relaxation time (IVRT), which could provide information on global systolic and 
diastolic ventricular function, independent of differences in HR. Also, diastolic 
cardiac function was not assessed in this Iso infusion model.  Performing 
Doppler echocardiography would provide more information about the overall 
cardiac structure and function and may identify any issues with ventricular 
relaxation after Iso infusion.  
Furthermore, although cardiac dilatation and dysfunction was observed in both 
studies, the values of LVIDd and LVIDs are larger in mice in the main study 
(saline 4.12 mm, 2.78 mm and Iso 4.54 mm, 3.46 mm, respectively‡) compared 
to the pilot study (saline 3.27 mm, 1.60 mm and Iso 4.30 mm, 3.00 mm 
respectively§), which consequently yielded different values for EF and FS (main 
study: saline 51.24%, 32.69%, Iso 30.7%, 23.82%*. Pilot study: saline 83.31%, 
61.42%, Iso 57.8%, 47.62%†).  
Therefore the extent of the change in a particular parameter after Iso infusion 
differs between the two studies, making it difficult to compare these two studies. 
However general trends do appear which are comparable between the studies. 
One discrepancy between the pilot and main investigation concerns the liver 
weight after Iso infusion. In the pilot study, there was no difference in liver 
weight between saline and Iso treated mice (figure 3.4) whereas in the main 
                                            
‡ Values taken from figure 3.15 after 4 weeks of treatment 
§ Values taken from figure 3.3 after 4 weeks of treatment 
* Values taken from figure 3.15 after 4 weeks of treatment 




study, there was an increase in liver weight in WT mice infused with Iso (figure 
3.16). Increased liver weight is reminiscent of systemic congestion, which has 
not been previously reported in mice after Iso infusion. Thus, to determine 
which result is valid, further study is recommended.  
Further, although hypertrophy increases wall thickness and subsequently 
increases LV mass, echocardiographic assessment of wall thickness and LV 
mass may be considered an inconclusive and potentially unreliable measure of 
hypertrophy. Echocardiographic measurements are subjective and dependent 
upon the position of the mouse, heart and probe as well as the quality of the 
images. Also, echocardiographic images were acquired from one viewpoint, 
which were then analysed and the wall thickness and LV mass were calculated. 
Therefore it is unknown how accurate these measurements are compared to 
the actual heart measurements as images were taken from one viewpoint and 
therefore measurements should be taken at different viewpoints to improve the 
accuracy and reliability of these measurements. Additionally, cardiac 
hypertrophy can also be demonstrated by physiological and molecular analyses 
(discussed below) and thereby support the echocardiographic findings if all are 
in agreement. 
 
3.3.2 Unusual cardiac phenotypes after excessive and chronic infusion of 
Iso in WT mice. 
Iso infusion in mice has been demonstrated to activate the cardiac hypertrophy 
programme, determined by thickened myocardial walls 330, elevated heart and 
LV mass 330, increased cardiomyocyte CSA 315 and re-expression of foetal 
genes 331. Other reports have discovered the induction of pro-inflammatory 
cytokines, IL1β, IL6 and TNFα 224 after Iso infusion, in addition to activation of 
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fibrosis and apoptosis 315. Thus activation of hypertrophic, fibrotic, inflammatory 
and apoptotic pathways were investigated after Iso infusion, to determine their 
contribution to the development of β- stimulant-induced cardiomyopathy.  
In terms of the cellular measurements of hypertrophic changes, WGA staining 
displayed an increase in cardiomyocyte CSA after Iso infusion in WT mice 
(figure 3.19) yet there was no induction of foetal genes (figure 3.20). The 
decrease in Nppa expression was most unexpected and was verified by primer 
validation and Taqman assay (figure 3.21 and 3.22). Decreased Nppa 
expression has been reported during pregnancy 332 and one report using an 
aortocarval shunt model of volume overload exhibited unchanged expression of 
foetal genes 287. It remains unknown why Nppa expression decreased in this 
model, however both of these reports suggest that this model of β-stimulant-
induced cardiomyopathy may exhibit similar phenotypes to physiological 
hypertrophy or volume overload models, indicating the uniqueness of this 
model. 
Activation of the cardiac hypertrophy programme after Iso infusion in this model 
was suggested by thickened posterior walls and increased heart weight. It was 
also supported by histological data displaying increased cardiomyocyte CSA 
after Iso infusion, however it has since been advised that prior to harvesting, the 
mice should be injected with potassium to ensure that the heart rested in 
diastole so all sections and samples are in the same phase of the cardiac cycle. 
Therefore this experiment needs to be repeated to confirm these findings. 
Using the data from this thesis, it remains questionable whether Iso infusion 
induced hypertrophy. The qRT-PCR data relayed no induction of foetal genes 
whilst thickened posterior walls and increased heart weight were observed by 
echocardiographic and physiological measurement. Measurements of heart 
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weight / tibia length and cardiomyocyte CSA are regarded as the gold standard 
for determining the activation of the hypertrophic response therefore this model 
may potentially induce cardiac hypertrophy, despite the qRT-PCR data, 
although further experiments are required. However another biochemical 
measurement of cardiac hypertrophy response would be to study any 
increments in protein synthesis using a [3H] leucine incorporation study 333, 
although this would be technically challenging in vivo.  
Most surprisingly, from the model used in this current study, there was no re-
expression of foetal genes, increased inflammation, fibrosis or apoptosis after 
Iso infusion in either WT or TLR9KO mice relayed by histological analyses 
(figures 3.24, 3.25, 3.27, 3.28, 3.32) and biochemical measurements (figures 
3.20, 3.26, 3.29, 3.33). With regards to the apoptotic data, previous reports 
demonstrate that Iso is myotoxic and induces apoptosis and necrosis however 
the activation of other cell death pathways has not been investigated. Necrosis, 
necroptosis and pyroptosis all involve inflammation and as figures 3.24 – 3.26 
display no differences in inflammatory responses after Iso treatment, it was 
unlikely that these other cell death programmes were activated. The lack of 
fibrosis, foetal gene reactivation, inflammation and apoptosis in this model of β–
stimulant-induced cardiomyopathy is highly unusual and opposes previous 
reports mentioned above. One possible explanation for this could be the low 
number of samples used for experiments. As mentioned after individual 
experiments, several trends were observed, however more samples are needed 
to either prove or disprove these tendencies. Other probable explanations for 
this could be due to the dose of isoproterenol used (5 – 30 mg/kg/day), duration 
of treatment (1 day up to 2 weeks), method of administration (injection or 
continuous infusion using a minipump), age and species of mouse. As a higher 
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dose and longer timecourse of Iso was used, with 4 weeks of constant infusion, 
it is plausible that an alternative cardiac response was activated, yielding the 
unusual response observed. Thus the data from this chapter yielded a model of 
β-stimulant-induced cardiomyopathy, which does not accurately represent the 
progression of cardiac hypertrophy to HF. 
 
3.3.3 Detrimental role of TLR9 in β-stimulant-induced cardiomyopathy 
It was previously postulated that TLR9-mediated inflammation contributed to the 
progression of HF induced by pressure overload 173. Thus this chapter 
questioned the association between β-AR signalling and TLR9-mediated 
inflammation and whether this interaction contributes to the development of HF. 
The echocardiographic and physiological data revealed many similarities but 
also a few notable differences between WT and TLR9KO mice after Iso infusion 
(figure 3.15). Intriguingly, there was partial rescue of cardiac function, posterior 
wall thickness and heart weight gain in TLR9KO mice after Iso infusion, 
compared to WT mice. The significant improvement in fractional shortening was 
about 3 - 4% higher than WT mice infused with Iso (figure 3.15d) which was a 
modest improvement, compared with the improvement seen between WT and 
TLR9KO mice subjected to TAC 173. Further, between WT Iso- and TLR9KO 
Iso- infused mice, the difference in LVPWd was 11.6% (figure 3.15b) and the 
heart weight / tibia length ratio was different by 15% (figure 3.16c).  
These findings demonstrate that TLR9 possesses the ability to influence cardiac 
function and heart weight, through an association with the β-AR signalling 
pathway. However, this partial rescue indicates that ablation of TLR9 was not 
able to fully rescue Iso-induced cardiac dysfunction and heart weight gain, 
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thereby suggesting that TLR9 partially influences cardiac function and heart 
weight, in addition to other pathways.  
However, the cause of this partial rescue of heart weight gain and cardiac 
dysfunction in TLR9KO mice after Iso infusion remains unknown, as there were 
no differences in fibrosis, apoptosis or surprisingly inflammation between WT 
and TLR9KO (figures 3.24 – 3.26, 3.27, 3.29, 3.32, 3.33). Therefore, this data 
suggests a detrimental role of TLR9 within the heart associated with β-AR 
signalling, which is independent of its inflammatory function. 
A major limitation of this study was the lack of power calculations to ensure that 
the data was conclusive. In several instances, a higher number of samples were 
needed to validate the claims made (discussed further in section 6.4). Further, 
though TLR9KO mice have been bred onto Bl/6 background, littermate controls 
are the most appropriate control for animal-related experiments and in this 
study, C57Bl/6 mice were used as WT controls which may considered as 
another experimental limitation (discussed further in section 6.4). Also, the 
blood concentration of Iso was not measured in mice treated within Iso. It is 
plausible that the mice may not be receiving the full dose of Iso and could be 
one reason for the unexpected findings described in section 3.3.2.  
Other limitations also include the preparation of samples for histology, the 
differential echocardiographic methods, use of echocardiography to determine 
cardiac hypertrophy and lack of diastolic function assessment, which are 
discussed above in sections 3.3.1 and 3.3.2.  
Collectively, this chapter has demonstrated that excessive, constant and 
chronic infusion of Iso induces β-stimulant-induced cardiomyopathy and that 




4 The reversible and NFκB-inducing properties of chronic, 
constant and excessive β-AR stimulation. 
 
4.1 Introduction 
The previous chapter demonstrated that 4 weeks infusion of Iso in mice induced 
cardiac dysfunction, LV chamber dilatation, hypertension, tachycardia, heart 
weight gain and pulmonary congestion, collectively referred to as β-stimulant-
induced-cardiomyopathy. However the data presented in chapter 3 displayed no 
induction of foetal genes, fibrosis, inflammation or apoptosis in this model, 
which conflicted with previous reports 224, 315, 331. As both a greater dose of Iso 
and a prolonged time period of administration was utilised in this model 
compared to previous reports 312, 313, 314, it was plausible that a different cardiac 
response was activated, which could elicit the responses observed. Therefore, 
further study of this model was necessary to understand the causes of β-
stimulant-induced cardiomyopathy.  
As very few structural changes to the myocardium were observed in this model, 
it was conceivable that Iso was inducing functional modifications, which might 
be reversed if the Iso was removed. There are several clinical cases of 
recoverable cardiomyopathies in which cardiac dysfunction is reversed, 
including TIC, SIC or myocardial stunning/hibernation 50, 334. Both TIC and SIC 
are relevant to this model of β-stimulant-induced cardiomyopathy as tachycardia 
is observed in β-stimulant-induced cardiomyopathy, whilst elevated circulating 
levels of catecholamines have been recorded in SIC patients and are proposed 
to induce SIC 334. Unfortunately, the causes of these clinical conditions remain 
unknown although alterations in metabolism, ischemia and oxidative stress 
pathways, β-AR expression and/or calcium handling have been proposed 50, 60, 
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335. These changes are functional adaptations rather than structural 
modifications and furthermore have been reported to be distorted after Iso 
infusion 300, 301, 302, pathological hypertrophy 80, 207, 251, 261 and in HF 22, 205, 206, 207, 
210, 263.  
Rats infused with Iso exhibited diminished LV FA and glucose metabolism 302 
whilst systemic β-AR stimulation increased lipolysis with increased lipid uptake 
and oxidation 336, 337. It was proposed that excessive amounts of 
catecholamines for a prolonged period may affect myocardial lipid homeostasis 
335. In addition, depleted energy stores have been reported in TIC patients 50 
whilst SIC patients exhibited reduced uptake of FAs and glucose 338, 339. 
Therefore, β-stimulant-induced cardiomyopathy could be associated with 
abnormal metabolism. 
It was proposed that chronic rapid HRs may result in ischemia which may 
induce reversible ventricular dysfunction 50. In addition, ROS production and 
activation of oxidative stress pathways are often observed in ischemia-related 
cardiomyopathies 207, 263 and have additionally been reported in chronically Iso-
infused rats 301. Nuclear factor erythroid 2–related factor 2 (Nrf2)-induced 
genes, triggered by oxidative stress were reported to be increased in SIC 
patients 60, 340. Collectively, these reports suggest that there could be alterations 
in the expression of ischemic and oxidative stress markers in this model of β-
stimulant-induced cardiomyopathy. 
Desensitisation of ARs has been previously reported alongside altered ratios of 
β1-AR : β2-AR expression in samples obtained from HF patients, preclinical 
models of HF and after chronic Iso infusion 22, 210, 222, 300. Additionally, 
diminished calcium transients and decreased SR calcium content were 
observed in an acute model of Iso infusion 299. SIC patients exhibited calcium 
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mishandling with altered expression of the functional proteins involved in this 
process 341 and it has been proposed that transient contractile dysfunction 
associated with SIC could be due to decreased calcium handling 59.  
It was therefore hypothesised that 4 weeks infusion of Iso may excessively 
stimulate β-ARs, leading to β-AR desensitisation and calcium overload, 
decreasing cardiac contractility. Additionally, the reported effects of Iso on 
oxidative stress and metabolic pathways suggested that changes in metabolism 
and oxidative stress-related pathways may also contribute to the progression of 
β-stimulant-induced cardiomyopathy. With these functional adaptations 
proposed to induce β-stimulant-induced cardiomyopathy, it was further 
hypothesised that removal of Iso might therefore lead to recovery of the 
dysfunctional myocardium and an improvement in cardiac function. 
Thus the aim of this chapter was to determine the mechanisms that contribute 
to the phenotype observed in this model of β-stimulant-induced 
cardiomyopathy, induced by Iso infusion. After determining whether the 
phenotype was reversible by Iso removal, analysis of the β-AR signalling 
cascade and metabolic pathways as well as the ischemic and oxidative stress 
networks were performed using WT C57Bl/6 mice infused with Iso for 4 weeks. 
 
4.2 Results 
4.2.1 Iso-induced cardiac dysfunction appears to be reversible in WT 
mice. 
A pilot study was designed and performed to initially test the hypothesis that the 
cardiac phenotypes observed after Iso infusion were caused by functional and 
potentially reversible changes within the myocardium. Preceding minipump 
implantation, echocardiography was performed in WT mice, followed by 
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implantation of minipumps infusing saline or Iso (figure 4.1). Echocardiographic 
parameters were re-measured 4 weeks after implantation followed by surgical 
exchange of the active minipumps (within the mice) to ineffective minipumps, 
thereby removing the source of the saline or Iso infusion (due to project licence 
regulations). As it was unknown how quickly the echocardiographic parameters 
would change after minipump exchange (if at all) echocardiography was 
performed daily until the echocardiographic parameters in Iso-treated animals 
were stable for 3 consecutive days after Iso removal (figure 4.1). Mice were 
harvested the day after 3 consistent echocardiographic readings. 
 
 
Figure 4.1 Timeline for pilot study for minipump exchange experiments. 
This study aimed to investigate how quickly the cardiac phenotype after 
Isoprenaline (Iso) infusion was reversible. 10– 11 –week-old WT (C57Bl/6) male 
mice (24 - 27 g) were subjected to echocardiography (echo) measurements pre-
implantation. Next day, the mice were fitted with minipumps infusing 50 
mg/kg/day Iso or saline. 4 weeks later, echo measurements were performed. 
The following day, the minipumps in the mice were exchanged with ineffective 
minipumps. Echo measurements were performed daily after minipump 
exchange until echo measurements were consistent for 3 days. The day after 
this was achieved, the mice were harvested. ‘Before’ refers to parameters 
measured before minipump exchange whilst ‘After’ signifies measurements 
recorded after minipump exchange. 
 
As described in section 3.2.2.3, 2 methods of anaesthetised echocardiography 
were performed on these mice. Mice were anaesthetised using 1.5% ISF in 
which differences in the HR were noted between saline- and Iso-infused mice 
(method 1) and using different percentages of ISF (1% for saline-infused mice 




Although the numbers of experimental replicates were too low to analyse the 
data statistically (saline, n = 1; Iso, n = 3), the echocardiographic data using 
method 1 (figure 4.2) demonstrated increases in LVPWd, LV mass and HR 28 
days after Iso infusion (before minipump exchange), compared to saline-treated 
mice, suggesting that Iso infusion induced tachycardia and thickened walls 
(figure 4.2b, e, f). Using method 2, 4 weeks of Iso infusion induced LV chamber 
dilatation, cardiac dysfunction and heart weight gain as suggested by increased 
LVIDd, LV mass and decreased FS  (figure 4.3c, d, e), compared to saline-
treatment. However, 1 day after minipump removal, these changes in 
echocardiographic parameters described above using both echocardiographic 
methods were no longer present and similar values for all parameters were 
detected in saline- and Iso- treated mice. These findings suggested potential 
recovery of tachycardia, LV chamber dilatation, cardiac dysfunction and heart 
weight gain after removal of Iso.  
The changes in echocardiographic parameters using both echocardiographic 
methods, in Iso treated mice 1 day after minipump exchange (day 30) remained 
consistent for the following 2 days (figures 4.2 and 4.3). Therefore, mice were 
harvested 4 days after minipump exchange (table 4.1).  Heart and lung weight 
appeared greater in Iso-treated mice compared to saline-treated mice, 
potentially suggesting that Iso-induced heart weight gain and pulmonary 





















Figure 4.2 Tachycardia and heart weight were potentially recoverable 1 
day after removal of Iso.  
Echocardiographic parameters using 1.5% isoflurane were determined before (-
1), after 4 weeks infusion (day 28) of saline or Iso (Before minipump exchange) 
and 1,2 and 3 days (days 30, 31, 32) after drug removal by minipump exchange 
(After). A, IVSd = End-diastolic interventricular septal wall thickness. B, LVPWd 
= End-diastolic left ventricular posterior wall thickness. C, LVIDd = End-diastolic 
left ventricle internal dimension. D, FS = Fractional shortening. E, HR = Heart 
rate. F, LV mass. Before minipump exchange, tachycardia and increased LV 
mass were observed in Iso-treated mice.  However 1 day after pump exchange, 
the tachycardia and increased LV mass were potentially abolished. Saline-





Figure 4.3 Cardiac dysfunction and chamber dilatation were potentially 
recoverable 1 day after removal of Iso.  
Echocardiography was performed to achieve heart rates (HR) between 450 and 
550 bpm in mice, before (-1) and after 4 weeks infusion (day 28) of saline or Iso 
(Before (minipump exchange)) and 1, 2 and 3 days (days 30, 31, 32) after drug 
removal by minipump exchange (After). A, IVSd = End-diastolic interventricular 
septal wall thickness. B, LVPWd = End-diastolic left ventricular posterior wall 
thickness. C, LVIDd = End-diastolic left ventricle internal dimension. D, FS = 
Fractional shortening. E, HR = Heart rate. F, LV mass. Before minipump 
exchange, cardiac dysfunction and chamber dilatation were observed in Iso-
treated mice.  However 1 day after pump exchange, the cardiac dysfunction and 
chamber dilatation were potentially reversed. Saline-treated mice (open bars) 




Table 4.1 Body and heart weight gain were observed 4 days after Iso 
removal.   
Physiological parameters were measured from mice after 4 days after removal 
of saline or Iso by minipump exchange. Increased body weight and heart weight 
were observed in Iso-infused mice compared to saline-treated mice. Saline-


















This pilot study suggested that changes in the myocardium induced by Iso 
infusion could be reversed within 24 hours of Iso removal. Therefore this 
experiment was repeated with sufficient mice to analyse the data statistically 
(figure 4.4). Similar to the initial study, mice were again subjected to 
echocardiographic and physiological analysis prior to implantation of minipumps 
infusing either saline or Iso and again 4 weeks after implantation. Minipumps 
were exchanged and echocardiography was performed 1 day after minipump 
exchange. The mice were harvested the following day. An additional cohort of 
mice were implanted with minipumps and were harvested 29 days after 
minipump implantation to enable comparison of physiological parameters before 
and after minipump exchange (figure 4.4). Echocardiographic and physiological 
measurements taken before minipump exchange were termed ‘before’ and 
those obtained after minipump exchange were labelled ‘after’ (figure 4.4). 
 
Physiological parameters Saline (n = 1) 
Iso 
(n = 3) 
Body weight (g) 30.90 31.03 ± 0.07  
Tibia length (mm) 17.80 17.50 ± 0.15 
   
Heart weight (mg) 159.70 174.50 ± 1.99 
Lung weight (mg) 153.10 171.33 ± 1.07 
Liver weight (mg) 1517.10 1511.53 ± 59.29 
   
Heart weight / tibia length 
(mg/mm) 8.97 9.97 ± 0.14 
Lung weight / tibia length 




Figure 4.4 Timeline of in vivo procedures for drug removal by pump 
exchange study. 
To determine if the cardiac phenotype after Isoprenaline (Iso) infusion was 
reversible, 10– 11 –week-old WT (C57Bl/6) male mice (24 - 27 g) were 
subjected to anaesthetised echocardiography (echo) and blood pressure (BP) 
measurements pre-implantation. Next day, the mice were fitted with minipumps 
infusing 50 mg/kg/day Iso or saline. 4 weeks later, echo and BP measurements 
were performed. Next day, half of the mice were sacrificed and physiological 
parameters were measured.  The minipumps in the remaining mice were 
exchanged with ineffective minipumps. Echo and BP measurements were 
performed the following day on these mice. The day after, the mice were 
harvested. ‘Before’ refers to parameters measured before minipump exchange 
whilst ‘After’ signifies measurements recorded after minipump exchange. 
  
4.2.1.1 Tachycardia and cardiac dysfunction recovered 1 day after removal 
of Iso. 
Prior to minipump implantation, the mice were divided into 2 groups and 
anaesthetised echocardiographic and physiological measurements were similar 
between these 2 groups (table 4.2).   
Table 4.3 includes the echocardiographic data 28 days after minipump 
implantation of all the mice in this study, including the mice that were harvested 
on day 29. Iso-treated mice mice exhibited increased systolic and diastolic BP, 
LVPWd and LV mass, decreased EF and FS and increased HR, compared to 
saline-treated mice. Changes in LVIDd were not observed after Iso treatment, 
suggesting that chamber dilatation was not observed in Iso-treated mice, 
though the LVIDs was increased after Iso treatment. 
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Table 4.2 No difference in echocardiographic or physiological parameters 
prior to minipump implantation in WT mice.  
Anaesthetised echocardiography was performed on 10-11-week-old WT mice to 
assess cardiac structure and function. No differences were observed in all 
echocardiographic or physiological parameters at baseline. Data were analysed 
by student’s t-test. BP = Blood pressure, IVSd = End-diastolic interventricular 
septal wall thickness, IVSs = End-systolic interventricular septal wall thickness, 
LVPWd = End-diastolic left ventricular posterior wall thickness, LVPWs = End-
systolic left ventricular posterior wall thickness, LVIDd = End-diastolic left 
ventricle internal dimension, LVIDs = End-systolic left ventricle internal 
dimension, EF = Ejection fraction, FS = Fractional shortening, HR = Heart rate. 




Besides this anomaly, these Iso-infused mice were considered to be 
representable of β-stimulant-induced cardiomyopathy with observations of 
tachycardia, thickened walls, hypertension and cardiac dysfunction. Therefore 




Parameters WT Saline WT Iso P value Significance (n= 12) (n= 12) 
Body weight (g) 24.50 ± 0.19 24.58 ± 0.23 0.68 n.s 
Systolic BP (mmHg) 99.02 ± 3.89 95.37 ± 3.88 0.51 n.s 
 Diastolic BP 
(mmHg) 72.60 ± 3.60 66.82 ± 2.74 0.21 n.s 
     
IVSd (mm) 0.92 ± .03 0.86 ± 0.02 0.12 n.s 
IVSs (mm) 1.34 ± 0.05 1.26 ± 0.05 0.26 n.s 
LVPWd (mm) 1.00 ± 0.03 0.98 ± 0.04 0.61 n.s 
LVPWs (mm) 1.24 ± 0.02 1.26 ± 0.04 0.67 n.s 
LVIDd (mm) 3.77 ± 0.07 3.84 ± 0.06 0.39 n.s 
LVIDs (mm) 2.61 ± 0.06 2.64± 0.06 0.73 n.s 
     
EF (%) 59.28 ± 1.10 60.06 ± 0.99 0.60 n.s 
FS (%) 30.92 ± 0.74 31.50 ± 0.66 0.57 n.s 
HR (BPM) 468.58 ± 5.15 475.96 ± 9.34 0.50 n.s 
LV mass (mg) 137.83 ± 4.90 134.96 ± 5.84 0.66 n.s 
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Table 4.3 Echocardiographic data 28 days after minipump implantation 
Anaesthetised echocardiography and blood pressure (BP) measurements were 
performed on WT mice 4 weeks after saline or Iso infusion. Iso induced 
hypertension, elevated LV mass, tachycardia and cardiac dysfunction. Saline-
treated mice n= 12, Iso-treated mice (blue bars) n= 12. Data were analysed by 
student’s t-test. *p<0.05. BP = Blood pressure, IVSd = End-diastolic 
interventricular septal wall thickness, IVSs = End-systolic interventricular septal 
wall thickness, LVPWd = End-diastolic left ventricular posterior wall thickness, 
LVPWs = End-systolic left ventricular posterior wall thickness, LVIDd = End-
diastolic left ventricle internal dimension, LVIDs = End-systolic left ventricle 
internal dimension, EF = Ejection fraction, FS = Fractional shortening, HR = 







Parameters WT Saline WT Iso 
(n= 12) (n= 12) 
Physiological 
parameters 
 SBP (mmHg) 99.09 ± 2.86 128.24 ± 4.89 * 
 DBP (mmHg) 69.92 ± 2.53 98.61 ± 4.69 * 




IVSd (mm) 0.87 ± 0.03 0.96 ± 0.04 
IVSs (mm) 1.24 ± 0.03 1.31 ± 0.05 
LVPWd (mm) 0.99 ± 0.03 1.10 ± 0.03 * 
LVPWs (mm) 1.34 ± 0.04 1.39 ± 0.04 
 LVIDd (mm) 4.12 ± 0.08 4.25 ± 0.11 
 LVIDs (mm) 2.86 ± 0.08 3.12 ± 0.13 
 EF (%) 58.61 ± 1.16 52.83 ± 2.17 * 
 FS (%) 30.69 ± 0.78 27.07 ± 1.34 * 
 HR (BPM) 436.83 ± 11.46 624.96 ± 9.92 * 
 LV mass (mg) 152.35 ± 5.75 186.09 ± 11.20 * 
    
Echocardiographic 
parameters using 
1-2% ISF to 
achieve similar HR 
IVSd (mm) 0.83 ± 0.04 0.91 ± 0.04 
IVSs (mm) 1.25 ± 0.05 1.15 ± 0.05 
LVPWd (mm) 1.04 ± 0.02 1.09 ± 0.14 
LVPWs (mm) 1.33 ± 0.03 1.35 ± 0.05 
LVIDd (mm) 4.11 ± 0.04 4.34 ± 0.11 
 LVIDs (mm) 2.83 ± 0.04 3.34 ± 0.10 * 
 EF (%) 59.27 ± 1.06 46.84 ± 1.37 * 
 FS (%) 31.13 ± 0.72 23.30 ± 0.80 * 
 HR (BPM) 471.29 ± 8.18 532.04 ± 7.16 * 









Figure 4.5 Loss of hypertension after removal of Iso. 
Blood pressure (BP) of mice were measured after 4 weeks infusion of saline or 
Iso (Before (minipump exchange)) and 1 day after drug removal by minipump 
exchange (After). Iso caused hypertension before minipump exchange, 
however 1 day after its removal, there were no differences in BP parameters 
between saline- and Iso- treated mice. Saline-treated mice (open bars), Iso-
treated mice (blue bars). n= 6 for all groups. Data analysed by paired two-way 
ANOVA with bonferroni’s post-hoc test. **p<0.01. 
 
Figures 4.5 - 4.7 display the echocardiographic and physiological parameters 
of the mice that underwent minipump exchange to directly compare mice before 
and after minipump exchange and to establish the effects of Iso removal. As 
expected, 4 weeks of Iso infusion (before minipump exchange) induced 
hypertension compared to saline-treated mice (figure 4.5). Interestingly, 1 day 
after minipump exchange, there were no significant differences in systolic and 
diastolic BP in the Iso-infused mice compared to saline-treated mice.  
Similar to the pilot study, echocardiography method 1 demonstrated an increase 
in HR (figure 4.6e), LVPWd (figure 4.6b) and LV mass (figure 4.6f) in mice 
infused with Iso before minipump exchange, compared with saline-infused mice, 
suggesting tachycardia and cardiac hypertrophy. However 1 day after drug 
removal by minipump exchange, there were no significant differences in these 
parameters between saline- and Iso- treated mice. The HR in Iso-treated mice 
was significantly lowered after minipump exchange, compared to the HR before 




Figure 4.6 Removal of Iso eliminated tachycardia.  
Echocardiographic parameters using 1.5% isoflurane were determined after 4 
weeks infusion of saline or Iso (Before (minipump exchange)) and 1 day after 
drug removal by minipump exchange (After). A, IVSd = End-diastolic 
interventricular septal wall thickness, IVSs = End-systolic interventricular septal 
wall thickness. B, LVPWd = End-diastolic left ventricular posterior wall 
thickness, LVPWs = End-systolic left ventricular posterior wall thickness. C, 
LVIDd = End-diastolic left ventricle internal dimension, LVIDs = End-systolic left 
ventricle internal dimension. D, EF = Ejection fraction, FS = Fractional 
shortening. E, HR = Heart rate. F, LV mass. Before minipump exchange, 
tachycardia, increased LV mass and cardiac dysfunction were observed in Iso-
treated mice.  However 1 day after pump exchange, the tachycardia was 
abolished. Saline-treated mice (open bars), Iso-treated mice (blue bars). n= 6 
for all groups. Data analysed by paired two-way ANOVA with bonferroni’s post-





Using the second method of echocardiography, LVIDs (figure 4.7c) and LV 
mass (figure 4.7f) were increased in Iso-infused mice, compared to saline-
treated mice. EF and FS were decreased before minipump exchange (figure 
4.7d) in Iso treated mice compared with saline-infused mice, suggesting cardiac 
dysfunction. However after minipump exchange, these parameters were no 
longer different between saline- and Iso- treated mice, with a significant change 
in LVIDs, EF and FS parameters in Iso-treated mice before and after minipump 
exchange, suggesting recovery of cardiac function after Iso removal. 
Therefore the data presented in this section found that tachycardia and most 
surprisingly, systolic function, were recoverable 1 day after minipump exchange.  
 
4.2.1.2 Heart weight gain was not recoverable after Iso removal. 
Mice were sacrificed 29 days after minipump implantation (before minipump 
exchange, termed Before) or 2 days after minipump exchange (referred to as 
After). The heart, lung and liver (tissues were harvested and weighed and the 
tibia lengths were recorded in order to determine any physiological variations 
that may be recoverable after minipump exchange (figure 4.8). No differences 
were observed in body weight, tibia length or lung weight / tibia length between 
saline- and Iso- treated mice before or after minipump exchange. The heart 
weight / tibia length ratio was increased in Iso-infused mice at both timepoints, 
compared to saline-treated mice (figure 4.8c). This finding suggested that Iso-





Figure 4.7 Cardiac systolic dysfunction was recovered 1 day after Iso 
removal.  
Echocardiography was performed to achieve heart rates (HR) between 450 and 
550 bpm in mice after 4 weeks infusion of saline or Iso (Before (minipump 
exchange)) and 1 day after drug removal by minipump exchange (After). A, 
IVSd = End-diastolic interventricular septal wall thickness, IVSs = End-systolic 
interventricular septal wall thickness. B, LVPWd = End-diastolic left ventricular 
posterior wall thickness, LVPWs = End-systolic left ventricular posterior wall 
thickness. C, LVIDd = End-diastolic left ventricle internal dimension LVIDs = 
End-systolic left ventricle internal dimension. D, EF = Ejection Fraction, FS = 
Fractional Shortening. E, HR. F, LV mass. Before minipump exchange, 
tachycardia and systolic cardiac dysfunction were observed in Iso-treated mice.  
However 1 day after pump exchange, the tachycardia and cardiac dysfunction 
were rescued. Saline-treated mice (open bars), Iso-treated mice (blue bars). n= 
6 for all groups. Data analysed by paired two-way ANOVA with bonferroni’s 




















Figure 4.8 Elevated heart weight was not recoverable after Iso removal. 
Half of the mice were harvested 29 days after minipump infusion of saline or Iso 
(Before (minipump exchange) whereas the remaining mice were submitted for 
pump exchange. These surviving mice were harvested 2 days after pump 
exchange (After). Physiological parameters were measured when harvesting 
tissues. A, Body weight (W). B, Tibia length (TL). C, Heart W and heart W / TL. 
D, Lung W and lung W / TL. Heart W / TL ratio was increased before and after 
pump exchange in Iso-treated mice. Saline-treated mice (open bars), Iso-
treated mice (blue bars). Before saline n= 6, Before Iso n= 6, After saline n= 6, 
After Iso n= 6. Data analysed by two-way ANOVA with bonferroni’s post-hoc 
test. *p<0.05, **p<0.01, ***p<0.001.  
 
Therefore the data presented in this section displayed that Iso-induced 
tachycardia and systolic function were recoverable 1 day after Iso removal and 
Iso-induced heart weight gain was not recoverable over the same timecourse.  
Further study is required to understand the mechanisms of this acute functional 
recovery (discussed further in section 4.3.1) though the recovery of the cardiac 
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function after Iso removal suggested that the causes of β-stimulant-induced 
cardiomyopathy were likely to be functional, transient changes that can be 
reversed very quickly (rather than structural amendments). 
 
4.2.2 Investigation of calcium handling, ischemia, oxidative stress and 
metabolism in β-stimulant-induced cardiomyopathy in WT mice.  
The data from section 4.2.1 suggested that functional, reversible changes that 
can be modified very quickly were likely to be the cause of β-stimulant-induced 
cardiomyopathy. Therefore, the expression of β-ARs, proteins involved in 
calcium handling, ischemic and oxidative stress markers and metabolic 
indicators were evaluated in myocardial tissue after 4 weeks saline or Iso 
infusion, to determine their relative contribution to the development of β-
stimulant-induced cardiomyopathy. 
 
4.2.2.1 Iso induced hypertension, chamber dilatation, cardiac dysfunction 
and increased heart weight. 
To further analyse this model of β-stimulant-induced cardiomyopathy, further 
heart samples were needed from additional cohorts of mice (figure 4.9). No 
differences were observed in echocardiographic and physiological parameters 
between the 2 groups of mice prior to minipump implantation (table 4.4). 
 
Figure 4.9 Timeline of in vivo procedures.  
10-11-week-old WT male mice (24 - 27 g) were subjected to echocardiography 
(echo) and BP measurements pre-implantation. Minipumps were implanted into 
those mice infusing Iso or saline. 4 weeks later, echo and BP measurements 




Table 4.4 Echocardiography confirms that Iso induces β-stimulant-
induced cardiomyopathy. 
 Echocardiographic and physiological data measured pre-implantation and 4 
weeks after infusion of saline and Iso. Increased body weight, hypertension, 
chamber dilatation, increased LV mass and cardiac dysfunction were observed 
in mice after 4 weeks of Iso treatment. BP = Blood pressure, IVSd = End-
diastolic interventricular septal wall thickness, IVSs = End-systolic 
interventricular septal wall thickness, LVPWd = End-diastolic left ventricular 
posterior wall thickness, LVPWs = End-systolic left ventricular posterior wall 
thickness, LVIDd = End-diastolic left ventricle internal dimension, LVIDs = End-
systolic left ventricle internal dimension, EF = Ejection fraction, FS = Fractional 
shortening, HR = Heart rate. n= 4 for all groups. Data analysed by two-way 
ANOVA with bonferroni’s post-hoc test. ‡p<0.05 compared to pre-implantation 
values. *p<0.05 compared to saline-infused mice 4 weeks post-implantation.  
 
4 weeks after minipump infusion, Iso-infused mice exhibited β-stimulant-induced 
cardiomyopathy, shown by increased body weight, systolic and diastolic BP, 
LVIDd and LVIDs, LV mass, body weight and heart weight / tibia length ratio 
alongside diminished EF and FS, compared to saline-treated mice (table 4.4 
and 4.5). Tachycardia was not observed after 4 weeks of Iso infusion (table 
4.4), compared to saline-treated mice, though this could be due to the use of 
conscious echocardiography for this experiment. Furthermore, no significant 
Parameter 










(g) 26.65 ± 0.46 26.58 ± 0.70 30.48 ± 0.89 
‡ 32.52 ± 0.15 *‡ 
Systolic BP 
(mmHg) 98.80 ± 6.74 99.56 ± 6.12 95.56 ± 5.60 122.35 ± 1.64 *
‡ 
Diastolic BP 
(mmHg) 69.34 ± 5.16 71.96 ± 5.29 68.16 ± 3.47 94.42 ± 1.15 *
‡ 
     
IVSd (mm) 0.97 ± 0.05 0.95 ± 0.02 0.96 ± 0.04 0.98 ± 0.05 
IVSs (mm) 1.63 ± 0.03 1.63 ± 0.03 1.61 ± 0.06 1.54 ± 0.03 
LVPWd (mm) 0.93 ± 0.04 0.88 ± 0.02 1.04 ± 0.03 0.95 ± 0.04 
LVPWs (mm) 1.47 ± 0.03 1.48 ± 0.04 1.68 ± 0.06 1.35 ± 0.15 
LVIDd (mm) 3.50 ± 0.07 3.61 ± 0.04 3.47 ± 0.08 4.09 ± 0.11 *‡ 
LVIDs (mm) 1.77 ± 0.07 1.86 ± 0.03 1.75 ± 0.04 2.60 ± 0.16 *‡ 
     
EF (%) 81.86 ± 0.98 80.83 ± 0.53 81.93 ± 0.25 66.83 ± 2.97 *‡ 
FS (%) 49.65 ± 0.99 48.62 ± 0.53 49.64 ± 0.24 36.71 ± 2.21 *‡ 
HR (BPM) 717.73 ± 13.14 737.92 ± 4.66 754.13 ± 14.89 768.18 ± 15.58 
LV mass (mg) 120.96 ± 4.45 119.65 ± 1.87 128.92 ± 9.88 157.01 ± 5.77 *‡ 
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differences in lung weight were observed after Iso infusion (table 4.5). Samples 
from these mice were used for further detailed study of the mechanisms of this 
model, although no changes in lung weight were observed in Iso-treated mice. 
 
Table 4.5 Body and heart weight gain were observed 4 weeks after Iso 
infusion.   
Physiological parameters were measured from mice after 4 weeks infusion of 
saline or Iso. Increased body weight and heart weight were observed in Iso-
infused mice compared to saline-treated mice. Data were analysed by student’s 
t-test. *p<0.05 compared to saline-infused mice. 
 
4.2.3 Examination of the expression of β-ARs and proteins involved in 
calcium handling after Iso infusion. 
To determine whether alterations in the expression of β-ARs and proteins 
involved in calcium handling contribute to the development of β-stimulant-
induced cardiomyopathy, the expression of β-ARs and calcium handling 
proteins were evaluated by qRT-PCR and Western blotting. 
 
4.2.3.1 β-AR and SERCA mRNA expression were not different after Iso 
infusion. 
qRT-PCR was performed using LV homogenates from mice infused with saline 
or Iso for 4 weeks to measure the mRNA levels of 2 different β-ARs expressed 
in the myocardium, Adrb1 and Adrb2. However, the mRNA expression of Adrb1 
and Adrb2 was similar between mice infused with saline and Iso (figure 4.10a), 
Physiological parameters Saline (n = 4) 
Iso 
(n = 4) 
Body weight (g) 30.87 ± 0.55 32.8 ± 0.36 * 
Tibia length (mm) 17.37 ± 0.17 17.18 ± 0.16  
   
Heart weight (mg) 158.34 ± 4.86 192.79 ± 8.92 * 
Lung weight (mg) 160.1 ± 7.61 170.86 ± 6.35 
   
Heart weight / tibia length (mg/mm) 9.28 ± 0.48 10.61 ± 0.21 * 
Lung weight / tibia length (mg/mm) 9.24 ± 0.50 9.95 ± 0.37 
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suggesting no changes in β-AR expression at the mRNA level after Iso 
treatment. Furthermore, the mRNA expression of SERCA2 (Atp2a2) was 
evaluated using these samples. However, no differences in Atp2a2 mRNA 
expression were detected using these samples (figure 4.10b). 
 
4.2.3.1.1 Optimisation of antibodies targeting PLN. 
Western blotting analysis was performed to evaluate the protein expression of 
calcium handling proteins, total (t)-PLN and phosphorylated (p)-PLN (Serine-16) 
using LV homogenates of mice treated with saline or Iso for 4 weeks. The 
datasheet of the antibodies for tPLN and pPLN stated that PLN exists in 2 
forms, as a monomer (6 kDa) or as a phosphorylated pentamer (25 kDa). 
However, as figure 4.11 illustrates, many bands were detected using the pPLN 
and tPLN antibodies and it was unknown which band represented the 
expression of PLN, although there appears to be no difference in the density of 
Figure 4.10 mRNA expression of β-adrenergic receptors (β-ARs) were 
unchanged at the mRNA levels after infusion of Iso. 
qRT-PCR was performed on myocardial samples from mice infused for 4 weeks 
with Iso or saline, to measure the mRNA levels of proteins involved in the β-
adrenergic signalling cascade. Using these samples, no differences were found 
in the expression of these markers. A, Expression of β-adrenergic receptors 
(Adrb1 and Adrb2), p = 0.87 and p = 0.70, respectively. B, Expression of 
sarco/endoplasmic reticulum calcium ATPase (SERCA2 or Atp2a2), p = 0.63. 




bands using both pPLN and tPLN antibody between saline- and Iso- treated 
mice.  
Western blotting was therefore performed using LV homogenates of mice 
treated with saline or Iso for 4 weeks, along with LV homogenates of mice 
displaying HF after pressure overload and sham-operated controls (kindly 
provided by Dr Manabu Taneike, King’s College London) (figure 4.12). In 
addition there were samples of LV homogenates that were treated with protein 
phosphatase 1 (PP1) to remove phosphate groups from PLN. 
 
Figure 4.11 Lack of specificity of antibodies used to examine 
phospholamban expression and post-translational modifications. 
Western blotting was performed on LV homogenates harvested from mice 
infused with Iso for 4 weeks to study expression of phosphorylated-
phospholamban (pPLN, Ser16) and total- phospholamban (tPLN). However, 
many bands were observed using antibodies targeting pPLN and tPLN 





The sham-operated heart samples showed higher expression of a wide band at 
25 kDa, with pPLN and tPLN antibodies, which was not observed in HF sample, 
as expected. However, this band, thought to be the pentameric form of PLN, 
had migrated further than the bands observed in saline- or Iso- treated mice and 
the intensity of this band was not reduced in PP1-treated samples. Therefore, 
the true bands for pPLN and tPLN could not be distinguished. Several studies 
have reported the observation of monomeric or dimeric PLN is at 9-12 kDa 342, 
343 and a potential band was seen at this molecular weight (figure 4.12).  
 
Figure 4.12 Optimisation of antibodies to study phospholamban 
expression. 
Western blotting for phosphorylated phospholamban (pPLN, Serine-16) and 
total phospholamban (tPLN) were performed using samples of saline- and Iso- 
treated mice, sham (Sh) mice and mice with failing hearts (HF) induced by 
pressure overload provided by Dr Manabu Taneike (King’s College London) and 
LV homogenates treated with protein phosphatase 1 (PP1) or untreated (X). As 
expected, Sh sample showed higher expression of a wide band at 25 kDa, 





4.2.3.1.2  Overexpression of PLN identified representative bands of PLN.  
As bands for PLN could not be distinguished using antibodies targeting pPLN 
and tPLN, it was decided to overexpress PLN to determine the correct bands. 
My laboratory possessed a vector containing the cDNA sequence encoding 
murine PLN (mPLN), which was cloned into the cloning vector, pDNR-lib (figure 
4.13a). Therefore mPLN was subcloned into the mammalian expression vector, 
pCMV-Sport6 (figure 4.13b, c), generating pCMV-Sport6-PLN, which was 
transfected into HEK293A cells. 24 and 48 hours after transfection, protein was 
isolated and Western blotting was performed to study pPLN and tPLN 
expression (figure 4.13d). SDS-PAGE was performed with different amounts of 
protein (20 µg or 40 µg) and different methods of incubating of protein 
denaturation (95oC for 5 minutes, or RT for 30 minutes). Dose- and time- 
dependent bands were observed using the tPLN antibody, representing the 
monomeric (12 kDa) and pentameric (25 kDa) forms of PLN. Faint bands were 
detected with pPLN (Serine-16) antibody at equivalent positions to those seen 
with tPLN antibody. Therefore the bands representing pentameric pPLN, 











Figure 4.13 Vectors utilised and procedures followed to overexpress 
phospholamban in HEK293A cells. 
A, pDNR-LIB-PLN vector contained chloramphenicol resistance, multiple 
cloning sites (MCS) which included restriction enzyme (RE) sites for EcoRI (E) 
and XhoI (X) and the cDNA sequence encoding murine phospholamban (PLN). 
B, pCMV-Sport6 vector possessed ampicillin resistance, MCS that contained 
RE sites for E, X and HindIII (H) and the CMV early promoter possessed RE 
site for NcoI. C, Procedure used to remove PLN sequence from pDNR-LIB-PLN 
and insert it into pCMV-Sport6 to generate pCMV-Sport6-PLN. D, Procedure to 






Figure 4.14 Overexpression of phospholamban. 
Western blotting was performed using samples of HEK293A cells transfected 
with pCMV-Sport-PLN. 2 different protein amounts (20 µg or 40 µg) and 
different methods of denaturing the protein with loading buffer prior to gel 
loading were performed (95oC for 5 minutes, or room temperature (RT) for 30 
minutes). In the membrane for total phospholamban (tPLN), there were clear 
bands that denoted monomeric (12 kDa) and pentameric (25 kDa) forms of PLN 
in a dose and time dependent manner. It was also found that incubating 
samples in loading buffer at RT for 30 minutes would yield clearer bands. Faint 
bands were observed with phosphorylated-phospholamban (pPLN, Ser16) 
antibody at same positions as tPLN membrane. 
 
 
4.2.3.1.3 Expression of proteins involved in calcium handling was 
unchanged after Iso infusion. 
Western blotting for calcium handling proteins, SERCA2, pPLN and tPLN was 
performed using samples of myocardial tissue harvested from mice after 4 
weeks infusion of saline or Iso (figure 4.15a). No differences in the protein 
expression of SERCA2, PLN or pPLN (Serine-16), in pentameric or monomeric 
form were observed between saline- and Iso- treated mice (figure 4.15). 
However a tendency towards a decrease in the protein expression of SERCA2, 
pentameric pPLN (Serine-16) and monomeric tPLN between saline- and Iso- 
treated mice is observed, though further samples would be required to validate 
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this claim. Therefore, the findings presented in figure 4.15 suggest that the 
protein expression of crucial calcium handling proteins were unchanged after 
the development of β-stimulant-induced cardiomyopathy. 
Figure 4.15 Expression of calcium handling proteins were unchanged 
after Iso infusion. 
LV homogenates from mice infused with Iso for 4 weeks were used to 
determine protein levels of calcium handling proteins - Sarcoplasmic/ 
endoplasmic reticulum calcium ATPase (SERCA)-2, phosphorylated 
phospholamban (pPLN, Ser16) and total phospholamban (tPLN).  α-Tubulin 
was used as a loading control. A, Membrane revealed no obvious difference in 
expression of calcium handling proteins. B-F, Densimetric analysis of 
membranes in (A). Red arrows in (A) dictate quantified bands. B, p = 0.12. C, p 
= 0.07. D, p = 0.29. E, p = 0.21. F, p = 0.21. Values expressed as mean ± SEM. 




4.2.3.2 No differences in oxidative stress and ischemic markers after Iso 
infusion. 
As no differences in the expression of β-ARs and calcium handling proteins 
were observed after Iso infusion, other hypotheses were considered. As 
mentioned, chronic rapid HRs are proposed to induce ischemia and chronic Iso 
infusion has previously been shown to cause oxidative stress 301. Therefore to 
determine if there was an association between ischemia, oxidative stress and β-
stimulant-induced cardiomyopathy, qRT-PCR analysis was performed to look at 
markers of ischemia and oxidative stress using LV homogenates harvested 
from mice infused with saline or Iso for 4 weeks.  Indicators studied include 
hypoxia inducible factor 1 α (Hif1a), a hypoxic marker whilst heme oxygenase 1 
(Hmox1), peroxisome proliferator-activated receptor gamma, coactivator 1 
alpha (Ppargc1a) and superoxide dismutase 2 (Sod2) are markers of oxidative 
stress 344, 345. However, no differences in Hif1a, Hmox1, Ppargc1a and Sod2 
mRNA expression were observed between mice infused with saline and Iso 
(figure 4.16), though a trend towards increased expression of Hmox1 after Iso 
infusion could be suggested (p = 0.13). More samples are needed to either 
prove od disprove this tendency.   
Analysis of the transcriptome of SIC patients demonstrated increased 
expression of Nrf2-induced genes compared to controls 340. The transcription 
factor, Nrf2, is triggered by oxidative stress and inflammation and positively 
regulates the expression of a plethora of antioxidant proteins 346, 347. Therefore 
the expression of Nrf2-induced genes were evaluated using LV tissue from mice 


















Figure 4.16 Expression of ischemic and oxidative stress markers was 
unchanged after Iso treatment. 
qRT-PCR was performed on LV homogenates from mice after 4 weeks Iso 
infusion to study mRNA expression of ischemia and oxidative stress markers. A, 
Hypoxia inducible factor 1 α (Hif1a), p = 0.61. B, Haem oxygenase 1 (Hmox1), p 
= 0.13. C, Peroxisome proliferator-activated receptor Gamma, coactivator 1 
Alpha (Ppargc1a), p = 0.14. D, Superoxide dismutase 2 (Sod2), p = 0.91. Using 
these samples, no differences were observed in the expression of these 
ischemic and oxidative stress markers. Glyceraldehyde 3-phosphate 
dehydrogenase (Gapdh) was used as a housekeeping gene. Values expressed 
as mean ± SEM. n= 4. Data analysed by student t-test. 
 
 
Using these samples, no differences were observed in the expression of Nrf2-
induced genes, glutamate—cysteine ligase (Gclc), glutathione S-transferase A2 
(Gsta2) and thioredoxin reductase 1 (Txnrd1) between saline- and Iso- treated 
mice (figure 4.17). Together these results suggest that Iso infusion did not 







Figure 4.17 Expression of Nrf2-induced genes was unchanged after 
treatment of Iso. 
qRT-PCR was used to measure the mRNA expression of genes upregulated by 
transcription factor, Nrf2 in myocardial tissue from mice after 4 weeks Iso 
treatment. A, Glutamate-cysteine ligase, catalytic (Gclc), p = 0.57. B, 
Glutathione S-transferase A2 (Gsta2), p = 0.32. C, Thioredoxin reductase 1 
(Txnrd1), p = 0.18. No differences were observed in these markers in these 
samples. Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) was used as a 
housekeeping gene. Values expressed as mean ± SEM. n= 4. Data analysed 
by student t-test. 
 
 
4.2.3.3 Cytoskeletal protein expression were similar between mice infused 
with saline and Iso. 
Decreased protein expression of cytoskeletal scaffolds, α-actinin, desmin and 
spectrin were observed in the stunned myocardium of guinea pigs 348. Thus the 
protein expression of α-actinin and desmin was explored in LV homogenates 
harvested from mice 4 weeks after saline or Iso infusion (figure 4.18). There 
were no significant differences in cytoskeletal protein expression of α-actinin 









Figure 4.18 Cytoskeletal protein expression was unchanged after Iso 
treatment. 
Protein expression of cytoskeletal proteins, α-actinin and desmin, were 
evaluated by Western blotting using LV homogenates from mice infused for 4 
weeks with saline or Iso. α-Tubulin was used as a loading control. A, Membrane 
revealed no obvious difference in expression of α-actinin and desmin. B, 
Densimetric analysis of membranes in (A). Red arrows in (A) dictate quantified 
bands. Values expressed as mean ± SEM. n= 4. Data analysed by student t-
test. Desmin, p = 0.34, α-actinin, p = 0.89. 
 
4.2.3.4 Maintained mitochondrial morphology and sarcomere alignment 
after Iso infusion. 
To investigate potential changes in sarcomere alignment and mitochondrial 
shape, size and internal structure, heart tissue from mice infused with saline or 
Iso were submitted for TEM analysis. Under low magnification (5,000x), 
sarcomere structure and alignment appear maintained after Iso infusion 
compared to saline-infused mice (figure 4.19). Under higher magnification 
(40,000x), mitochondrial shape and size (not quantified) also appear to be 
consistent between saline- and Iso- infused myocardium, with no obvious 
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differences in the cristae or inner mitochondrial structure. As mitochondrial 
shape, size and cristae structure were maintained after Iso infusion, this 
suggests that mitochondrial function is not changed as a result of Iso infusion.  
 
Figure 4.19 Appearance of maintained sarcomeric alignment and 
mitochondrial structure were observed after 4 weeks Iso treatment.  
Electron microscopy was performed on myocardium harvested from mice after 
4 weeks infusion with Iso (n= 2). Low magnification images (scale bar = 2 µm) 
show conserved sarcomeric alignment whilst high magnification images (scale 
bar = 500 nm) reveal consistent mitochondrial structure, shape and size (not 






4.2.3.5 Study of cellular energetics, glucose metabolism and FA 
metabolism after Iso infusion. 
As metabolic abnormalities, such as decreasing FA and glucose metabolism 
have been reported after Iso infusion 302, histology, Western blotting and qRT-
PCR analyses were performed to evaluate any alterations in FA metabolism 
and glucose metabolism that may contribute to the development of β-stimulant-
induced cardiomyopathy. 
 
4.2.3.5.1 Lipid deposition and FA metabolism were unchanged after Iso 
infusion. 
To determine any differences in lipid deposition in the myocardium, Oil Red O 
staining was performed on cryosections of myocardium harvested from mice 
after 4 weeks infusion of saline or Iso (figure 4.20a). Image J software was 
used to quantify the lipid deposition in 5 images per section and expressed as a 
percentage of lipid deposition. No differences in lipid deposition were observed 














Figure 4.20 No differences in lipid deposition after Iso treatment. 
A, Cryosections of myocardial tissue harvested from mice infused with saline or 
Iso for 4 weeks were subjected to Oil-Red-O staining. B, Quantification of Oil-
Red-O staining of 5 images per section to determine percentage of lipid 
deposition in myocardium using Image J software. p = 0.40. No differences in 
lipid deposition were observed. Values expressed as mean ± SEM. n= 4. Data 
were analysed by student t-test. Scale bar = 30 µm. 
 
The mRNA expression of proteins involved in FA transport and metabolism 
were evaluated by qRT-PCR using samples from mice after 4 weeks Iso 
treatment. The expression of markers of β-oxidation of long chain FAs, carnitine 
palmitoyltransferase (Cpt)-1b, Cpt2, carnitine O-acetyltransferase (Crat) and 
Acetyl-CoA carboxylase b (Acacb) were assessed, as well as indicators of FA 
synthesis, Acaca and FA synthase (Fasn). However no differences were 
observed in the expression of these markers between saline- and Iso- infused 
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mice (figure 4.21). Together with the histological data, these finding suggests 
that FA metabolism is unchanged in this model and does not contribute to β-
stimulant-induced cardiomyopathy. 
 
Figure 4.21 Expression of fatty acid (FA) transport and metabolism 
markers was unchanged after Iso infusion. 
mRNA expression of proteins involved in FA transport and metabolism were 
evaluated by qRT-PCR using samples from mice after 4 weeks Iso treatment. 
A, Carnitine palmitoyltransferase (Cpt)-1 and Cpt2, p = 0.84 and p = 0.07, 
respectively. B, Carnitine O-acetyltransferase (Crat), p = 0.70. C, Acetyl-CoA 
carboxylase (Acac)-a and Acacb, p = 0.57 and p = 0.79, respectively. D, Datty 
acid synthase (Fasn), p = 0.80. Using LV homogenates from mice after 4 weeks 
Iso treatment no differences were observed in the expression of these markers. 
Indicators of β-oxidation of long chain FAs include carnitine palmitoyltransferase 
(Cpt)-1, Cpt2, carnitine O-acetyltransferase (Crat) and Acetyl-CoA carboxylase 
b (Acacb) whilst (Acac)-a and FA synthase (Fasn) are considered to be markers 
of FA synthesis. Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) was 
used as a housekeeping gene. Values expressed as mean ± SEM. n= 4. Data 






4.2.3.5.2 Cellular energy production was unchanged after Iso infusion.  
To estimate changes in cellular energy production, the expression of AMPKα 
was studied. AMPKα is a subunit of heterotrimeric protein, AMPK. This protein 
acts as a cellular fuel sensor and is an essential regulator of cellular energy 
homeostasis 349. AMPK is activated when ATP levels are diminishing, which 
may occur under circumstances such as low glucose, hypoxia, ischemia and 
heat shock. Stimulation of AMPK boosts cellular energy levels by inhibiting 
anabolic energy consuming pathways (FA and protein synthesis) and activating 
energy producing, catabolic pathways (FA oxidation, glucose transport, and 
autophagy).  
Therefore, total (t) AMPKα and phosphorylated (p) AMPKα (Threonine-172) 
expression were evaluated by Western blotting in samples of myocardial tissues 
harvested from mice infused with Iso or saline for 4 weeks (figure 4.22a). Using 
these samples, no differences in the expression of pAMPKα or tAMPKα were 
found, signifying there were potentially no changes in energy homeostasis after 








Figure 4.22 Adenosine monophosphate-activated protein kinase subunit 
alpha (AMPKα) protein expression was unchanged after Iso treatment. 
Protein expression of total (tAMPKα) and phosphorylated levels (pAMPKα, 
Thr172), were evaluated by Western blotting using LV homogenates from mice 
infused for 4 weeks with saline or Iso. α-Tubulin was used as a loading control. 
A, Membrane revealed no obvious difference in expression pAMPKα or 
tAMPKα. B, Densimetric analysis of membranes in (A). Red arrows in (A) 
dictate quantified bands. Values expressed as mean ± SEM. n= 4. Data were 
analysed by student t-test. pAMPKα, p = 0.51;  tAMPKα, p = 0.45; pAMPKα/ 
tAMPKα, p = 0.74. 
 
 
4.2.3.5.3 Glucose transport and metabolism were unchanged after Iso 
infusion. 
Next, potential changes in the mRNA expression of proteins involved in glucose 
transport and metabolism were evaluated by qRT-PCR using LV homogenates 
from mice after 4 weeks infusion of saline or Iso. The expression of markers of 
pyruvate decarboxylation, such as pyruvate dehydrogenase kinase isozyme 1 
(Pdk1), Pdk4 and pyruvate dehydrogenase alpha 1 (Pdha1) were assessed to 
provide information about the relevant levels of aerobic metabolism. 
Additionally, the expression of glucose transporter 1 (GLUT 1 or solute carrier 
family 2 facilitated glucose transporter member 1 (Slc2a1)) and GLUT 4 
(Slc2a4) were investigated as markers of glucose transport, whilst levels of 
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lactate dehydrogenase a (Ldha) were assessed as an indicator of anaerobic 
metabolism. Once again, no differences were observed in the mRNA 
expression of these markers of glucose transport and metabolism between mice 
infused with saline and Iso for 4 weeks (figure 4.23), suggesting that glucose 
transport and metabolism remained unchanged after Iso infusion. However, a 
tendency towards an increase in Ldha expression could be noted between 
saline and Iso infused hearts (p = 0.18), though more samples are required.  
 
Figure 4.23 No differences in mRNA expression of markers involved in 
glucose transport and metabolism. 
qRT-PCR was performed on LV homogenates from mice after 4 weeks Iso 
infusion to study mRNA expression of proteins involved in glucose acid 
transport and metabolism. A, Pyruvate dehydrogenase kinase isozyme 1 (Pdk1) 
and Pdk4, p = 0.74 and p = 0.66, respectively. B, Pyruvate dehydrogenase 
alpha 1 (Pdha1), p = 0.77. C, Glucose transporter 1 or Solute carrier family 2 
facilitated glucose transporter member 4, (GLUT1 or Slc2a1) and Glucose 
transporter 4 (GLUT4 or Slc2a4), p = 0.28 and p = 0.59, respectively. D, Lactate 
dehydrogenase a (Ldha), p = 0.18. Pdk1, Pdk 4 and Pdha1 are involved in 
pyruvate decarboxylation, therefore are markers of aerobic metabolism. Ldha is 
a marker of anaerobic metabolism whilst Glut 1 and Glut 4 are markets of 
glucose transport and insulin-sensitivities. No differences were observed in the 
mRNA expression of these markers of glucose transport and metabolism 
between saline- and Iso- treated mice. Glyceraldehyde 3-phosphate 
dehydrogenase (Gapdh) was used as a housekeeping gene. Values expressed 




4.2.3.6 Degradation of IκB after Iso infusion 
Iso has been reported to induce NF-κB translocation into the nucleus 350. While 
NFκB is notorious for its role within the immune system, it also regulates the 
expression of genes involved in cell survival and stress responses to ischemia, 
hypoxia and cellular stretch 185, 186, 351. Therefore it is considered to be both 
cardioprotective and cardiotoxic. 
To provide an insight into NFκB activity after Iso infusion, Western blotting was 
performed to examine the expression of IκB and phosphorylated (p)IκB. As 
mentioned in section 1.5.2) IκB binds to NFκB, preventing the translocation of 
NFκB into the nucleus. However phosphorylation of IκB targets IκB for 
ubiquitination and degradation, permitting the translocation of NFκB into the 
nucleus to bind to DNA and induce expression of NFκB-regulated genes.  
Expression of IκB and pIκB (Serine-32 / Serine-36) was evaluated using LV 
homogenates from mice infused with saline or Iso for 4 weeks (figure 4.24a). 
No differences in pIκB levels were observed between saline- and Iso- treated 
mice. However decreased IκB expression was noted in Iso-treated mice 
compared with saline-infused mice, inducing an increase in the pIκB / IκB ratio 
in Iso-treated mice (figure 4.24b), subsequently suggesting degradation of IκB. 
This consequently implies potential increased translocation of NFκB into the 
nucleus after Iso infusion, which may contribute to the development of β-









Figure 4.24 IκBα protein expression was reduced after Iso treatment. 
Protein expression of inhibitor of kappa B (IκBα) and phosphorylated levels 
(pIκBα, Ser32/Ser36) were determined by Western blotting using LV 
homogenates from mice infused with saline or Iso for 4 weeks. α-Tubulin was 
used as a loading control. A, Membrane revealed decreased expression of IκBα 
after Iso infusion. B, Densimetric analysis of membranes in (A). Red arrows in 
(A) dictate quantified bands. Values expressed as mean ± SEM. n= 4. Data 





Intriguingly, the data presented in this chapter suggest that the tachycardia and 
cardiac dysfunction observed in β-stimulant-induced cardiomyopathy were 
recoverable 1 day after Iso removal. Additionally, the data suggested that genes 
induced by NFκB may contribute to the development of β-stimulant-induced 
cardiomyopathy. However the mechanism behind this model of reversible β-




4.3.1 Iso-induced tachycardia and cardiac dysfunction were reversible 
The cardiac phenotype observed after β-stimulant-induced cardiomyopathy was 
reversible. Changes in HR and cardiac function after 4 weeks of Iso infusion, 
were partially recoverable 1 day after removal of Iso (figures 4.2, 4.3, 4.5 - 4.7 
summarised in table 4.6). Furthermore, heart weight normalised to tibia length 
was consistently increased in Iso-treated mice before and after minipump 
exchange (figure 4.8c), suggesting that gain in heart weight was not 
recoverable 2 days after minipump exchange. It is unlikely that the gain in heart 
weight would be recoverable so acutely and it should also be noted that these 
measurements were taken 1 - 2 days after minipump exchange and further 
changes or complete recovery of changes in HR and cardiac function may 
become apparent after longer recovery times. It has been reported that cardiac 
function in SIC patients improves 1 week after the manifestation of SIC, with 
complete recovery within 3 weeks 59. In rats, reversible effects of Iso-induced 
hypertrophy were observed 3 days after minipump exchange, although the LV 
weight remained significantly increased compared with saline-treated mice 352. 
This is in broad agreement with some of the findings of this current study, 
although the rate of reversibility was quicker in the model used in this chapter. 
There were some inconsistencies in the echocardiographic and physiological 
data obtained in the minipump exchange experiments, compared with that 
described in chapter 3 (figures 3.3, 3.4) after 4 weeks infusion of Iso. Chamber 
dilatation, measured by LVIDd and LVIDs parameters and pulmonary 
congestion, as assessed by lung weight, were not observed in these 
experiments (figures 4.6 – 4.8). The reason for these discrepancies is not 
known, but could be due to environmental factors such as the time of year that 
these experiments were performed. 
197 
 
Table 4.6 Summary table of minipump exchange study. 
Table to review differences in echocardiographic and physiological parameters 
at baseline, before minipump exchange (after 4 weeks minipump infusion) and 
after minipump exchange to remove drugs. Findings recorded in this table are 
relative to saline-treated mice at same timepoint (✓ = significant difference, X = 
no difference). Before minipump exchange, Iso induced hypertension, 
tachycardia, cardiac dysfunction, thickened posterior walls, heavier hearts and 
systemic congestion. However, 1 day after minipump exchange, these 
phenotypes had been abolished, except for heart weight, suggesting that 
aspects of β-stimulant-induced cardiomyopathy are recoverable. HR = Heart 
rate, LVIDd = End-diastolic left ventricle internal dimension, LVIDs = End-
systolic left ventricle internal dimension, EF = Ejection fraction, FS = Fractional 
shortening, IVSd = End-diastolic interventricular septal wall thickness, LVPWd = 
End-diastolic left ventricular posterior wall thickness, W = Weight, TL = Tibia 
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Another interesting feature of this study was how quickly the cardiac function 
depicted by EF and FS improved and recovered after Iso removal (figure 4.7d). 
Nef et al (2008) reported that genes involved in FA metabolism and oxidative 
phosphorylation were upregulated in patients that had recovered from SIC, 
compared with patients suffering from SIC 340. Though the mechanisms which 
facilitated this acute recovery of Iso-induced tachycardia and cardiac 
dysfunction was not evaluated in this thesis, this report by Nef et al (2008) 
indicate one possible mechanism that may induce rapid recovery of the 
myocardium after Iso removal. Therefore, further study is required to identify the 
causes of this acute recovery and could focus upon the gene expression of 
proteins involved in FA metabolism and oxidative phosphorylation. 
These experiments identified that Iso-induced tachycardia and cardiac 
dysfunction were recoverable 1 day after Iso removal, yet Iso-induced gain of 
heart weight was not recoverable within this same timeframe. Whilst the cause 
of the acute recovery remains unstudied, these findings suggested that 4 weeks 
of Iso infusion caused reversible changes to the function of the myocardium, 
which were likely to be functional amendments rather than structural 
modifications. 
 
4.3.2 Infusion of Iso does not change calcium handling, oxidative stress- 
signalling or metabolism in mice  
The reversibility of β-stimulant-induced cardiomyopathy suggested that 
functional, reversible changes had occurred in the myocardium after Iso 
infusion. Therefore it was hypothesised that desensitisation and changes in β-
AR expression and calcium handling were likely causes of the phenotype 
observed and this may impact oxidative stress-related proteins and metabolism. 
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New samples were obtained which exhibited β-stimulated cardiomyopathy, 
excluding the tachycardia and pulmonary congestion associated with this 
condition. As mentioned, echocardiography was performed on conscious mice, 
which could be the reason why the HR was unchanged after Iso infusion. 
Furthermore, no differences in lung weight (similar to figure 4.3) were observed 
after 4 weeks of Iso infusion. This highlights the inconsistency of this model and 
it remains unknown whether Iso actually induces pulmonary congestion. 
In this model of β-stimulant-induced cardiomyopathy the mRNA expression of 
the β-ARs were unchanged (figure 4.10a). However the protein expression and 
localisation of these receptors should be evaluated, as qRT-PCR experiments 
do not consider post-transcriptional regulation of mRNA, β-AR localisation and 
the phosphorylation status of the receptors.  
Calcium handling is often impaired in clinical HF cases, preclinical HF models 
and in models of Iso infusion and is proposed to contribute to TIC and SIC. 
However in the experiments described here, no differences in the protein 
expression of calcium handling proteins were observed after Iso infusion, 
though a decreased tendency was observed in the expression of SERCA2, 
pentameric pPLN (Serine-16) and monomeric tPLN between saline- and Iso- 
treated mice was observed. Further samples are required to validate that 
tendency. One study reported differences in calcium activity after Iso infusion 
whilst the protein expression of calcium handling proteins (PLN, SERCA2 or 
RyR2) remained unchanged 299 whilst another study reported similar findings 
using samples from DCM patients 242. Therefore, although expression of the 
proteins involved in calcium handling have been analysed, activity of the 
enzymes and receptors should be examined and calcium transients and 
amplitudes should be studied. 
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Attempts to measure RyR2 protein expression by Western blotting after Iso 
infusion were endeavoured (not shown). However, after multiple attempts to 
optimise the Western blotting procedure (SDS-PAGE, transfer, antibody 
incubations), RyR2 was undetectable. This could be due to the difficulties 
associated with transferring large molecular weight proteins (565 kDa) from 
SDS-PAGE gel to nitrocellulose membrane or due to degradation of RyR2 
within the samples.  
Next it was demonstrated that the expression of ischemic and oxidative stress 
markers after Iso infusion was unchanged in this model of β-stimulant-induced 
cardiomyopathy (figure 4.16). A trend towards increased expression of Hmox1 
after Iso infusion could be observed but more samples are required to validate 
that claim. Furthermore, the unchanged expression of hypoxic marker, Hif1a, 
after Iso infusion, compared to saline treatment, implied that the cardiomyocytes 
were not hypoxic after treatment with Iso.   
It was reported that Nrf2-induced genes were elevated in SIC patients 340, 
however, no differences were observed in the mRNA levels of Nrf2-induced 
genes (Gclc, Gsta2, Txnrd1) between saline- and Iso- treated mice (figure 
4.15). These findings were corroborated after examination of Hmox1 
expression, another gene regulated by Nrf2 (used as oxidative stress marker in 
this current study) (figure 4.16b). In the original report 340, changes were 
highest in glutathione peroxidase (Gpx1) and catalase (Cat) which were not 
examined in this model. Therefore the expression of these and other Nrf2-
induced genes should be measured in this model of β-stimulant-induced 
cardiomyopathy. 
Iso has been reported to lessen oxidative metabolism, boost oxidative stress 
and reduce FA oxidation 299, 302, all of which would be affected by abnormal 
201 
 
mitochondrial function. In SIC patients, damage to contractile proteins, 
contraction band necrosis and hypercontracted sarcomeres were reported 58, 63. 
Together all these parameters suggest that the mitochondrial function and 
sarcomere alignment may be impaired after Iso treatment. TEM analysis found 
that overall mitochondrial shape and structure was maintained after Iso infusion 
(figure 4.19, not quantified). However, quantitative analysis of the images to 
analyse mitochondrial shape and structure would support and confirm this 
statement. The ‘observed’ conservation of mitochondrial shape and structure 
after Iso infusion also suggested that mitochondrial function would be 
unchanged after Iso infusion. This was supported by unchanged expression of 
Ppargc1a (oxidative stress marker and regulator of mitochondrial biogenesis 
and function) (figure 4.16c), Cpt1b and Cpt2 (markers of FA oxidation located 
in mitochondria) (figure 4.21a), Pdk1, Pdk 4 and Pdha1 (markers of glycolytic 
metabolism, also located in mitochondria) (figure 4.23a, b) between saline- and 
Iso- treated mice. 
Reports that Iso induced metabolic abnormalities 302 compelled the investigation 
to study the expression of several markers of lipid and glucose metabolism and 
transporters after Iso infusion. However, no differences were observed in 
markers for FA synthesis, β-oxidation of long chain FAs, aerobic metabolism, 
anaerobic metabolism and glucose uptake between mice infused with saline or 
Iso (figure 4.21 and 4.23). In addition, Hif1a expression is also considered a 
marker of FA β-oxidation 335 and its expression after Iso infusion concurs with 
the findings of the other markers (figure 4.16a). However, a trend towards 
increased expression of Ldha was noted between saline and Iso infused hearts 
(p = 0.18), though more samples are required to support this assertion. 
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Whilst no differences were observed after Iso infusion in the metabolic 
parameters mentioned above as well as in lipid deposition and cellular 
energetics, it is important to note that other aspects of metabolism (such as 
protein synthesis and oxidative phosphorylation) should be measured, 
alongside the levels of metabolites (ATP, FAs, glucose).  
In summary, no differences in β-AR expression, calcium handling proteins and 
markers of ischemia and oxidative stress and metabolism were observed in this 
model of β-stimulant-induced cardiomyopathy, highlighting its unusualness. 
However more samples for each experiment are required to further support 
these assertions. 
One limitation of this study was the lack of power calculations to ensure that the 
data was irrefutable. The number of samples needs to be increased for several 
experiments to validate the claims made (discussed further in section 6.4). 
Other limitations include the differential methods of echocardiography yielding 
different findings and the use of qRT-PCR to determine expression of particular 
proteins (discussed further in section 6.4). Further experiments would focus 
upon studying the protein expression of markers measured by qPCR in this 
chapter (if antibodies are available) and the activity of these proteins as well as 
measuring metabolite levels. 
 
4.3.3 Potential role of NFκB in β-stimulant-induced cardiomyopathy. 
Iso was reported to induce NFκB translocation into the nucleus 350 and 
interestingly, in this model of β-stimulant-induced cardiomyopathy, the 
expression of IκB was decreased after Iso infusion (figure 4.24b).  This finding 
suggests that Iso infusion induces degradation of IκB, enabling the translocation 
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of NFκB into the nucleus. However the upstream and/or downstream effects of 
this remain unanswered.  
To validate these findings, attempts to study the expression and localisation of 
NFκB and IκB after Iso infusion by IF using tissue samples were undertaken, as 
demonstrated by several studies 353, 354. However, very few cells on each 
section emitted fluorescent signal representing NFκB and IκB. This was 
unexpected as NFκB is ubiquitously expressed, suggesting that this IF protocol 
requires optimisation. Alternatively, another experiment using inhibitors of NFκB 
may be designed and used to prove an association between β-AR signalling 
and NFκB.  Treatment of Iso-infused mice with NFκB inhibitors may be used to 
prove such an association. 
To determine the upstream signalling that induced degradation of IκB, the 
signalling cascade upstream of NFκB and IκB should be considered. The 
kinases reported to phosphorylate IκB include IKKα, IKKβ or c-Jun N-terminal 
kinases (JNK), all of which are activated by different signalling pathways. 
Therefore if the kinase that phosphorylates IκB is identified, then it is possible to 
identify the signalling pathway upstream and possible stimuli that induced the 
phenotype observed in β-stimulant-induced cardiomyopathy. However, cellular 
conditions that are known to induce NFκB activity include inflammation, cell 
death, hypoxia or ischemia. As demonstrated by chapter 3 and this chapter, 
inflammation, apoptosis and ischemia were not upregulated in this model of β-
stimulant-induced cardiomyopathy, therefore other pathways which activate 
NFκB activity should be evaluated such as cellular stretch and cell survival. 
Additionally, to determine whether there is increased translocation of NFκB into 
the nucleus, the expression of genes downstream of NFκB should be evaluated. 
NFκB is a transcription factor for genes involved in immune activation and 
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regulation, including cytokines and chemokines, regulators of apoptosis, growth 
factors and other transcription factors 355.  
In the report that demonstrated Iso stimulated DNA binding activity of NFκB, 
that same report also demonstrated Iso induced DNA binding activity of AP-1 
and JNK 350. Therefore expression and translocation of both AP-1 and JNK 
should also be evaluated. 
In summary, this chapter demonstrated that continuous, excessive and chronic 
infusion of Iso may induce NFκB activity and its downstream effects may 

















5 Imperative and novel functions of TLR9 in wound healing 
during acute ventricular remodelling post-MI.  
 
5.1 Introduction 
MI is a leading cause of HF 356, 357. Rupture of atherosclerotic plaques is the 
most common cause of MI, restricting the flow of blood through the coronary 
artery and hence inducing myocardial ischemia. This subsequently disrupts 
cardiomyocyte function, provoking cell death, inflammation and scar formation, 
which sequentially causes permanent damage to the myocardium that may 
contribute to the progression of HF 263.  
In mice, several models that mimic MI have been generated in order to 
understand the molecular mechanisms that contribute to the myocardial 
damage observed after MI 358. The best-characterised model involves complete 
ligation of the LAD coronary artery, which fully restricts the blood flow to the 
anterior and apical regions of the heart 359. This area, known as the ischemic 
area at risk, subsequently develops into an infarct associated with a cross-
linked collagen scar (figure 5.1). 
A multitude of studies using samples from HF patients and various preclinical 
models have demonstrated a distinct role for inflammation in the pathogenesis 
of HF 19, 20, 360, 361. Whilst the mechanisms that underlie the stimulation of 
inflammatory responses within the myocardium are currently unresolved 20, this 
subject is presently an area of intense study. It was recently reported that the 
immune sensor, TLR9, instigates an inflammatory response during the 














Several reports have demonstrated that inflammatory responses are elicited 
post-MI 362, 363, 364, 365. Although, the impact of TLR9 stimulation on LV 
remodelling after MI has thus far not been elucidated, mice deficient in TLR2, 
TLR3 or TLR4 exhibited smaller infarcts, diminished cardiac remodelling and 
reduced inflammation after MI and I/R injury 366, 367, 368, 369. These studies 
insinuate that inflammation is detrimental to LV remodelling post-MI, causing 
damage to the myocardium. However, inflammation is reported to play a crucial 
role during LV remodelling post-MI by aiding the clearance of dead cells from 
the infarcted myocardium and promoting tissue repair 32, 36, 362. Therefore 
inflammatory responses must be tightly balanced. 
Increased levels of circulating mtDNA, a known stimulus for TLR9, have been 
recorded in acute MI patients 305, which could potentially activate TLR9 to 
induce an inflammatory response post-MI. In a model of cardiac pressure 
overload, mtDNA was incompletely digested by autolysosomes within 
cardiomyocytes, leading to TLR9-mediated inflammation 173. By contrast, after 
Figure 5.1 Murine model of MI. 
To investigate the pathophysiology of MI, a model was established by ligating 
the left anterior descending (LAD) coronary artery, completely occluding the 




MI mtDNA is released extracellularly from necrotic cells and may be internalised 
by other cell-types (fibroblasts, endothelial cells, leukocytes) within the 
myocardium or systemic circulation. Thus these 2 models mimic different 
myocardial conditions, which could confer distinct TLR9-mediated inflammatory 
responses. Additionally, the prevalence of cell death is greater after MI than in 
response to pressure overload and therefore a more intense inflammatory 
response may be required after MI to remove dead cells. Thus both the 
regulation and role of TLR9-mediated inflammation induced by mtDNA may be 
different between these 2 murine models.  
It was therefore hypothesised that TLR9 might contribute to the inflammation 
associated with ventricular remodelling post-MI and this chapter will explore 
whether TLR9-mediated inflammation is beneficial or detrimental after MI. The 
aim of this study was to investigate the role of TLR9-mediated inflammation in 
the infarcted myocardium. The differences in LV remodelling between WT and 
TLR9KO mice, subjected to ligation of the LAD, were assessed to inform on the 
contribution of TLR9-mediated inflammation to cardiac remodelling after MI.  
 
5.2 Results 
5.2.1 TLR9KO mice had higher mortality after MI compared with WT mice. 
To study the contribution of TLR9 signalling to the inflammatory response post-
MI, 8 – 10-week old male C57Bl/6 (WT) and global TLR9KO mice were 
subjected to MI by ligation of the LAD (figure 5.1) or sham surgery. Prior to 
surgery, the physiological and echocardiographic parameters were measured to 
ensure there were no differences at baseline between WT and TLR9KO mice 
(table 5.1).  
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Table 5.1 Echocardiographic and physiological parameters were not 
different between WT and TLR9KO mice prior to surgery.  
Conscious echocardiography and blood pressure measurements were 
performed on 8-10-week old WT and TLR9KO mice before surgery to reveal no 
difference between groups. Values are expressed as mean ± SEM. Data were 
analysed by one-way ANOVA with bonferroni’s post-hoc test. Sig. = 
significance, n.s = no significance, IVSd = End-diastolic interventricular septal 
wall thickness, LVPWd = End-diastolic left ventricular posterior wall thickness, 
LVIDd = End-diastolic left ventricle internal dimension, LVIDs = End-systolic left 
ventricle internal dimension, EF = Ejection fraction, FS = Fractional shortening, 
HR = Heart rate, BW = Body weight, MBP = Mean blood pressure.  
 
 
Operations to induce MI or sham surgery were performed on WT and TLR9KO 
mice. The mice were observed closely for 2 weeks for signs of stress or injury 
after surgery. Surprisingly, 4 days after operation, MI-operated TLR9KO mice 
began to die, whilst MI-operated WT mice persisted. Only 4/11 TLR9KO mice 
survived until 14 days following MI operation, whilst 8/9 WT mice survived this 
period (36.4% versus 88.9% survival rate) (figure 5.2). All WT- and TLR9KO- 
sham mice survived throughout the experiment. The cause of death for the WT 
and TLR9KO mice subjected to MI was cardiac rupture, indicated by blood 
coagula in the chest cavity and small slits located on the free wall of the LV 
ascertained by post-mortem analyses (figure 5.3). These intriguing results 
indicate that TLR9 is fundamental for LV remodelling post MI, during the acute 
phase 4 - 6 days after operation. 
Parameters 
WT Sham WT MI TLR9KO Sham TLR9KO MI 
Sig. 
(n= 6) (n= 9) (n= 7) (n= 11) 
IVSd (mm) 0.79 ± 0.05 0.72 ± 0.04 0.74 ± 0.02 0.75 ± 0.01 n.s 
LVIDd (mm) 2.89 ± 0.07 3.02 ± 0.06 3.14 ± 0.12 3.13 ± 0.07 n.s 
LVIDs (mm) 1.54 ± 0.10 1.48 ± 0.05 1.51 ± 0.09 1.60 ± 0.07 n.s 
LVPWd (mm) 0.76 ± 0.05 0.72 ± 0.02 0.72 ± 0.03 0.73 ± 0.01 n.s 
      
EF (%) 82.84 ± 0.94 83.59 ± 0.78 84.22 ± 1.30 81.50 ± 1.24 n.s 
FS (%) 50.17 ± 1.09 51.13 ± 0.88 52.10 ± 1.52 49.13 ± 1.36 n.s 
HR (BPM) 725.89 ± 6.03 723.72 ± 6.64 700.69 ± 10.94 699.54 ± 8.86 n.s 
LV mass (mg) 62.71 ± 3.43 64.91± 1.62 69.98 ± 3.57 70.77 ± 2.33 n.s 
      
BW (g) 24.20 ± 0.63 24.30 ± 0.40 24.61 ± 0.47 24.81 ± 0.31 n.s 





















Figure 5.3 Cardiac rupture was the cause of mortality after MI in WT and 
TLR9KO mice.  
Post-mortem analysis revealed that cause of death of WT (n=1) and TLR9KO 
(n=7) mice was cardiac rupture indicated by blood in the chest cavity and small 




Figure 5.2 TLR9KO mice have a lower survival rate after MI.  
WT and TLR9KO mice were followed for 14 days after sham or MI surgery. 
TLR9KO mice subjected to MI showed significantly higher mortality than WT 
mice 4 days after surgery. WT Sham (pink, n = 6, 100% survival), WT MI 
(orange, n= 9, 88.9% survival), TLR9KO Sham (purple, n = 7, 100% survival) and 
TLR9KO MI (green, n = 11, 36.4% survival).  Data were analysed by Mantel-Cox 
Log-Rank test. *p<0.05 versus all other murine groups. 
210 
 
5.2.2 Ischemic area at risk, wall thicknesses and haemodynamic 
parameters were consistent between WT and TLR9KO mice after MI.  
To ensure there were no differences in the ischemic area at risk between WT 
and TLR9KO mice after MI operation, which may influence infarction size and 
incidence of cardiac rupture, Evans Blue staining was performed on a separate 
cohort of animals. Evans Blue reagent was directly injected into the inferior 
vena cava of WT and TLR9KO mice immediately after ligation of the coronary 












Figure 5.4 No difference in the ischemic area of risk between WT and 
TLR9KO mice subjected to MI. 
Evans Blue reagent was injected into the inferior vena cava to determine the 
ischemic area at risk immediately after operating to induce MI. The ischemic 
area at risk represents the area of the myocardium that is no longer connected 
to the circulation. A, Images of stained heart; areas stained blue are healthy and 
viable, whereas unstained areas represent the ischemic area at risk. Scale bar 
= 5 mm. B, Graphical representation of the ischemic area at risk calculated as a 
percentage of the whole heart. There was no difference in the ischemic area at 
risk between WT and TLR9KO mice. Values are expressed as mean ± SEM. 
WT MI (open, n= 5), TLR9KO Sham (green, n = 6). Data were analysed by 
student’s t-test. 




The unstained area represented the ischemic area at risk that was 
disconnected from the circulation and may have developed into an infarct, whilst 
the healthy, viable myocardium was stained blue. Image quantification indicated 
no significant differences in the ischemic area at risk between WT and TLR9KO 
mice after MI (figure 5.4b). 
Cardiac rupture is an adverse consequence of thinning of the myocardial walls, 
and is also a common feature of MI 370, 371. Thus cardiac MRI was performed on 
WT and TLR9KO mice 3 days after induction of MI to determine if there were 
any changes in cardiac structural and functional parameters and infarct size 
(figure 5.5).  However, no significant differences were observed in the 
thickness of the walls in the border or infarct zones, infarct size or 
haemodynamic parameters between WT and TLR9KO mice subjected to MI 
(table 5.2).  
Figure 5.5 Cardiac MRI revealed no difference in cardiac structure 3 days 
after MI between WT and TLR9KO mice. 
Representative images of cardiac MRI performed on WT and TLR9KO mice 3 
days after surgery to induce MI. LV cavity = Red area, Infarct area = blue area. 




Table 5.2 No differences in left ventricular structure and function 3 days 
post MI between WT and TLR9KO mice revealed by cardiac MRI. 
Cardiac MRI was performed on anaesthetised MI-operated WT and TLR9KO 
mice. Wall thickness was measured in 10 random points in the border and 
infarct regions from images acquired 3 mm from the apex. The other 
parameters were calculated from 7 – 9 images taken at 1 mm intervals along 
the short axis. No differences were observed in the wall thickness, infarct size, 
LV mass and functional parameters of WT and TLR9KO mice 3 days after MI. 
Values are expressed as mean ± SEM. Data were analysed by student’s t-test. 
Sig. = Significance, n.s = no significance. 
 
5.2.3 Lack of fibrosis in infarcted myocardium of WT and TLR9KO mice. 
To investigate the molecular mechanisms that boosted the incidence of cardiac 
rupture in TLR9KO mice after MI, histological and biochemical analyses were 
performed on the myocardium harvested from WT and TLR9KO mice. Hearts 
were harvested from WT and TLR9KO mice, 1 day and 3 days after operation, 





p value Sig. 
(n= 4) (n= 4) 
Wall thickness (border) (mm) 0.52 ± 0.01 0.52 ± 0.01 0.99 n.s 
Wall thickness (infarct) (mm) 0.53 ± 0.02 0.55 ± 0.04 0.72 n.s 
LV mass (mg) 65.42 ± 4.86 79.38 ± 2.85 0.09 n.s 
Infarct size (%) 50.18 ± 4.01 51.17 ± 4.89 0.90 n.s 
     
End-diastolic LV volume (µl) 74.21 ± 2.40 81.49 ± 8.33 0.55 n.s 
End-systolic LV volume (µl) 53.79 ± 2.59 56.85 ± 7.90 0.79 n.s 
Stroke Volume (ml/min) 20.42 ± 1.46 24.64 ± 1.05  0.10 n.s 
Cardiac Output (µl) 9.53 ± 0.50 13.59 ± 1.24 0.08 n.s 
Ejection Fraction (%) 27.57 ± 2.08 31.71 ± 3.01 0.33 n.s 
Figure 5.6 Timecourse of experiments. 
To investigate the cause of higher mortality seen in TLR9KO mice after MI, WT 
and TLR9KO mice were harvested 1 and 3 days after sham or MI operations. 
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H & E staining was executed on myocardial cryosections obtained from WT and 
TLR9KO mice to assess overall cell infiltration (leukocytes or fibroblasts) into 
the myocardium post-MI (figure 5.7). The hearts of WT and TLR9KO mice 
subjected to MI at both timepoints were highly heterogeneous, compared to 
sham-operated animals. The healthy parts of the MI-operated heart, termed the 
remote area, had similar myocardial structure as sham-operated animals. 
 
 
Figure 5.7 H & E staining revealed increased infiltration of cells into the 
myocardium in WT and TLR9KO subjected to MI. 
H & E staining was performed on cryosections from WT and TLR9KO mice after 
MI. 3 different regions of mice subjected to MI are shown – remote, border and 
infarct. There appears to be excessive infiltration of cells into the border and 
infarcted regions 1 day after MI, but more so after 3 days (shown by arrow 
heads). n= 4 for all groups. A, Myocardium 1 day after surgery. B, Myocardium 




However, in the infarct area there was excessive cell infiltration and/or 
cardiomyocyte death, suggested by the presence of haematoxylin stain (blue) 
but not eosin (red) stain (not quantified). The transitional zone from the remote 
area to infarcted myocardium, termed the border zone, displayed a substantially 
greater number of these infiltrating or necrotic cells (not quantified). Thus it was 
decided that future staining performed on MI-operated hearts should be 
analysed in 3 different areas, remote, border and infarct areas.  
After myocardial injury, the wounded area matures into a collagen- and 
connective tissue- containing fibrotic scar. Thus, histological staining and qRT-
PCR analyses were implemented to study the extent of fibrosis in WT and 
TLR9KO mice after surgery. MT staining was performed on WT and TLR9KO 
hearts harvested 1 and 3 days after MI surgery (figure 5.8). Areas stained blue 
by MT reagent represented fibrotic areas, however there was very little blue 
staining observed in the myocardium of WT and TLR9KO mice at both time 
points after sham or MI surgery (not quantified), suggesting no difference in 
fibrosis between WT and TLR9KO mice, 1 or 3 days after sham or MI surgery.  
To determine if there were changes in fibrotic markers at the mRNA level, the 
quantity of Col1a, Col3a1, transforming growth factor (Tgf)b1 and Tgfb2 was 
measured by qRT-PCR using LV homogenates from WT and TLR9KO mice 
after sham or MI surgery (figure 5.9). Using these samples, there were no 
differences in the levels of Col1a2 and Col3a1 1 day after operation between 
sham- and MI- operated WT mice, but levels were significantly increased after 3 







Figure 5.8 Masson’s Trichrome staining found no difference in fibrosis in 
WT and TLR9KO mice after MI. 
3 different areas of MI-operated mice are shown – remote, border and infarct. 
Although excessive infiltration of cells can be seen in these images (white grey 
areas) in the border and infarcted regions of mice 3 days after operation, WT 
and TLR9KO mice did not show any fibrosis (blue signal) after MI at both 
timepoints. n= 4 for all groups. A, Myocardium 1 day after surgery. B, 
Myocardium 3 days after surgery. Scale bars = 60 µm. 
 
 
Surprisingly, these markers were elevated in sham-operated WT mice 3 days 
after operation compared with sham-operated WT mice harvested 1 day after 
surgery. Additionally, mRNA levels of Tgfb1 and Tgfb2 were elevated 1 and 3 
days after MI in WT mice compared to sham-operated mice. Whilst levels of 
Tgfb2 remained consistent in MI-operated WT mice between 1 and 3 days after 
surgery, Tgfb1 expression increased between these timepoints. Finally, the 
expression of fibrotic markers between sham- and MI- operated TLR9KO mice 
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was analogous to WT sham- and MI- operated mice at 1 and 3 days after 
operation and no differences were identified in the levels of Col1a, Col3a1, 
Tgfb1 and Tgfb2 between WT and TLR9KO mice subjected to MI. Therefore 
these findings infer that fibrosis did not contribute to the increased incidence of 














Figure 5.9 mRNA levels of fibrotic markers were similar between WT and 
TLR9KO mice after MI. 
qRT-PCR was performed on LV samples of mice to measure levels of fibrotic 
markers. Levels of collagen type 1 alpha 2 (Col1a2) and Col3a1 were 
increased 3 days after MI whereas levels of transforming growth factor β1 
(Tgfb1) and Tgfb2 were increased 1 and 3 days after surgery compared to 
sham (S)- operated mice.  Yet no difference was observed between WT (open 
bars) and TLR9KO (green bars) mice after MI. Glyceraldehyde 3-phosphate 
dehydrogenase (Gapdh) was used as a housekeeping gene. Values are 
expressed as mean ± SEM; Day 1 WT sham n= 6, Day 1 WT MI n= 7, Day 3 
WT sham n= 5, Day 3 WT MI n= 6, Day 1 TLR9KO sham n= 6, Day 1 TLR9KO 
MI n= 5, Day 3 TLR9KO sham n= 5, Day 3 TLR9KO MI n= 5. Data were 
analysed by two-way ANOVA with bonferroni post-hoc test. † p<0.05 versus 
corresponding sham animals at same timepoint, ‡ p<0.05 versus same 
treatment at different timepoints.  
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5.2.4 Investigation of the wound healing response after MI. 
To comprehend the cause of cardiac rupture in TLR9KO mice after infarction, 
other avenues were explored. It was stated that myocardial inflammation, 
impaired ECM remodelling and dampened fibrotic healing are fundamental 
mechanisms for acute ventricular remodelling and for the pathogenesis of 
cardiac rupture 36. Thus these components were investigated by biochemical 
and histological experiments to determine whether they contribute to the greater 
frequency of cardiac rupture observed in TLR9KO mice after MI.  
 
5.2.4.1 Inflammation did not influence the mortality of TLR9KO mice 
subjected to MI. 
The hypothesis postulated that TLR9-mediated inflammation may contribute to 
LV remodelling post-MI. The increased incidence of cardiac rupture in MI-
operated TLR9KO mice, compared to WT mice observed in figure 5.2, 
suggested that TLR9 is beneficial in acute-remodelling post MI. TLR9-mediated 
inflammation may therefore be critically vital for LV remodelling post-MI, by 
potentially facilitating the clearance of dead cells and initiating would healing. 
However, previous studies have shown to correlate inflammation with increased 
occurrence of cardiac rupture 372, 373, highlighting the detrimental effects of 
inflammatory responses within the myocardium. It could be speculated that 
although the overall inflammatory response is detrimental for risk of cardiac 
rupture, TLR9-mediated inflammation may be a very specific response that is 
crucial for the removal of dead cells and the activation of tissue repair 
processes. 
Thus the inflammatory response was evaluated in this model by IHC staining 
and qRT-PCR analysis to determine the infiltration of inflammatory cells and 
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levels of pro-inflammatory chemokines and cytokines in the myocardium. IHC 
staining of cryosections of cardiac tissue from WT and TLR9KO mice subjected 
to MI, were performed to assess the levels of leukocytes (CD45) in addition to 
macrophages (CD68), neutrophils (Ly6G/C) and T cells (CD3). Sham-operated 
WT animals and the remote region of MI-operated WT animals comprised of a 
similar number of inflammatory cells at all timepoints (figures 5.10, 5.11 and 
5.12). In MI-operated WT sections, compared to the remote region, infiltration of 
inflammatory cells (CD45-, CD68- and Ly6G/C- positive cells) was greatest in 
the border regions at both timepoints followed by the infarct areas, indicating 
the active recruitment of cells to the damaged myocardium post-MI. A day after 
MI surgery, an increase in CD45-positive and CD68-positive cells in the border 
and infarct regions were seen in WT mice, compared to sham-operated WT 
mice and this was vastly enhanced 3 days after MI operation. The numbers of 
Ly6G/C-positive cells were consistently elevated in the infarct and border 
regions of MI-operated WT mice 1 and 3 days after surgery, compared to sham-
operated mice.  Minimal changes in the numbers of CD3-positive cells were 
observed between WT sham and all distinct regions of MI-operated animals, 
although a slight increase was seen in the border region 3 days after MI, 
compared to sham-operated animals. The differences between WT sham- and 
MI- operated mice mentioned above, were consistent with sham- and MI-
operated TLR9KO mice at all timepoints, yet there were no significant 
differences in the number of CD45-, CD68-, Ly6G/C- and CD3- positive cells 
between WT and TLR9KO mice subjected to MI (figures 5.10, 5.11 and 5.12). 
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Figure 5.10 Immunohistochemical staining suggests no differences in the 
number of inflammatory cells in the myocardium in WT and TLR9KO mice 
1 day after MI. 
Staining was performed to detect cells expressing CD45 = leukocytes, CD68 = 
macrophages, Ly6G/C = neutrophils and CD3 = T-cells. 3 different regions of 
MI-operated hearts are displayed – remote, border and infarct. In the border 
and infarct regions of MI-operated hearts, there appears to be greater infiltration 
of CD45-, CD68- and Ly6G/C- positive cells, compared to sham-operated 
hearts, however no obvious difference in the filtration of inflammatory cells into 
the myocardium of WT and TLR9KO mice 1 day after surgery. n= 4 for all 





Figure 5.11 No disparities in the number of inflammatory cells in the 
myocardium in WT and TLR9KO mice 3 days after MI suggested by IHC 
staining.  
Staining was performed to detect cell-specific markers; CD45 = leukocytes, 
CD68 = macrophages, Ly6G/C = neutrophils and CD3 = T-cells. 3 different 
areas of hearts subjected to MI are shown – remote, border and infarct. Similar 
to day 1 (figure 5.10) there appears to be greater infiltration of CD45-, CD68- 
and Ly6G/C- positive cells into the border and infarct regions of MI-operated 
hearts. No obvious difference in the filtration of inflammatory cells into the 





Figure 5.12 Quantification of infiltrating inflammatory cells into the 
myocardium of WT and TLR9KO mice revealed no difference between WT 
and TLR9KO mice subjected to MI.  
Number of positive cells were counted from 5 different images per heart section 
in sham (S) mice and per region (R = Remote, B = Border, I = Infarct) in MI-
operated animals (figures 5.10 and 5.11). Cell markers that were investigated 
include: CD45 = leukocytes, CD68 = macrophages, Ly6G/C = neutrophils and 
CD3 = T-cells. Number of CD45-, CD68- and Ly6G/C- positive cells were 
increased in the border and infarct regions of MI-operated hearts 1 and 3 days 
after MI. CD3-positive cells were increased in the border region of mice 3 days 
after MI. No differences in the quantity of inflammatory cells in the myocardium 
of WT and TLR9KO mice. Values are expressed as mean ± SEM. n= 4 for all 
groups. Data were analysed by two-way ANOVA with bonferroni’s post-hoc test. 
† p<0.05 versus corresponding sham animals at same timepoint, ‡ p<0.05 
versus same treatment at different timepoints.  
 
To confirm these findings, the mRNA levels of pro-inflammatory chemokines 
and cytokines were measured by qRT-PCR in LV homogenates of WT and 
TLR9KO mice after MI surgery (figure 5.13). Expression of Ccl2, Tnfa, Il1b and 
Il6 were increased 1 and 3 days after MI in WT mice compared with sham-
operated mice. The anti-inflammatory marker, Il10, was not elevated 1 day after 
MI, but was significantly upregulated 3 days after surgery in MI-operated WT 





Figure 5.13 mRNA expression levels of chemokine and cytokines were not 
different between WT and TLR9KO mice after MI. 
Levels of pro-inflammatory chemokine and cytokines mRNA were measured by 
qRT- PCR. Expression of chemokine (C-C motif) ligand (Ccl2), tumour necrosis 
factor (Tnf)a, interleukin (Il)1b and Il6 were upregulated in WT and TLR9KO 
mice subjected to MI compared with sham (S) mice. The anti-inflammatory 
marker, Il10, was increased 3 days after MI in WT and TLR9KO mice compared 
to sham mice. Tnfa expression was different between WT and TLR9KO 1 day 
after MI, however the other markers displayed no difference between WT and 
TLR9KO mice subjected to MI. A, mRNA expression of chemokines. B, mRNA 
levels of cytokines. Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) was 
used as a housekeeping gene. Values expressed as mean ± SEM.; Day 1 WT 
sham n= 6, Day 1 WT MI n= 7, Day 3 WT sham n= 5, Day 3 WT MI n= 6, Day 1 
TLR9KO sham n= 6, Day 1 TLR9KO MI n= 5, Day 3 TLR9KO sham n= 5, Day 3 
TLR9KO MI n= 5. Data were analysed by two-way ANOVA with bonferroni’s 
post-hoc test. † p<0.05 versus corresponding sham animals at same timepoint, 
‡ p<0.05 versus same treatment at different timepoints. # p<0.05 versus WT 
animal at same timepoint with same treatment. 
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TLR9KO mice expressed similar mRNA levels of cytokines and chemokines 
(excluding Tnfa) as WT mice mentioned above, after sham and MI surgery at 
both timepoints. Interestingly, the increase in Tnfa expression in TLR9KO mice 
1 day after MI was significantly less than WT mice 1 day after MI. However no 
significant differences in Tnfa levels were detected between MI-operated WT 
and TLR9KO mice 3 days after surgery. Therefore the qRT-PCR results, 
excluding Tnfa, corroborated the findings of the IHC staining, implying that 
inflammation may not contribute to the increased mortality of TLR9KO mice 
after MI.  
 
5.2.4.2  Decreased Timp1 mRNA expression may diminish survival of 
TLR9KO mice after MI. 
Injury to the myocardium instigates remodelling of the ECM by MMPs to 
facilitate infiltration of inflammatory cells to remove necrotic cells 374, 375. MMP 
activity is profoundly regulated by TIMPs, although an imbalance between 
MMPs and TIMPs has been reported in various cardiac diseases 376, 377, 378.  
To determine whether alterations in the remodelling of the ECM contributed to 
the survival of TLR9KO after MI, the mRNA levels of two primary MMPs (Mmp2 
and Mmp9) involved in cardiac remodelling were measured by qRT-PCR using 
LV homogenates of WT and TLR9KO mice 1 and 3 days after MI (figure 
5.14a). Mmp2, which is constitutively expressed in the myocardium, was 
significantly decreased in MI-operated WT mice compared to relative sham-
operated mice 1 and 3 days after surgery. In contrast, Mmp9 expression was 
increased in WT mice subjected to MI compared with sham-operated WT mice 




Figure 5.14 mRNA expression of tissue inhibitor of metalloproteinases 
(TIMP) 1 was decreased in TLR9KO mice 3 days after MI. 
qRT-PCR was performed to evaluate the mRNA expression of A, Matrix 
metalloproteinases and B, TIMPs.  Mmp2 expression was decreased in mice 
subjected to MI compared to sham mice at both timepoints, whereas Mmp9 
levels were increased in MI-operated hearts compared with sham (S) -operated 
mice. Timp1 was increased 1 and 3 days after MI compared to sham mice and 
a difference in Timp1 expression was observed 3 days after MI between WT 
and TLR9KO mice. Minor changes were present in the expression of Timp2, 
Timp3 and Timp4 were observed after MI in WT and TLR9KO mice. 
Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) was used as a 
housekeeping gene. Values expressed as mean ± SEM.; Day 1 WT sham n= 6, 
Day 1 WT MI n= 7, Day 3 WT sham n= 5, Day 3 WT MI n= 6, Day 1 TLR9KO 
sham n= 6, Day 1 TLR9KO MI n= 5, Day 3 TLR9KO sham n= 5, Day 3 
TLR9KO MI n= 5. Data were analysed by two way ANOVA with bonferroni 
post-hoc test. † p<0.05 versus corresponding sham animals at same timepoint, 
‡ p<0.05 versus same treatment at different timepoints. # p<0.05 versus WT 





The expression of Mmp2 and Mmp9 between sham- and MI- operated TLR9KO 
mice followed similar tendencies to WT sham- and MI- operated mice and no 
differences in Mmp2 and Mmp9 expression were observed between WT and 
TLR9KO mice 1 and 3 days after MI. 
Following this, the expression of Timp1, -2, -3 and -4 was studied by qRT-PCR 
using these samples (figure 5.14b). Timp1 expression increased in a time 
specific manner in MI-induced WT hearts compared to sham-operated mice. 
Elevated Timp2 and decreased Timp4 expression was observed in WT MI-
operated hearts between 1 and 3 days after operation. Timp3 levels were 
increased in WT MI–operated hearts compared to sham-operated mice at day 
1. MI-operated TLR9KO mice exhibited decreased Timp3 and Timp4 
expression between 1 and 3 days after MI, whilst sham-operated TLR9KO mice 
unexpectedly displayed decreased Timp4 expression between these two 
timepoints. Timp1 expression in MI-operated TLR9KO mice, showed similar 
trend to MI-operated WT mice, compared to relative sham animals. However, 
most intriguingly, the increase in Timp1 expression was significantly less in 
TLR9KO mice 3 days after MI, compared to WT mice 3 days after MI. 
Conversely, Timp2, -3 and -4 mRNA levels were consistent between MI-
operated WT and TLR9KO mice at all timepoints. The exciting difference in 
Timp1 expression 3 days after MI between WT and TLR9KO mice suggests 
potential alterations in ECM remodelling which may contribute to the increased 
incidence of cardiac rupture in TLR9KO mice. However further supporting 
evidence measuring MMP activity is required to validate this (section 5.3.2 for 




5.2.4.3 Fewer fibroblasts and myofibroblasts in the infarcted myocardium 
of TLR9KO mice may promote cardiac rupture.  
The wound healing response also encompasses the formation of granulation 
tissue at the wound site to promote angiogenesis as well as accommodating 
inflammatory cells and connective tissue cells. Predominately, fibroblasts 
facilitate construction of granulation tissue, although macrophages and 
myofibroblasts also participate 36. IHC and IF staining were implemented to 
evaluate the infiltration of fibroblasts and myofibroblasts into the infarcted 
myocardium of WT and TLR9KO mice to determine whether there were any 
changes in the development of the granulation tissue.  
Fibroblast specific protein 1 (FSP1) was used as a marker for fibroblasts 379 to 
estimate the number of fibroblasts after MI by IHC staining (figure 5.15a). The 
number of FSP1-positive cells were quantified in 5 different regions per heart 
section and expressed as cells per mm2 (figure 5.15b). Compared to sham-
operated WT mice, no changes in the number of FSP1-positive cells were 
observed 1 day after MI operation in WT mice. However there were dramatic 
increases in the number of positive cells in the border and infarct areas of WT 
mice 3 days after MI surgery, compared to sham-operated WT mice. TLR9KO 
mice subjected to sham and MI operation displayed similar patterns regarding 
the number of FSP1-positive cells, as sham- and MI- operated WT mice; both 
WT and TLR9KO exhibited an increase in the numbers of FSP1-positive cells in 
the border areas 3 days after MI, compared to sham-operated mice. However at 
this timepoint, there were fewer FSP1-positive cells counted in the border and 
infarct regions in MI-operated TLR9KO mice compared to WT mice subjected to 
MI.  This exciting discovery suggests that there were less fibroblasts in the 
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border zone and infarct regions of TLR9KO mice compared to WT mice 3 days 


















Figure 5.15 Fibroblast specific protein 1 (FSP1) staining revealed a 
decrease in the number of fibroblasts in TLR9KO hearts subjected to MI.  
Immunohistochemical analysis for FSP-1 was performed on cryosections of WT 
and TLR9KO hearts after MI. 3 different regions of hearts subjected to MI are 
shown – R = Remote, B = Border, I = Infarct. There are few FSP1-positive cells 
1 day after surgery, however 3 days after MI; there is a significant increase in 
both MI-operated WT and TLR9KO mice. However, there were fewer FSP1-
positive cells counted in TLR9KO mice compared to WT mice 3 days after MI. 
A, Scale bars = 30 µm. B, Quantification of FSP1-postive cells. Number of 
positive cells were counted from 5 different images per heart section in Sham 
(S) mice and per region (R, B and I) in MI operated animals. Values are 
expressed as mean ± SEM. n= 4 for all groups. Data were analysed by two-way 
ANOVA with bonferroni’s post-hoc test. † p<0.05 versus corresponding sham 
animals at same timepoint, ‡ p<0.05 versus same treatment at different 




To support these results, IF staining of cryosections with α-smooth muscle actin 
(α-SMA) and Ki67 was performed on WT and TLR9KO mice after MI (figures 
5.16 and 5.17). α-SMA is considered a marker of myofibroblasts 32 whereas 
Ki67 is utilised as an indicator of proliferation 380. The numbers of α-SMA-
positive (myofibroblasts) and double positive cells (α-SMA and Ki67, 
proliferating myofibroblasts) were quantified from 5 different areas of each 
section (figure 5.18). Similar to FSP-1 staining, no differences in the number of 
positive cells were exhibited 1 day after surgery between sham- and MI- 
operated WT mice. The numbers of α-SMA-positive and double positive cells 
was increased in the border and infarct regions 3 days post-MI in WT mice, 
compared to sham-operated animals. TLR9KO mice presented similar 
tendencies as WT mice after sham and MI operation 1 day after operation. 
However, the numbers of α-SMA-positive and double positive cells was not 
significantly increased in the border and infarct regions of MI-operated TLR9KO 
3 days, compared to sham animals and the numbers of α-SMA-positive and 
double positive cells was significantly less in MI-operated TLR9KO mice 3 days 
after surgery, suggesting there were fewer myofibroblasts and proliferative 
fibroblasts in TLR9KO mice 3 days after MI. 
Therefore the intriguing data demonstrated in this section indicates a diminished 
number of fibroblasts, myofibroblasts and proliferative myofibroblasts in the 
infarcted myocardium of TLR9KO mice, compared to WT mice may impair the 
































Figure 5.16 Immunofluorescence (IF) staining suggests no differences in 
the number of fibroblasts in the infarcted myocardium 1 day after surgery. 
IF analysis for α-smooth muscle actin (αSMA) and Ki67 was performed on 
cryosections of WT and TLR9KO hearts 1 day after MI. 3 different regions of 
mice subjected to MI are shown – remote, border and infarct. No differences in 
the expression of αSMA and Ki67 were detected in all groups. DAPI (DNA), 
FITC (Ki67 for proliferation), TRITC (αSMA for myofibroblasts). Scale bar = 60 





Figure 5.17 Immunofluorescence (IF) staining reveals a reduced number 
of proliferative myofibroblasts in TLR9KO mice 3 days after MI. 
α-smooth muscle actin (αSMA) and Ki67 staining was performed on 
cryosections of WT and TLR9KO hearts 3 days after MI. 3 different regions of 
MI-operated hearts are shown – remote, border and infarct. There appears to 
be a reduction in αSMA-positive and Ki67-positive cells in the border and infarct 
regions on TLR9KO mice compared with WT mice. DAPI (DNA), FITC (Ki67 for 






















Figure 5.18 Quantification of IF staining confirms reduced numbers of 
proliferative myofibroblasts in TLR9KO mice 3 days after MI. 
Quantification of α-smooth muscle actin (αSMA)-positive and Ki67-postive cells 
(A) and total number of αSMA-positive cells (B). Number of positive cells were 
counted from 2 different images per heart section (as shown in figures 5.16 and 
5.17) in sham (S) mice and per region (R = Remote, B = Border, I = Infarct) in 
MI-operated animals. There were no differences in the number of αSMA-
positive-Ki67-postive cells and number of αSMA-positive cells 1 day after 
operation. 3 days after MI, there was a significant increase in these cells in the 
border and infarct regions of WT mice subjected to MI, which was not observed 
in TLR9KO mice. Values are expressed as mean ± SEM. n= 4 for all groups. 
Data were analysed by two-way ANOVA with bonferroni post-hoc test. † p<0.05 
versus corresponding sham animals at same timepoint, ‡ p<0.05 versus same 
treatment at different timepoints. # p<0.05 versus WT animal at same timepoint 





Overall this chapter demonstrates the beneficial functions of TLR9 during post-
MI acute LV remodelling (table 5.3). After MI surgery, the incidence of cardiac 
rupture and mortality was substantially elevated in TLR9KO mice, compared to 
WT mice. This reduced rate of survival may be attributable to impaired wound 
healing with the observation of decreased levels of Timp1 mRNA and fewer 
fibroblasts and myofibroblasts in TLR9KO mice post-MI. Most unexpectedly, 
TLR9-mediated inflammation may not contribute to the mortality of TLR9KO 
mice after MI. Collectively, these findings suggest novel and vital, yet life-
preserving roles of TLR9 that potentially influences Timp1 mRNA expression 
and numbers of fibroblasts and myofibroblasts that are fundamental to post-MI 
acute LV remodelling.  
 
5.3.1 ECM remodelling, inflammation and initiation of scar formation were 
observed after MI in WT mice. 
Cardiac rupture is a common observation in both acute-MI patients and 
preclinical models. After MI induction by LAD ligation, incidence of cardiac 
rupture in C57Bl/6 mice was reported to be between 20 – 31% 372, 381, 382. 
However in this study a rupture incidence of 11.1% was achieved in WT 
(C57Bl/6) mice (figure 5.2). The low value for rupture incidence is possibly due 
to the experienced surgical technique of Dr Shigemiki Omiya (King’s College 
London). 
As TLR9KO mice began to die 4 days after MI operation, mice were harvested 
1 and 3 days after MI. Acute LV remodelling post-MI involves the recruitment of 
inflammatory cells and fibroblasts to facilitate removal of dead cells and ECM 
remodelling. Yang et al (2002) demonstrated infiltration of neutrophils 1 - 2 days 
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after MI whilst the number of macrophages increased between 1 - 3 days after 
MI 382. Additionally, the same report showed that lymphocytes, such as T-cells, 
were expressed in the myocardium 4 days after infarction and that fibrosis was 
detected 1 week after MI. In other studies levels of inflammatory mediators such 
as Tnfa and Il6 have been described to be upregulated 24 hours after MI 365, 383, 
384. Furthermore, in terms of ECM remodelling, it was reported that Mmp9 
expression was detected 1 day after MI and peaks 2 days later 385 whereas 
Mmp2 and Timp1-4 expression was elevated 4 days after MI 386, 387. Additionally 
it was demonstrated that fibroblasts are observed at all stages of LV 
remodelling post-MI, yet are most prominent, along with myofibroblasts during 
the proliferative stage that occurs roughly 3 days after MI 381, 388.  
It was therefore anticipated that in the mouse model described here, a robust 
inflammatory response entailing leukocyte recruitment and increased pro-
inflammatory cytokine expression would be observed after both harvesting 
timepoints (1 and 3 days after MI), but very few T-cells and little fibrosis would 
be observed at these timepoints. Additionally, upregulation of Mmp9 levels 
might be expected at both 1 and 3 days after MI in this model alongside 
infiltration of fibroblasts and myofibroblasts, particularly 3 days after operation. 
By contrast, expression of Mmp2 and Timp1-4 was expected to remain 
unchanged, as exhibited by previous studies.   
As predicted, MT staining revealed little overt fibrosis in the myocardium of MI-
operated mice at both 1 and 3 days after operation (figure 5.8). qRT-PCR 
analysis detected a time-specific increase in the mRNA levels of fibrotic 
molecular markers, Col1a2, Col3a1 and Tgfb1 (figure 5.9), suggesting that 
fibrosis would be observed after the timepoints which mice were harvested. 
Unexpectedly, Col1a2 and Col3a1 mRNA levels were also increased between 1 
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and 3 days after operation in sham-operated mice. The elevated levels could be 
a consequence of the operation and thus highlights the necessity for 
appropriate controls. 
Table 5.3 Summary table for findings in this chapter. 
After MI, TLR9KO mice had a higher incidence of cardiac rupture 4 days than 
WT mice. No differences were found in the ischemic area at risk, infarct size, LV 
wall thickness, levels of fibrosis, inflammation or MMP expression. Interestingly, 
mRNA expression of Tnfa (tumour necrosis factor α), Timp1 (an inhibitor of ECM 
remodelling) and the number of fibroblasts and proliferative myofibroblasts were 
decreased in TLR9KO mice 3 days post MI compared to WT mice. 
 
Analysis WT Sham vs 
WT MI 
TLR9KO Sham 
vs TLR9KO MI 
WT MI vs 
TLR9KO MI 
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The data presented in this study regarding inflammatory cell recruitment and 
expression of pro-inflammatory and anti-inflammatory mediators concur with 
previous studies (figures 5.10 – 5.13) 365, 382, 383, 384, 389. Although pro-
inflammatory cytokines were expressed 3 days post-MI, the enhanced 
expression of the anti-inflammatory marker, Il10, between 1 and 3 days post-MI 
(figure 5.13b, table 3.1), suggested a transition from an inflammatory phase to 
a proliferative phase of LV remodelling 3 days post-MI 32, 33. This was 
additionally supported by the time-specific increase of fibroblasts, 
myofibroblasts and proliferating myofibroblasts between 1 and 3 days after MI 
(figures 5.15 – 5.18) as myofibroblasts, in particular, are known to appear 
during the phenotypic switch between the 2 phases 32, 381, 388.  
Mmp2 expression in MI-operated WT mice unexpectedly decreased 
significantly, compared with sham mice, at all timepoints (figure 5.14a). This 
surprising result suggested possible transcriptional regulation of the Mmp2 gene 
in MI-operated mice, during the acute phase of LV remodelling. Mmp9 
expression was upregulated at both harvest points after MI as expected. Whilst 
there were only small changes in Timp2, -3 and -4 mRNA levels, Timp1 
expression was significantly elevated in MI-operated mice at both timepoints 
(figure 5.14b, table 3.1). However, it has been reported that although Timp1 
mRNA increases 3 days after MI and peaks at day 7, an increase in TIMP1 
protein levels was only detected 2 weeks after MI 390, 391, suggesting post-
translational processing of the TIMP1 protein. Therefore protein expression of 
TIMP1 should be evaluated in this current model to validate its increase in 
expression at the protein level. 
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Together, these experiments demonstrate the induction of a robust 
inflammatory response, ECM remodelling and tissue repair processes in this 
model of MI, which corroborates with previous reports. 
 
5.3.2 Diminished wound healing contributes to increased incidence of 
cardiac rupture in TLR9KO mice after MI.  
The surprising and intriguing mortality of TLR9KO mice, 4 – 6 days after MI 
(figure 5.2, table 3.1) indicated that TLR9 was fundamental for acute LV 
remodelling post-MI. Post-mortem analysis revealed that cardiac rupture of the 
LV free wall was the cause of death of MI-operated TLR9KO mice (figure 5.3), 
which is frequently observed in patients and murine MI models 36. Previous 
reports demonstrate that cardiac rupture is commonly observed 2 – 6 days after 
MI surgery in mice, with a peak seen at 3 - 4 days 392, which corroborates with 
incidence of mortality of TLR9KO mice in this model (figure 5.2). 
No preceding cardiac phenotypes that may increase susceptibility to cardiac 
rupture were ascertained by echocardiography or physiological measurements 
prior to MI operation in TLR9KO mice (table 5.1). Thus the cause of cardiac 
rupture was investigated and included factors such as; enlargened infarct size, 
decreased wall thickness, inflammation, altered ECM remodelling and modified 
granulation tissue formation. The BP of WT and TLR9KO mice was not 
measured prior to and after surgery. Baseline BP should be similar between WT 
and TLR9KO mice (as shown in table 3.3), however as differences in BP is 
another contributing factor to the increased incidence of cardiac rupture, BP 
should be investigated in future studies between WT and TLR9KO mice.  
A previous investigation demonstrated that activation of TLR9 by administration 
of CpG ODN did not influence infarct size in WT mice subjected to I/R injury 356. 
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Although the I/R injury is distinctive to LAD ligation, it could potentially suggest 
that there would be no differences in infarct size in this current model. 
Assessment of the ischemic area at risk (figure 5.4) and infarct size (table 5.2) 
by Evans Blue staining and cardiac MRI (figure 5.5) demonstrated this 
expectation to be true, indicating that infarct size was unrelated to the incidence 
of cardiac rupture in TLR9KO.  
The increased susceptibility of cardiac rupture in TLR9KO mice, suggested that 
TLR9 and potentially TLR9-mediated inflammation were important for tissue 
repair and debris removal after MI. Surprisingly in this study, no differences in 
the inflammatory response (except Tnfa mRNA expression) between WT and 
TLR9KO mice after MI were observed at all timepoints (figures 5.10 - 5.13, 
table 3.1). Although, Tnfa expression was reduced 1 day after MI in TLR9KO 
mice compared to WT mice, the levels of Tnfa were similar 3 days after MI 
between MI-operated WT and TLR9KO mice, prior to occurrence of cardiac 
rupture (figure 5.13b). One report stated that MI-operated TNFαKO mice had a 
lower incidence of rupture compared to WT controls with a reduced 
inflammatory response 393. Therefore it was unlikely that inflammation or Tnfa 
itself contributed to the incidence of cardiac rupture as the levels of Tnfa were 
similar 3 days after MI. However due to the time required for translation, protein 
levels of TNFα expression should be evaluated 3 days after MI in WT and 
TLR9KO mice to determine any differences in the protein expression of TNFα, 
that may contribute to the increased incidence of cardiac rupture in TLR9KO 
mice. Additionally, the comparable inflammatory response between MI-operated 
WT and TLR9KO mice implied that inflammation observed after MI is 
independent of TLR9 and may be mediated by other immune sensors, such as 
TLR2, TLR3 and TLR4 366, 367, 368, 369. 
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Investigation of ECM remodelling found no differences in the mRNA levels of 
Mmp2, Mmp9, Timp2, 3 and 4 between WT and TLR9KO mice 1 and 3 days 
after MI. Interestingly, Timp1 mRNA expression measured by qRT-PCR was 
significantly different between WT and TLR9KO mice 3 days after MI (figure 
5.14, table 3.1). It remains unclear how differences in Timp1 expression may 
contribute to the incidence of cardiac rupture. One report observed accelerated 
LV remodelling 14 days after MI in TIMP1KO mice compared to WT mice, 
however the incidence of cardiac rupture was unchanged 394. As TIMP1 is an 
inhibitor of MMPs, it affects MMP activity rather than their expression. As 
previously mentioned, it was reported that TIMP1 may undergo post-translation 
processing 390, 391. Thus zymography should be performed to measure MMP 
activity in the myocardium of MI-operated WT and TLR9KO mice to determine 
and validate any differences in ECM remodelling.   
In this study, fewer fibroblasts and proliferative myofibroblasts were observed in 
the infarcted myocardium of TLR9KO mice 3 days after MI, compared to WT 
mice after MI (figures 5.15 – 5.18, table 3.1). This may have diminished the 
formation of granulation tissue post-MI in TLR9KO mice, impairing the tissue 
repair process, provoking rupture of the myocardium. Possible reasons for 
observing fewer fibroblasts within the myocardium of TLR9KO mice include 
differences in fibroblast activation or differentiation or recruitment of fibroblasts. 
Myofibroblasts are differentiated from different categories of fibroblasts as well 
as other cell types 32 and it has been demonstrated that TLR9 activation 
contributes to the differentiation of pulmonary fibroblasts into myofibroblasts 395. 
Conversely, in vitro experiments conducted by Ohm et al (2014) found that 
TLR9 had no effect on CF differentiation into myofibroblasts, but reduced the 
proliferation and migration of CFs which opposes the findings presented in 
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figures 5.16 - 5.18 176. Reports that TIMP1 can stimulate the growth of 
fibroblasts 112, may provide a mechanism in which TLR9 signalling may regulate 
fibroblast migration by altering TIMP1 expression (figure 5.19). Nonetheless 
further studies are needed to uncover a possible association between TLR9 and 









Figure 5.19 The proposed mechanism of TLR9-signalling in acute left 
ventricular remodelling after MI.  
Induction of MI leads to stimulation of TLR9, which sequentially increases 
expression of Timp1. This consequently increases the number of fibroblasts and 
induces proliferation of fibroblasts into myofibroblasts. However, TLR9 does not 
contribute to the inflammation observed in acute left ventricular post-MI. 
 
One limitation of this study was the use of C57Bl/6 mice as the WT control. 
Though TLR9KO mice have been bred onto Bl/6 background, littermate controls 
are the most appropriate control and this is further discussed in section 6.4. 
Another limitation involves the use of a global TLR9KO mice, as this does not 
relay much information about which cell type(s) mediate the observed effect, 
whether it be cardiomyocytes, fibroblasts or endothelial cells. Further, MMP 
activity needs to be measured by zymography to validate any claims about 
TLR9 influencing ECM remodelling (mentioned above). Also, due to the 
heterogeneity of the heart post-MI, qRT-PCR of inflammatory, fibrotic and ECM 
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remodelling markers should have been performed using LV samples that had 
been dissected into remote, border and infarct areas. However it may be difficult 
to dissect a heart 3 days post- surgery as the infarct areas may be difficult to 
see. Further work could focus upon the effects of TLR9 after reperfusion to 
determine whether similar or alternate effects are observed and this may be 
more relevant to clinical MI cases in which reperfusion of a blocked artery has 
been achieved. 
In summary, this chapter identified novel, beneficial downstream functions of 
TLR9 in tissue repair after myocardial injury. These life-preserving functions of 
TLR9 may influence MMP activity and the numbers of fibroblast and 
myofibroblasts, preventing the induction of cardiac rupture and adverse 
consequences.  However more supporting evidence is required to validate 

















6 General Discussion 
HF is associated with increased levels of pro-inflammatory cytokines and 
inflammation 19, 20, 21. Although, the mechanisms of cardiac inflammation remain 
unclear, it was proposed that ‘sterile inflammation’ contributes to the 
pathogenesis and progression of HF 20. Previous data identified that the 
immune sensor and inflammatory instigator, TLR9 is associated with pressure 
overload-induced myocardial inflammation and cardiac remodelling 173. 
However, the mechanisms by which TLR9-mediated inflammation contribute to 
HF remain unknown, though reports of the immunomodulatory properties of β-
AR signalling 224, 225, which is also impaired in pressure overload and HF, 
suggested a potential avenue to investigate.  Furthermore the role of TLR9 in 
MI, a common cause of HF has not yet been elucidated. As the role of TLR9 
within the failing heart is unclear, this thesis aimed to investigate the potential 
role of TLR9-mediated inflammation in the pathogenesis of HF, with particular 
focus on β-AR signalling and in MI. 
Using an Iso infusion model, it was shown that TLR9 induced cardiac 
dysfunction, thickened posterior walls and heart weight gain. These interactions 
suggest a detrimental role of TLR9 in β-AR-induced cardiac remodelling. 
Furthermore, the Iso infusion model used to stimulate the β-AR signalling 
cascade, appeared to be unique and warranted further study. Iso infusion 
caused β-stimulant-induced cardiomyopathy that was devoid of changes to β-
AR signalling and calcium handling, oxidative stress, metabolic abnormalities 
and cardiac remodelling (fibrosis, apoptosis or inflammation). However, β-
stimulant-induced cardiomyopathy exhibited IκB degradation, suggesting NFκB 
activation. Furthermore, 1 day after removal of Iso, recovery of cardiac 
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dysfunction and tachycardia associated with β-stimulant-induced 
cardiomyopathy was observed.  
A beneficial role of TLR9 in post-MI acute LV remodelling was uncovered, which 
prevented cardiac rupture. This function was associated with differences in 
Timp1 mRNA expression and the number of fibroblasts and myofibroblasts. 
These findings highlight two things: firstly, the opposing roles of TLR9 in these 
two different circumstances and secondly, that the role of TLR9 in these two 
situations was independent of inflammation. However, whilst these findings are 
highly exciting, unfortunately, neither of the models used in this thesis enabled 
the study of TLR9-mediated inflammation in the pathogenesis of HF, which was 
the original aim of this thesis. Both models have been reported to induce HF 33, 
224, 362, 375, however notable phenotypes were observed in these models before 
HF was recognised. Therefore this thesis transferred its focus to investigate the 
roles of TLR9 in cardiac dysfunction, LV remodelling and tissue repair.  
 
6.1 The multifunctional role of TLR9 in cardiac remodelling.  
The data presented in this thesis demonstrated the double-edged nature of 
TLR9 in cardiac remodelling. Although cardiac remodelling aims to alleviate 
increased workload, these remodelling processes eventually lead to cardiac 
dysfunction and the development of HF 66. Further study to comprehend the 
transition from adaptive to maladaptive remodelling is required to highlight 
potential therapeutic targets that could manipulate pathways to preserve 
adaptive mechanisms and reverse maladaptive remodelling. It often appears 
that the same pathway is involved in both adaptive and maladaptive processes, 
though the observed phenotype depends on its balance, such as NFκB and 
TNFα 185, 186, 187. Additionally, components of cardiac remodelling appear to 
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interact with one another, for example, inflammation is connected to fibrosis and 
cell death, whilst fibrosis in turn is connected to cell death and inflammation 32, 
131. Therefore dissecting and targeting one process may influence the effects of 
other components.  
The presented data identified the detrimental function of TLR9 in β-AR-induced 
cardiac remodelling, alongside its beneficial role in post-MI acute LV tissue 
repair. Furthermore the nature of remodelling disrupted by TLR9 activation in 
these two models was different; in chapter 3, heart weight and function were 
influenced by TLR9 whereas in chapter 5, TLR9 manipulated Timp1 mRNA 
expression and the number of fibroblasts and myofibroblasts. These findings 
propose novel roles of TLR9 in cardiac remodelling after Iso infusion or post-MI. 
These functions are added to its well-documented function within the immune 
system as a sensor 177, 181 and its newly reported protective role against stress 
by modulating energy metabolism in cardiomyocytes 183, 184 (figure 6.1). 
In a model of pressure overload, TLR9KO mice displayed reduced chamber 
dilatation and improved cardiac function and the authors suggested this was 
due to the observation of fewer infiltrated myocardial macrophages, less fibrosis 
and reduced hypertrophy compared to control mice 173. This report indicated 
additional roles of TLR9 in cardiac remodelling, suggesting a potential role of 
TLR9-mediated inflammation in pressure overload-induced cardiac remodelling. 
Many signalling pathways are activated during pressure overload and it was 
hypothesised that the β-AR signalling pathway, a major regulator of calcium 
handling and cardiac contractility, could be involved in mediating the observed 





Figure 6.1 Reported and potential roles of TLR9 within the myocardium. 
Known (grey arrows) functions of TLR9 include its role as an immune sensor 
stimulating inflammation as well as providing protection against CpG-induced 
stress. Novel potential functions of TLR9 observed in this thesis (red arrows), 
suggest that TLR9 is involved in tissue repair and cardiac remodelling and 
potential mechanisms have been outlined, supported by data from other 
reports.  
 
The current data suggests that an interaction between the TLR9 signalling 
pathway and the β-AR signalling cascade, which was detrimental to cardiac 
function and structure, could partially contribute to the rescued phenotype 
observed in the pressure overload model in TLR9KO mice. In addition, fibrosis 
is a typical consequence of cardiomyocyte death and the reduced fibrosis 
detected after pressure overload in TLR9KO mice compared to control mice 
could be due to diminished cell death. However it may also potentially be due to 
the reduced number of fibroblasts and myofibroblasts in TLR9KO mice after 
myocardial injury (which was observed in the acute MI model). Therefore, 
TLR9-mediated regulation of fibroblast and myofibroblast numbers may be 
beneficial after MI for tissue repair, but could have adverse consequences after 
pressure overload and induce fibrosis. Thus the signalling pathways 
245 
 
downstream of TLR9 that mediate these observations should be studied in 
further detail.  
The opposing nature of TLR9 after Iso infusion or MI is not uncommon as many 
proteins play various roles under different physiological and pathological 
conditions. It was reported that MAPK p38, calpains and NFkB signalling are 
protective against pressure overload-induced haemodynamic stress 306, 396, 397 
whereas in I/R injury, these proteins are suggested to be detrimental 398, 399, 400, 
401, 402, 403. In combination with the findings of this thesis, these reports highlight 
that the aetiologies of the cardiac remodelling should be considered, as it is 
likely that remodelling is mediated through different mechanisms and induced 
by different causes.  
 
6.2 Role of TLR9-mediated inflammation in the failing heart 
TLR9 is recognised for its role in inflammation with many papers documenting 
that the stimulation of TLR9 induces expression of pro-inflammatory cytokines 
181, 404. However the data presented here demonstrated that TLR9-mediated 
inflammation was not involved in influencing cardiac function and heart weight 
in a model of β-stimulant-induced cardiomyopathy and was not implicated in 
acute tissue repair post-MI. These findings were surprising as both MI and the 
β-AR signalling cascade have been reported to involve inflammation 33, 224, 362, 
375. One factor that should be considered is the temporal aspects of 
inflammation, the acute versus chronic inflammatory periods and the rise / fall of 
different inflammatory mediators at different stages of myocardial injury and 
inflammation. In comparison with the pressure overload study 173, the 
measurements were performed 9 weeks after the induction of pressure-
overload, whereas similar measurements were recorded 4 weeks after Iso 
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infusion or 3 days after MI surgery. Therefore temporal myocardial inflammatory 
activities and the timepoint of harvest may advocate one reason as to why no 
differences in inflammation were observed in the models utilised in this thesis 
and may indicate a role of TLR9 in chronic myocardial inflammation, rather than 
acute inflammation. Moreover, pressure overload is known to damage the 
structure of mitochondria and induce mitochondrial dysfunction 405, 406, which in 
turn, could provoke a TLR9-mediated inflammatory response due to incomplete 
degradation of mtDNA 173. However after Iso infusion no mitochondrial structural 
damage was observed by electron microscopy, which could suggest why no 
inflammation was observed in this model. It is also plausible that pressure 
overload and Iso infusion induce cardiac remodelling by different stimuli, which 
activate different pathways. The cardiac phenotype observed after pressure 
overload is a culmination of the activation of many signalling pathways, whereas 
the Iso infusion model focuses on one signalling pathway. Therefore the data 
from this thesis suggests that TLR9-mediated inflammation observed after 
pressure overload may possibly be independent of β-AR signalling. 
Though the pressure overload model suggested a role of TLR9-mediated 
inflammation to induce chamber dilatation and cardiac dysfunction, this was 
based on the observation of mild infiltration of CD68+ macrophages 10 weeks 
after pressure overload. However, no significant differences were detected in 
the cytokine mRNA levels between pressure overload control and TLR9KO 
mice at this timepoint. This questions the activity of these macrophages as no 
changes in cytokine expression were detected.  
Additionally, it could be postulated from this current data that TLR9-mediated 
inflammation may not be involved in the progression of HF, but inflammation 
may be stimulated by other immune receptors and pathways including TLR2, 
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TLR3, TLR4 and the inflammasome 169. However TLR9 may contribute to the 
pathogenesis and progression of HF with the novel roles involved in tissue 
repair and cardiac remodelling demonstrated by this thesis. Therefore the data 
from this thesis questions the influence of TLR9-mediated inflammation on 
cardiac remodelling and the failing heart. 
 
6.3 Uniqueness of Iso infusion model 
The renounced Iso infusion model was utilised to model HF. However this 
current Iso model could be considered unusual and unique as it developed into 
a condition referred to as β-stimulant-induced cardiomyopathy, which exhibited 
cardiac dysfunction and heart weight gain but no other aspects of cardiac 
remodelling (fibrosis or apoptosis). Additionally, as the data stands no changes 
where observed in the metabolic state, oxidative stress, β-AR expression or 
calcium handling of Iso-infused myocardium. Although trends were observed in 
some of these parameters, more samples are required to confirm and validate 
these statements. These findings conflicted with previous reports as discussed 
(sections 3.3.2 and 4.3.2) and could be due to the dose of Iso used, duration of 
treatment, method of administration, age and strain of mouse and species of 
animal (table 6.1).  
Additionally, reports of polymorphisms within the AR signalling cascade have 
been described in humans, which can affect ligand binding and the activity of 
proteins 407. Though there are no reports as of yet, it is possible that 
polymorphisms in the AR signalling cascade may exist between different strains 
of mice, as well as between animals which may contribute to the unique 
phenotype observed in this thesis in comparison with previous reports.  
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Table 6.1 Features of reported models of Iso infusion 
Table to illustrate doses and durations of Iso infusion alongside, age, weight 
and sex of animal utilised in reported models and the associated effects in 
comparison to the findings of this thesis (in red). MP= minipump, LV(W)/BW = 
left ventricular weight / body weight, HW/BW = heart weight / body weight, 
LVPW = left ventricular posterior wall, IVS = intraventricular septum, TL = tibia 
length, Lung W = lung weight, LVID = left ventricular internal diameter. FS = 
fractional shortening, EF = ejection fraction, β-AR = β- adrenergic receptor, AC 
= adenylate cyclase, Ca2+ = calcium, FA = fatty acids, Tgfb = transforming 
growth factor-beta, Il6 = interleukin-6, Col1 = collagen type 1, Col3 = collagen 
type 3, Nppa = natriuretic peptide A, Nppb = natriuretic peptide B 
 





dose of Iso 





24 – 27g  
50 mg/kg/day, 
28 days, MP 
Hypertrophy (é HW/TL, CSA), 
chamber dilatation (é LVID), cardiac 
dysfunction (ê EF, FS), 
hypertension, tachycardia, weight 
gain, pulmonary congestion (é 




7 weeks 30 mg/kg/day, 
13 days, MP 
Hypertrophy (é LV/BW ratio), 
fibrosis (histology), ê β-AR 





Male, 20 g 15 mg/kg/day 
1 week, MP 
Hypertrophy (é LVPW, HW/BW), 
fibrosis (éTgfb, Col1, Col3 mRNA), 








4 days, MP 
Hypertrophy (é LV/BW, IVS, LVPW, 




6 months 60 mg/kg/day  
10 days, MP 








10 days, MP 
Hypertrophy (é HW/BW, histology), 
tachycardia, fibrosis  (histology), 










mg/kg, 5 days 
SC injection 




Mouse 4 months 60 mg/kg/day, 
3 weeks, MP 
Hypertrophy (é HW/BW), cardiac 









7 days, MP 












Hypertrophy (é LVPW), chamber 
dilatation (é LVID), hypertension, 








Cardiac dysfunction (ê EF, FS), 






5 mg/kg/day, 7 
days, MP 
Hypertrophy (LVW), cardiac 
dysfunction (ê EF), fibrosis 
(histology), impaired metabolism 
(ê FA and glucose metabolism) 
302 
Rat Male, 280 











These potential polymorphisms could alter signalling downstream of the 
receptor and thereby mediate different effects after Iso infusion between 
different species of animals or even between strains of mice. 
As well as cardiac dysfunction, this current Iso infusion model induced both 
tachycardia and hypertension. Both of these are risk factors for the 
development of HF and may induce diastolic dysfunction and pulmonary 
congestion leading to HFpEF 25, 26. Additionally, tachycardia itself can reverse 
cardiac dysfunction once the tachycardia is corrected, as seen in TIC patients, 
50, 51. Therefore it is probable that Iso-induced cardiac dysfunction was due to 
tachycardia and that removal of Iso ceased the tachycardia and enabled 
recovery of cardiac function. Another potential cause for Iso-induced cardiac 
dysfunction could be catecholamine-induced stunning, which is described as a 
cause for SIC 65. Interestingly, several of the characteristics of this model 
resemble features of rapid-pacing models performed in dogs, which is used to 
model aspects of TIC and atrial fibrillation 411, 412. Rapid-pacing models have 
been shown to induce LV systolic dysfunction, cardiomyocyte contractile 
dysfunction and neurohormonal activation and upon cessation of the pacing, the 
myocardium recovers 413. Whilst fibrosis is not a common attribute of this model, 
elevated ANP levels, reduced β-AR density and apoptosis are molecular and 
cellular features of rapid-pacing 412. Therefore, whilst there are similarities 
between the Iso infusion model presented in this thesis and rapid-pacing, there 
are several distinctions.  
Therefore, the model of Iso infusion utilised in this study contradicts the findings 
of previous reports, which use lower doses of Iso for shorter time periods (table 
6.1). As a stronger dose and longer infusion period of Iso was utilised in this 
current model, it is plausible that a different cardiac response was activated, 
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yielding the unusual response observed. In addition, the current Iso infusion 
model, correlates with some, but not all features of other models (rapid-pacing). 
Therefore this model of Iso infusion is unique and further investigation to 
understand the mechanisms by which Iso induces cardiac dysfunction is 
required. 
 
6.3.1 Role of NFκB in Iso infusion model 
After treatment of Iso, degradation of IκB was observed, suggesting increased 
nuclear translocation of the transcription factor, NFκB. The stimuli and 
downstream effects of this observation have not yet been uncovered, however 
NFκB is known for its pleiotropic nature. Stimuli that induce NFκB activity 
include cytokines, oxidative stress, inflammatory stimuli, stress, growth factors 
and DNA damage which mediate responses such as stress, growth, 
inflammation and cell survival/ death 414. 
Neither oxidative stress or inflammation were detected after Iso infusion and 
were therefore unlikely to induce NFκB translocation. However NFκB activation 
can be induced by other stimuli such as cellular stretch and cell survival 
pathways 351, 415. Whilst, Nppa expression, a marker of cellular stretch, was 
decreased after Iso infusion, dilation of the LV chamber was observed, which is 
the resulting phenomena of cellular stretch. Though NFκB activation has been 
reported after Iso infusion 350, there are no reports that address the possible 
associations of NFκB activation with the β-AR signalling cascade. Therefore, 
the expression and activity of other markers of cell survival and cellular stretch 




In addition, the downstream response of NFκB activation remains unanswered. 
Therefore, the expression of genes downstream of NFκB should be evaluated 
after Iso infusion. Neither inflammation nor apoptosis, both of which are 
downstream responses to NFκB activation, were observed after Iso infusion, 
implying that these were not the responses induced by NFκB translocation. 
However reports that NFκB is associated with the development of cardiac 
hypertrophy 416, which was potentially observed in this model of Iso infusion 
(though further study is required), indicate a pathway that could be pursued.  
 
6.3.2 An unreliable and inconsistent Iso infusion model? 
The Iso infusion model developed in this thesis is inconsistent, as there have 
been discrepancies in echocardiographic and physiological data in and between 
chapters of this thesis. There were inconsistencies in LV chamber size, body 
weight, lung weight and liver weight which were increased after Iso infusion, 
compared to saline-treated mice in several studies and unchanged in other 
studies. Whilst Iso has been reported to induce chamber dilatation, weight gain 
and pulmonary congestion as measured by lung weight 304, 317, increased liver 
weight, which is an indicator for systemic congestion has not been previously 
reported in mice after Iso infusion. These inconsistencies question the 
reproducibility of this model and it remains unknown why these parameters 
were different on different occasions. The C57Bl/6 mice used for experiments 
reported in this thesis were ordered from the same company and mice of the 
same gender, age and body weight were utilised for experiments. The 
experimental protocol was consistent for all studies. However external 
environmental factors, such as time of day and/or time of year in which the 
experiments were conducted as well as the number of mice in a cage may 
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cause some discrepancies in the data, therefore further evaluation of this model 
and a higher number of samples per experiment is required to confirm these 
findings.  
 
6.4 Study limitations 
One major limitation of the experiments performed in this thesis were the lack of 
power calculations to establish and validate the data. With the challenging issue 
surrounding the ethical use of animals in scientific research, experiments are 
required to be performed with enough animals to prove beyond reasonable 
doubt a hypothesis, without using an excessive number to limit the number of 
animals sacrificed.  Therefore power calculations are used to calculate the 
number of animals required for an experiment and the current data shown in 
this thesis requires more samples for several experiments to support and 
validate the claims made. 
Several studies employing Iso infusion were performed (pilot study, WT versus 
TLR9KO, minipump exchange and new samples) in this thesis. However the 
echocardiographic data was difficult to analyse, comprehend and compare 
between these different studies as multiple forms of echocardiography were 
performed. Conscious and anaesthetised echocardiographic analyses were 
performed, with 2 methods employed for anaesthetised echocardiography, 
using the same percentage of ISF (1.5%) and secondly, using different 
percentages of ISF to obtain HRs between 450-550 bpm. Mice were scruffed to 
perform conscious echocardiography, which may induce stress, and alter the 
cardiac function through increased catecholamine levels. However, 
anaesthetised echocardiography subdued the cardiac function and therefore did 
not represent the physiological cardiac phenotype. Additionally, awake 
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echocardiography had to be performed very quickly with images taken from one 
viewpoint (short-axis M-mode) whereas with anaesthetised echocardiography, 
the heart can be analysed more thoroughly by difference viewpoints (long axis, 
short axis, four chamber view), enabling more information regarding cardiac 
function and structure. Performing echocardiography using same ISF%, 
detected differences in the HR between saline and Iso treated mice. However, 
as echocardiographic parameters are HR dependent, echocardiography was 
performed to match the HR using different ISF%, therefore the mice were under 
different depths of anaesthesia, which again may influence the cardiac function. 
Therefore, there was no ideal way to analyse the cardiac parameters of mice 
after Iso infusion so the echocardiographic data from the different methods of 
analysis were collated to provide an overall view of the effects of Iso infusion. 
Moreover, C57Bl/6 mice were used as WT controls for experiments using 
TLR9KO mice. Ideally, experiments would have been performed using 
littermates, comparing TLR9+/+ versus TLR9-/- (TLR9KO) mice to eliminate any 
differences in the genetic background between the mice. However, as TLR9KO 
mice were bred onto a C57Bl/6 background for more than five generations, this 
permitted the use of C57Bl/6 as the WT control. Additionally, to minimise the 
influence of external environmental effects, WT and TLR9KO mice would be 
bred and maintained under similar conditions. 
Furthermore, global TLR9KO mice were used in these experiments. Though it 
can be speculated that TLR9 expressed within cardiomyocytes may contribute 
to TLR9-mediated cardiac remodelling whereas TLR9 in fibroblasts influences 
tissue repair, use of a cell-specific knockout would substantiate which cell-type 
is involved and validate these postulations.  
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In this study, in order to investigate the signalling pathways involved in cardiac 
hypertrophy, calcium handling and apoptosis, q-RT PCR and Western blot 
analysis was performed to study mRNA and protein expression. However the 
level of mRNA and protein does not always correlate with their functionality 
and/or activity. Additionally, great care should be taken when harvesting tissue 
in order to study protein expression and/or phosphorylation. In this current 
study, weighing the heart was an important parameter for analysis so harvested 
heart samples remained at room temperature, which could affect protein 
expression, phosphorylation levels and its activity. Moreover the availability of 
specific and reliable antibodies to detect the protein can be challenging. 
Therefore evaluating the activity of different enzymes, pumps or transporters, 
and/or translocation of proteins to different cellular compartments would further 
investigate the roles of these proteins in various models and would be 
considered as future work for these projects. 
Furthermore, DAB+ cell staining in IHC experiments was used to quantify cells 
that expressed specific markers. Though this method is considered to be semi-
quantitative, it provides an approximation on the number of positively stained 
cells. However flow cytometry, which accurately quantifies the number of cells 
with a specific marker, would have been an ideal tool to use. 
 
6.5 Future directions 
Further experiments would focus upon validating the current findings by 
increasing the number of samples in experiments where mentioned. Also, the 
function of NFκB activation after Iso infusion in the model created in this thesis. 
DNA microarray analysis could be used to identify the downstream effects of 
NFκB activation after Iso infusion. Moreover, Western blotting and 
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immunoprecipitation experiments may distinguish the signalling pathways that 
are activated to induce IκB degradation and NFκB activity downstream of Iso 
stimulation. 
Additionally other avenues that could be explored as causes for the 
development of β-stimulant-induced cardiomyopathy include measurements of 
contractile function and the expression of contractile proteins as well as 
mitochondrial function and ATP levels. Decreased ATP levels and reduced 
mitochondrial function are both an observation and potential cause of TIC. 
Although mitochondrial structure, pyruvate decarboxylation and β-oxidation of 
FAs appear to be maintained after Iso infusion, suggesting intact mitochondrial 
function, activity of the complexes within the electron transport chain would 
validate this speculation. Therefore further investigation is required to 
understand the molecular mechanisms of β-stimulant-induced cardiomyopathy. 
Also identification of the mechanisms by which acute reversal of Iso-induced 
tachycardia and cardiac dysfunction was observed requires further study. 
However as mentioned, one possible mechanism is amendments to the 
expression of proteins involved in FA metabolism and oxidative 
phosphorylation.  
Cell-specific function and expression is a common trait of many proteins. As 
TLR9 is expressed in both cardiomyocytes and fibroblasts, further investigations 
would be directed to identify and comprehend the cell-types that mediate the 
various functions of TLR9. One experiment involves the use of isolated cells 
(cardiomyocytes, fibroblasts, endothelial cells), which could be treated with 
synthetic CpG ODNs that either stimulate or inhibit TLR9. From this the proteins 
that interact with TLR9 and the downstream signalling pathways that mediate 
the responses observed after Iso infusion or LAD ligation (mimicked by using 
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Iso treatment or ischemic cell culture conditions) could be identified by western 
blotting or immunoprecipitation. Also co-cultures (cardiomyocytes, fibroblasts, 
macrophages) could also be utilised in the aforementioned experiments to 
determine the relative association and interactions between different cell types 
to influence TLR9 activity as well as cell-specific TLR9KO mice. Cre-Lox P 
technology would be employed to delete TLR9 in these cells by expressing Cre 
under the promoter of α-myosin heavy chain (cardiomyocytes), periostin 
(activated fibroblasts) and tie2 (endothelial cells), generating cell-specific 
TLR9KO mice. By identifying the cell-type that mediates these roles of TLR9, 
this may possibly allude to the proteins or the pathways that connect TLR9 
signalling to its observed impact on cardiac function, heart weight, Timp1 mRNA 
expression and numbers of fibroblasts and myofibroblasts. Co-
immunoprecipitation and mass spectrometry experiments of proteins involved in 
the TLR9 signalling cascade and DNA microarrays may identify potential 
mediators.  
 
6.6 Clinical implications 
Using Iso as a β-AR stimulant has validated the importance of the β-AR 
signalling cascade in the development of cardiac dysfunction and heart weight 
gain, emphasising the benefits of utilising β-blockers as a common treatment for 
HF. 
Combining the data of Oka et al (2012) demonstrating that TLR9 ablation 
attenuated pressure overload-induced HF 173 and the data from this Iso model, 
the impact of TLR9 on cardiac function could potentially be a therapeutic target. 
Furthermore, in vivo experiments have exhibited that TLR9 inhibition attenuated 
pressure overload-induced HF 173. Therefore, inhibition of TLR9 may prevent or 
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reduce cardiac dysfunction in patients associated with hypertension or aortic 
stenosis, as these are known causes of myocardial pressure overload. 
Additionally in vivo inhibition of TLR9 diminished CpG-induced myocardial 
dysfunction associated with sepsis 203, suggesting another potential use of 
therapeutics which inhibit TLR9. Furthermore, whilst findings from this thesis 
suggest that β-AR signalling interacts with NFκB and therefore IκB/NFκB could 
be considered as a potential therapeutic target, further work is needed to 
understand its pleiotropic role within the myocardium. 
However, the consequences of TLR9 inhibition could be detrimental if the 
patients treated with TLR9 inhibitors suffered from a MI, especially during the 
acute phase of remodelling post-MI. The data presented in this thesis has 
demonstrated that the incidence of cardiac rupture was increased in TLR9KO 
mice after MI due to impaired tissue repair, eluding that inhibition of TLR9 may 
have adverse outcomes. Therefore, further study is required to identify the 
downstream mechanisms involved in TLR9-mediated cardiac dysfunction and 
tissue repair, so the molecules downstream of the TLR9 receptor that cause 
cardiac dysfunction could be therapeutically targeted and not those involved in 
TLR9-mediated tissue repair. 
Also, the temporal and spatial aspects of inflammation and TLR9 activity need 
to be considered in terms of treatment design and duration. Though the data 
presented in this thesis saw no difference in TLR9-mediated inflammation in the 
models used in this thesis (discussed in section 6.2), TLR9-mediated 
inflammation may be a chronic affect. Therefore a therapy targeting TLR9 would 
need to consider the varied roles of TLR9 and their temporal regulation as well 




6.7 Concluding remarks 
The sensory nature of TLR9 recognising unmethylated CpG motifs on DNA and 
provoking the initiation of an inflammatory response is well acknowledged. 
However the data presented here proposes novel roles for TLR9 in cardiac 
remodelling that are independent of inflammation. One role of TLR9 identified 
from this project was its ability to induce cardiac dysfunction in β-stimulant- 
induced cardiomyopathy, whilst, another role of TLR9 has been described in 
tissue repair processes post-MI. To identify the intricate pathways that connect 
TLR9 to the observed phenomena, further study is required. 
Moreover, chronic, excessive infusion of Iso induces a reversible cardiac 
dysfunctional phenotype, which may be mediated by NFκB signalling, however 
further investigation is needed to evaluate this model. 
Finally, though the contribution of the TLR9-mediated inflammation in the 
pathogenesis of HF remains unanswered, novel roles of TLR9 were identified in 
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